CONFIDENTIAL  
 THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION AND MUST NOT BE COPI[INVESTIGATOR_73197]0145 -1376  
 
 
A phase 2a, randomised, double -blind , placebo -controlled, multi -site, proof  of concept trial 
to evaluate the efficacy and safety of LEO 138559  in adult subjects with moderate  to severe 
atopic dermatitis (AD).  
 
Phase 2a Proof of Concept  
This clinical trial will be conducted in compliance with the clinical trial protocol, ICH GCP, 
and the applicable regulatory requirement(s).  
 
 
 
 
 
 
 
 
LEO Pharma  A/S Trial ID:  LP0145 -1376 
 Date:   31-Jan-[ADDRESS_79350] n o: 2020 -005541 -16  
 Version:  4.0 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79351] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Clinical trial protocol statement s 
Approval statement LEO Pharma A/S  
Electronic signatures made within eTMF LEO Pharma are considered to be a legally binding 
equivalent of traditional handwritten signatures. The following persons have approved this 
clinical trial protocol  by [CONTACT_73276]:  
, MMath, PhD   
Biostatistics  lead, Medical Sciences   
  
, MD   
Vice president , Medical Sciences   
  
, MD , PhD   
Vice president , Translational Medicin e  
  
, PhD  
Clinical operations lead, Global Clinical Operations   
  
, MD   
Signatory investigator   
 
 
 
 
 
 
Acknowledge ment statement investi gators  
Each participating investigator must agree to the approved clinical t rial protocol by [CONTACT_2960] a  
clinical trial protocol acknowledgement form or similar document . 
TMF-000616809 - Version 4. 0
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79352] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Protocol amendment summary  
Document history  
Document  Date  Type of protocol amendment  
Amendment  3 (substantial)  31-Jan-2022  Global  
Amendment  2 (non-substantial)  17-Nov-2021  Global  
Amendment  1 (substantial)  07-May-2021  Global  
Original protocol  12-Mar-2021  NA 
Abbreviations : NA  = not applicable.  
Note that protocol amendment summary of changes table s for the previous amendment s are 
provided in  Appendix10 . 
Amendment  3 (31-Jan-2022 ) 
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council of the Europe an Union 
or subsequent regulation .  
Overall rationale for the amendment  
The main purpose for this protocol amendment is to change the event of a positive 
SARS -CoV-[ADDRESS_79353] (COVID -19) from  leading to permanent discontinuation of IMP 
(Section  10.2.1 ) to leading to a possible temp orary discontinuation of IMP  (Section  10.2.2 ).  
At the time of protocol preparation , COVID -[ADDRESS_79354], the COVID -19 situation in many countries including [LOCATION_013], Poland, 
US, and Canada, has changed. At the beginning of the pandemic, t he number of infected 
patients was lower than now , but with a higher risk of severe illness. Now , a very high number 
of new ly infected people each day is observed (possibly due to a combination of more 
contagious mutations and a higher test capacity), but with an overall lower number of patients 
with severe illness (possibly due to the introduction of vaccines and virus variants leading to 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79355] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
milder sympt oms in the majority of the infected people). Based on this, a potential safety 
concern for the patients in relation to SARS CoV -2 infection is now reduced.  
The observed development in the SARS CoV -2 infection rate s, result s in a risk of a potential 
higher trial attrition rate than previously expected. With the current knowledge of COVID -19 
disease course, presenting with many cases of mild disease , it is considered reasonable to not 
per default discontinue subjects with a SARS CoV -2 infection  from IMP treatme nt. Based on  
local guidelines and regulations on handling of SARS  CoV-2 infection , it is considered 
relevant to allow temporary, instead of per default permanent discontinuation of IMP similar 
to other COVID -19 related disruptions ( Section 10.2.2  and Appendix  9). Note  that as per 
investigator discretion, the IMP can still be permanently discontinued.  
Introducing this amendment increases  the possibility of retain ing patients  in the trial, thereb y 
fulfilling our ethical obligation to all the participating subjects  and investigators . Furthermore, 
the amendment does not affect the total number of subjects , statistical analysis , and 
interpretation of the trial results, and has no impact on patient safety, thus no impact on the 
scientific value or integrity of the trial.  
All changes to the protocol are presented in the summary of changes table below except for a 
few minor editori al changes (e.g. spelling errors).  
Summary of changes  
Section no. and name  [CONTACT_18054] 9.[ADDRESS_79356] complaints  Fax number: +45  7226 3287 6910  2468  Editorial.  
Section 10.2.1  Reasons 
for permanent 
discontinuation of IMP  • Infection with SARS -CoV -2 (COVID -19). Due to change in the global SARS 
CoV -2 (COVID -19) situation.  
Section 10.2.2  Reasons 
for temporary  
discontinuation of IMP  • COVID -19 related disruption leading to 
site closure . Due to change in the global SARS 
CoV -2 (COVID -19) situation.  
Section 13.4.1  
Investigator reporting 
responsibilities  Fax number: [PHONE_1766]  [ADDRESS_79357] 
and data confidentiality  Processing of personal data on behalf of 
LEO Pharma requires a written agreement 
between LEO Pharma and the relevant party 
which covers collection, processing, a nd 
transfer of personal data in the clinical trial 
as well as reporting obligations in the 
event of any data breach . In certain cases, 
an agreement on transfer of personal data 
may also be required.  Editorial.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79358] testing positive  for 
COVID -19 after randomisation may be 
temporarily discontinued from IMP . IMP 
treatment may be reinstitute d at the 
investigator ’s discretion.  Due to change in the global SARS 
CoV -2 (COVID -19) situation.  
Appendix  10 Protocol 
amendment history  Protocol amendment 2, Summary of changes 
table moved to Appendix  10. Editorial.  
Appendix  10 Protocol 
amendment history  Amendment 2 (1 97-Nov-2021)  Editorial.  
 
TMF-000616809 - Version 4. 0
Trial ID: LP01 45-1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79359]  ................................ ....................  32 
5.3 Trial rationale  ................................ ................................ ................................ ..............  34 
5.4 Ethical considerations  ................................ ................................ ................................ . 34 
5.5 Benefit/risk assessment  ................................ ................................ ...............................  [ADDRESS_79360] treatment  ................................  52 
9.4 Background treatment (emollients)  ................................ ................................ ............  53 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79361] to follow -up ................................ ................................ ................................ ........  62 
11 Trial assessments and procedures  ................................ ................................ ....................  64 
11.1 Overview ................................ ................................ ................................ .....................  64 
11.2 Assessments performed only at screening/baseline  ................................ ....................  65 
11.2.1  Demographics ................................ ................................ ................................  65 
11.2.2  Body assessment (height)  ................................ ................................ ..............  65 
11.2.3  Medical history  ................................ ................................ ..............................  65 
11.2.4  Other assessments  ................................ ................................ .........................  66 
11.3 Efficacy assessments  ................................ ................................ ................................ .. 66 
11.3.1  Eczema Area and Severity Index (EASI)  ................................ ......................  66 
11.3.2  Validated Investigator Global Assessment Scale for Atopic Dermatitis 
(vIGA -AD) ................................ ................................ ................................ .... 68 
11.3.3  Body surface area involvement  ................................ ................................ ..... 68 
11.3.4  Patient -reported outcomes  ................................ ................................ .............  69 
11.4 Safety assessments  ................................ ................................ ................................ ...... 70 
11.4.1  Vital signs  ................................ ................................ ................................ ...... 70 
11.4.2  Physical examination ................................ ................................ .....................  71 
11.4.3  Weight  ................................ ................................ ................................ ...........  72 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79362]  ................................ ................................ . 89 
13.6.2  Overdose ................................ ................................ ................................ ........  89 
13.6.3  Medication error  ................................ ................................ ............................  90 
13.6.4  Misuse or abuse  ................................ ................................ .............................  90 
13.6.5  Aggravation of condition  ................................ ................................ ..............  91 
13.7  Follow -up for final outcome of adverse events  ................................ ..........................  91 
13.8  Handling of an urgent safety measure  ................................ ................................ ........  91 
14 Statistical methods  ................................ ................................ ................................ .............  93 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79363] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
14.1  Sample size  ................................ ................................ ................................ .................  93 
14.2  Trial analy sis sets  ................................ ................................ ................................ ........  93 
14.3  Statistical analysis  ................................ ................................ ................................ ....... 94 
14.3.1  General principles  ................................ ................................ .........................  94 
14.3.2  Handling of missing values  ................................ ................................ ...........  94 
14.3.3  Handling of intercurrent events related to the COVID -19 pandemic  ...........  95 
14.3.4  Disposition of subjects  ................................ ................................ ..................  96 
14.3.5  Demographics and other baseline characteristics ................................ ..........  96 
14.3.6  Exposure and treatment compliance  ................................ .............................  96 
14.3.7  Testing strategy  ................................ ................................ .............................  96 
14.3.8  Analysis of primary endpoint  ................................ ................................ ........  97 
14.3.9  Analysis of secondary endpoint  ................................ ................................ .. 105 
14.3.10  Analysis of exploratory efficacy endpoints  ................................ .................  105 
14.3.11  Analysis of patient -reported outcomes  ................................ ........................  106 
14.3.12  Analysis of pharmacodynamics  ................................ ................................ .. 107 
14.3.13  Exploratory analyses  ................................ ................................ ...................  107 
14.3.14  Analysis of safety  ................................ ................................ ........................  107 
14.3.15  Analysis of pharmacokinetics  ................................ ................................ ..... 110 
14.3.16  Interim analysis  ................................ ................................ ...........................  110 
15 References  ................................ ................................ ................................ ..........................  111 
Appendix 1: Definitions of adverse events and serious adverse events  ...........................  118 
Appendix 2: Classification of adverse events  ................................ ................................ ..... 120 
Appendix 3: Trial governance considerations  ................................ ................................ ... 124 
Appendix 3A: Regulatory and ethical considerations  ................................ ..............  124 
Appendix 3B: Informed consent process  ................................ ................................ . 125 
Appendix 3C: Subject and data confidentiality  ................................ .......................  125 
Appendix  3D: Record keepi[INVESTIGATOR_007], quality control, and data handling  .........................  127 
Appendix 3E: Registration, reporting, and publication policy  ................................  130 
Appendix 3F: Insurance  ................................ ................................ ...........................  131 
Appendix 3 G: Financial disclosure  ................................ ................................ ..........  131 
Appendix 3H: Committee structure  ................................ ................................ .........  131 
Appendix 3I: Trial and trial site closure  ................................ ................................ ... 131 
Appendix 3J: Responsibilities  ................................ ................................ ..................  132 
Appendix 4: AAD Consensus Criteria for the diagnosis of AD  ................................ ........  133 
Appendix 5: Guidance for anaphylaxis diagnosis  ................................ .............................  135 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79364] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Appendix 6: Country -specific requirements  ................................ ................................ ...... 137 
Appendix  7: Short version and justification for eligibility criteria  ................................ . 138 
Appendix 8: Contact [CONTACT_4111]  ................................ ................................ ................................ ...... 143 
Appendix  9: COVID -19 pandemic contingency plan ................................ ........................  144 
Appendix  10: Protocol amendment history  ................................ ................................ ....... 146 
 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376 Date: 31-Jan-2022  Version: 4.[ADDRESS_79365] of panels 
Panel 1:  Trial design  ................................ ................................ ................................ .................  20 
Panel 2:  Schedule of trial procedures  ................................ ................................ .......................  21 
Panel 3:  Objectives and endpoints  ................................ ................................ ...........................  38 
Panel 4:  Identification of investigational medicinal products  ................................ ..................  49 
Panel 5:  Prohibited medication(s) and/or procedure(s)  ................................ ............................  56 
Panel 6:  Sequence of assessments  ................................ ................................ ............................  64 
Panel 7:  Calculation of the Eczema Area and Severity Index  ................................ ..................  67 
Panel 8: Eczema Area and Severity Index severity score scale and area score scale  ..............  67 
Panel 9 : Validated Investigator Global Assessment Scale for Atopic Dermatitis  ....................  68 
Panel  10: Clinical laboratory tests  ................................ ................................ ............................  74 
Panel 11: Adverse events of special interest ................................ ................................ .............  89 
Panel 12: Objective and estimands for primary endpoint  ................................ ........................  98 
Panel 13:  Handling of intercurrent events and analyses of estimands for the primary endpoint
 ................................ ................................ ................................ ........................  104 
 
 
 
 
 
 
 
 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79366]  
ANCOV A  analysis of covariance  
anti-HBc hepatitis  B core antibody  
anti-HBs hepatitis  B surface antibody  
BCC  basal cell carcinoma  
BP blood pressure  
BMI  body m ass index  
BSA  body surface area  
CCL17  chemokine (C -C motif) ligand 17  
CDISC  Clinical Data Interchange Standards Consortium  
CI confidence interval  
CMH Cochran –Mantel –Haenszel  
CMO  contract manufacturing organisation  
CONSORT  Consolidated Standards of Reporting Trials  
COVID -[ADDRESS_79367] 50% reduction in EASI score  
EASI  [ADDRESS_79368] 75% reduction in EASI score  
EASI  [ADDRESS_79369] 90% reduction in EASI score  
ECG  electrocardiogram  
eCRF  electronic case report form  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79370] visit  
GCP  Good Clinical Practice  
GINA  Global Ini tiative for A sthma  
HbsAg hepatitis  B surface antigen  
HCP  healthcare professional  
HIV human immun odefi ciency virus  
HRQoL health -related quality of life  
ICF informed consent form  
ICH International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use  
ID identification number  
IEC independent ethics committee  
IFN- γ interferon gamma  
IGA Investigator ’s Global Assessment  
IgE immunoglobulin E  
IgG immunoglobulin G  
IgM immunoglobulin M  
IL interl eukin  
IL-10R2 interleukin [ADDRESS_79371]  
IND Investigational New Drug  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79372]  
IRT interactive response technology  
IUD intrauterine device  
IUS intrauterine hormone -releasing system  
IV Intravenous (ly) 
JAK janus kinase inhibitor  
JP Japan  
KLH  keyhole limpet hemocyanin  
LEO [ADDRESS_79373] level  
NRI non-responder imputation  
NRS  numeric rating scale  
PCR  polymerase chain reaction  
PD pharmacodynamics  
PDE -4 phosphodiesterase -4  
PEF peak expi[INVESTIGATOR_73198] -Oriented Eczema Measure  
[COMPANY_003] purified protein derivative  
PRO  patient -reported outcome  
Q2W  every second week  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79374] on an ECG tracing  
RNA  ribonucleic acid  
rRNA  ribosomal RNA  
SAD  single ascending dose  
SAE  serious adverse event  
SARS -CoV-2 severe acute respi[INVESTIGATOR_6507] 2  
SC Subcutaneous (ly) 
SCC  squamous cell carcinoma  
SD standard deviation  
SDTM  standard data tabulation model  
SOC  system organ class  
STAT  signal transducer and activator of transcription  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
TARC  thymus and activation -regulated chemokine  
TCI topi[INVESTIGATOR_73199](s)  
TCS topi[INVESTIGATOR_11977](s)  
Th2 T-helper [ADDRESS_79375]  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79376] no.  
IND no . LP01 45-1376 
2020 -005541 -16 
04922021  
146054  
Title of trial  A phase 2a, randomised, double -blind, placebo -controlled, multi -site, proof  of 
concept trial to evaluate the efficacy and safety of LEO 138559 in adult 
subjects with moderate  to severe atopic dermatitis (AD).  
Short title of trial  An evaluation of LEO 138559 in adults with moderate  to severe atopic 
dermatitis . 
Main objectives 
and endpoints   Objectives  Endpoints  
Primary objective  Primary endpoint  
To compare the efficacy of 
LEO  138559 with placebo 
in subjects with moderate  
to severe AD.  • Change in Eczema Area and Severity 
Index (EASI1) score from baseline to 
Week 16.  
Secondary objective  Secondary endpoints  
To compare the safety of 
LEO 138559 with placebo in 
subjects with moderate  to 
severe AD.  • Number of treatment -emergent adverse 
events from baseline to Week [ADDRESS_79377].  
 
1 The EASI is a validated measure used in clinical practice and clinical trials 
to assess the severity and extent of AD. The EASI is a composite index with 
scores ranging from 0 to 72, with higher values indicating more severe  
and/or  more extensive conditio n. 
 
Final collection of 
data for the 
primary endpoint  Week 16  
Trial design  The trial design is illustrated in the figure below:  
 
 
aScreening phase of up to 4 weeks (Weeks -4 to 0) including a washout phase of 
1 week (Week -1 to 0). Subjects must stop treatment with TCS, TCI, topi[INVESTIGATOR_22732] -4 
inhibitors, or other topi[INVESTIGATOR_73200] 1 week prior to randomisation . All 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79378] use an emollient twice daily (or more frequently , if needed) for at least 
7 days before Day 1 (baseline) and throug hout the treatment period (until Week 16).  
bIn addition to the Q2W dosing schedule during the treatment phase, both treatment 
groups will receive an additional dose of their allocated treatment (LEO 138559 
450 mg or placebo) at Visit 4 (Week 1).  
cA 16 -weeks safety follow -up period including 3 phone visits at V isits 1 3, 14, and 1 5 
(Weeks 20, 24, and 28 ), and 1 safety follow -up visit at the site at Visit 16 ( Week 32 ). 
Abbreviations:  PDE -4 = phosphodiesterase -4; Q2W = every second week; TCI = 
topi[INVESTIGATOR_73199](s); TCS = topi[INVESTIGATOR_11977](s).  
 
The trial will consist of a screening period of up to  4 weeks (Weeks -4 to -0) 
including an applicable  washout period of 1 week ( Week  -1 to 0), a treatment 
period of 16 weeks (Weeks 0 to 16), and a 16-week s off-treatment follow -up 
period for the assessment of safety and anti-drug antibodies ( ADA ) (Weeks 16 
to 32).  
After providing informed consent and successful completion of the screening 
and washout period,  subjects will be randomised in a 1:[ADDRESS_79379] will receive  SC 
injections (each  mL) of  mg LEO 138559 or placebo to receive a total 
dose of 450 mg LEO 138559 (  mL) or placebo   mL) . In addition to this 
Q2W dosing schedule,  both treatment groups will receive an additional dose of 
their allocated treatment (LEO 138559 450 mg or placebo)  at Visit 4 (Week 1) . 
Randomisation will be stratified by [CONTACT_73277] ; one 
stratum , ‘stratum A’, will be defined as having EASI <21 and the other stratum, 
‘stratum B’, will be defined as having EASI ≥21.  
During the treatment period, final dosing will be administered at Week 14 , 
regardless of AD improvement.  Rescue treatment : if medically necessary ( i.e.,  
due to worsening of AD or intolerable AD symptoms), rescue treatment for AD 
in the form of TCS/TCI may be used from Week 4 at the discretion of the 
investigator.  The primary endpoint will be assessed at Week 16, and the final 
safety assessment will be conducted at Week 3 2. 
Main assessments  • EASI. 
• Treatment -emergent adverse events.  
Main criteria for 
inclusion  • 18-64 years  old (both included)  at screening . 
• Diagnosis of AD [as defined by [CONTACT_73278] (1)] that has 
been present for ≥1 year prior to screening.   
• Subjects who have a recent history (within 6 months before screening) of 
inadequate response to treatment with topi[INVESTIGATOR_73201], or for whom 
topi[INVESTIGATOR_12432].  
• EASI score ≥12 at screening and ≥16 at baseline . 
• vIGA -AD score ≥3 at screening and baseline.  
• Body surface area (BSA) of AD involvement ≥10% at screening and 
baseline.  
• Worst Daily Pruritus NRS (weekly average) of ≥3 points at baseline.  
Main criteria for 
exclusion  • Treatment with systemic immunosuppressive/immunomodulating 
medication, immunoglobulin/blood products, or phototherapy within 4 
weeks or 5 half -lives prior to randomisation, whichever is longer.  
TMF-000616809 - Version 4. 0
CCI
CCI
CCI
CCI
CCI
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79380] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
• Treatment with biologics within 5 half -lives (if known) or 16 weeks prior 
to randomisatio n, whichever is longer.  
• Treatment with TCS, TCI, topi[INVESTIGATOR_22732] -4 inhibitor , or other topi[INVESTIGATOR_73202] 1 week prior to randomisation.  
• Treatment with a live (attenuated) vaccine within 12 weeks prior to 
randomisation.  
• Clinically significant active chronic or acute infection requiring systemic 
treatment within [ADDRESS_79381].  
• Skin infection within 1 week prior to randomisation . 
• Presence of hepatitis B or C infection at screening.  
• History of human immunodeficiency virus (HIV) infection or positive HIV 
serology at screening.  
• Subject has a positive or indeterminate test for tuberculosis at screening . 
• Subject is pregnant or lactating.  
Investigational 
medicinal 
product s  • Name [CONTACT_73377]: LEO 138559.   
• Active substance : LEO 138559,  mg/mL (following reconstitution).  
• Dosage form : Lyophilised powder for reconstitution (using 1.0  mL 
sterili sed water)  adding up to a volume of 1.2 mL/vial.  
• Concentration :  mg/mL.  
• Dose and frequency : 450 mg Q2W  ( injections of  mg /mL). 
• Method of administration:  Subcutaneous . 
 
• Name [CONTACT_73377]: Placebo . 
• Active substance: Placebo contains the same excipi[INVESTIGATOR_73203] 138559 only lacking the active ingredient . 
• Dosage form:  Solution for injection  (contains 1.2  mL/vial). 
• Concentration: Not applicable.  
• Dose and frequency: Not applicable and  injections of  mL placebo 
solution Q2W. 
• Method of administration:  Subcutaneous . 
Duration of trial 
participation  Up to 3 6 weeks  
Number of 
subjects  A total of 52 subjects will be randomised 1:1 to: 
• LEO 138559 450  mg Q2W (26 subjects).  
• Placebo Q2W  (26 subjects).  
Number and 
distribution of 
trial sites  Approximately  20 sites in Canada , [LOCATION_013],  Poland , and  the US.  
Statistical 
methods  Primary and secondary endpoints:  All subjects randomized and exposed to IMP 
will be included in the full analysis set ( FAS) and will be analysed for the 
primary endpoint, based on  treatment assigned. All subjects who will be 
exposed to IMP will be included in the safety analysis set and will be analysed 
for the secondary endpoint, based on actual treatment received.  
TMF-000616809 - Version 4. 0
CCI
CCI
CCI
CCI
CCI
CCI
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79382] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
 A primary and 3  supplementary estimands will be defined for the primary 
endpoint to ensure that occurrence of intercurrent events is taken into account.  
• The primary estimand for the primary endpoint w ill use a hypothetical  
strategy which attempts to quantify the effect of treatment, in the 
hypothetical situation, where one  or more intercurrent events do not 
occur.  
• A first supplementary estimand will use a composite  strategy which 
accounts for occurrenc e of pre -defined intercurrent events (initiation of 
rescue treatment and permanent discontinuation of IMP) as a component 
of the endpoint.  
• A second supplementary estimand will use a pandemic -modified 
composite  strategy which follows a composite strategy for intercurrent 
events independent of the COVID -[ADDRESS_79383] of the randomised treatment as if the COVID -19 pandemic did 
not happen.  
• A third supplementary estimand will use a treatment polic y strategy 
which attempts to quantify the effect of the randomised treatment 
regardless of whether an intercurrent event occurs.  
For the primary analysis of the primary estimand , missing  data at Week  16 due 
to an intercurrent even t will be im puted using MI (100  iterations) assuming 
MAR within each treatment group and whether the subject has experienced a n 
intercurrent event. Within a given treatment group, observed data from subjects 
not experiencing an intercurrent event will be used to imput e missing data for 
subjects who experience an intercurrent event.  
For each of the 100 complete datasets after imputation , the change in EASI 
score from baseline to Week 16 will be analysed using an ANCOVA model 
adjusted for treatment, region, baseline EASI  score, and baseline disease 
severity. The pooled estimate of the difference in the LS -mean change from 
baseline, along with the associated 95%  CIs and nominal p -values will be 
presented based on applying Rubin’s rules to the estimates and standard errors 
from the ANCOVA analysis of the imputed datasets.  
The 3 supplementary estimands will be analysed using the same ANCOVA 
model with diff erent imputation methods for intercurrent events.   
The s econdary endpoint (number of treatment -emergent AEs from  baseline to 
Week  [ADDRESS_79384] ) will be reported descriptively by [CONTACT_1570] . 
Signatory 
investigator    
  
 
 
 [LOCATION_013]  
Sponsor  LEO Pharma A/S, Industriparken 55, DK 2750 Ballerup, Denmark  
TMF-000616809 - Version 4. 0
[COMPANY_003]
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79385] number:  [ADDRESS_79386] nu mber: 04922021  
IND number:  146054  
The clinical trial protocol will be registered in local registries if required by [CONTACT_19666] . 
3 Schematic of t rial design  
The trial design is illustrated in  Panel 1 and described in Section 7.1. 
Panel 1: Trial design  
 
 
aScreening phase of up to 4 weeks (Weeks -4 to 0) including a washout phase of 1 week (Week -1 to 0). Subjects 
must stop treatment with TCS, TCI, topi[INVESTIGATOR_22732] -[ADDRESS_79387] use an emollie nt twice daily (or more frequently , if needed) for at least 
7 days before Day 1 (baseline) and throughout the treatment period (until Week 16).  
bIn addition to the Q2W dosing schedule during the treatment phase, both treatment groups will receive an 
additi onal dose of their allocated treatment (LEO 138559 450 mg or placebo) at Visit 4 (Week 1).  
cA 16 -weeks safety follow -up period including 3 phone visits at Visits 1 3, 14, and 1 5 (Weeks 20, 24, and 28 ), 
and 1 safety follow -up visit at the site at Visit 16 (Week 32 ). 
Abbreviations:  PDE -4 = phosphodiesterase -4; Q2W = every second week; TCI = topi[INVESTIGATOR_22776](s); TCS = topi[INVESTIGATOR_73204](s) . 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79388] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
4 Schedule of trial procedures  
Panel 2: Schedule of trial procedures  
 
Screeninga) 
Washouta) 
Baseline/  
Start of treatment  
Treatment 
 
End of treatmentb) 
Primary endpointc) 
SFU phone calls  
SFU site visitd) 
Early IMP 
termination, if 
applicablee) 
Unscheduled. Visitf) 
 
 References (Section 
in protocol)  
 
Visit  1 2 3 4 5 6 7 8 9 10 11 12 13, 14, 15  16    
Week  -4 -1 0 1 2 4 6 8 10 12 14 16 20, 24, 28  32 
Day -28 -7 1 8 15 29 43 57 71 85 99 113 141, 169, 197  225 
Visit window  
(days)g)  NA NA NA ±1 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 
Trial population and eligibility  
Informed consenth)  X                Append ix 3B  
Subjects eligibility  X  X              8.2 and 8.3 
Investigator assessments at screening and/or baseline only  
Demographicsi) X  X              11.2.1  
Body assessment 
(height )  X                11.2.2  
Medical historyj) X  X              11.2.3  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79389] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
 
Screeninga) 
Washouta) 
Baseline/  
Start of treatment  
Treatment 
 
End of treatmentb) 
Primary endpointc) 
SFU phone calls  
SFU site visitd) 
Early IMP 
termination, if 
applicablee) 
Unscheduled. Visitf) 
 
 References (Section 
in protocol)  
 
Visit  1 2 3 4 5 6 7 8 9 10 11 12 13, 14, 15  16    
Week  -4 -1 0 1 2 4 6 8 10 12 14 16 20, 24, 28  32 
Day -28 -7 1 8 15 29 43 57 71 85 99 113 141, 169, 197  225 
Visit window  
(days)g)  NA NA NA ±1 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 
Hepatitis B, C, HIV  X  
              11.2.4  and 
Exclusion 
criteri on no. 
14 and 15 
Tuberculosis  
(Mycobacterium 
tuberculosis  IFN-γ 
release assay)k)  X  
              11.2.[ADDRESS_79390] (females only)l)  X  
             
 11.4.5  and 
Inclusion 
criteri on no. 
10 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79391] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
 
Screeninga) 
Washouta) 
Baseline/  
Start of treatment  
Treatment 
 
End of treatmentb) 
Primary endpointc) 
SFU phone calls  
SFU site visitd) 
Early IMP 
termination, if 
applicablee) 
Unscheduled. Visitf) 
 
 References (Section 
in protocol)  
 
Visit  1 2 3 4 5 6 7 8 9 10 11 12 13, 14, 15  16    
Week  -4 -1 0 1 2 4 6 8 10 12 14 16 20, 24, 28  32 
Day -28 -7 1 8 15 29 43 57 71 85 99 113 141, 169, 197  225 
Visit window  
(days)g)  NA NA NA ±1 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±[ADDRESS_79392]  X  
             
 11.2.4 , 
11.4.5 , and 
exclusion  
criterion 
no. 30 
Randomisation and treatments  
Randomisation    X              9.3 
IMP administration 
at the trial site    X Xm) X X X X X X X     (X) 9.2 
Treatment 
compliance at the 
trial site    
X X X X X X X X X     
(X) 9.8.4  
Drug accountability    X X X X X X X X X     (X) 9.8.3  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79393] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
 
Screeninga) 
Washouta) 
Baseline/  
Start of treatment  
Treatment 
 
End of treatmentb) 
Primary endpointc) 
SFU phone calls  
SFU site visitd) 
Early IMP 
termination, if 
applicablee) 
Unscheduled. Visitf) 
 
 References (Section 
in protocol)  
 
Visit  1 2 3 4 5 6 7 8 9 10 11 12 13, 14, 15  16    
Week  -4 -1 0 1 2 4 6 8 10 12 14 16 20, 24, 28  32 
Day -28 -7 1 8 15 29 43 57 71 85 99 113 141, 169, 197  225 
Visit window  
(days)g)  NA NA NA ±1 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 
Background 
treatment 
(emollients )n)   At least twice daily      9.4 
Concomitant 
medications/  
concurrent 
procedureso) X X X X X X X X X X X X X X X X 9.[ADDRESS_79394] assessments (eDiary)  
eDiary hand -out / 
training   X                
Return of eDiaryp)              X (X)   
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79395] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
 
Screeninga) 
Washouta) 
Baseline/  
Start of treatment  
Treatment 
 
End of treatmentb) 
Primary endpointc) 
SFU phone calls  
SFU site visitd) 
Early IMP 
termination, if 
applicablee) 
Unscheduled. Visitf) 
 
 References (Section 
in protocol)  
 
Visit  1 2 3 4 5 6 7 8 9 10 11 12 13, 14, 15  16    
Week  -4 -1 0 1 2 4 6 8 10 12 14 16 20, 24, 28  32 
Day -28 -7 1 8 15 29 43 57 71 85 99 113 141, 169, 197  225 
Visit window  
(days)g)  NA NA NA ±1 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 
Investigator assessment s of efficacy  
EASI  X  X X X X X X  X  X  X (X) (X) 11.3.1  
vIGA -AD X  X X X X X X  X  X  X (X) (X) 11.3.2  
BSA involvement  X  X X X X X X  X  X  X (X) (X) 11.3.[ADDRESS_79396] Daily Pruritus  
NRSq)  Daily    [IP_ADDRESS]  
POEMr)   X X X X X X  X  X   (X) (X) [IP_ADDRESS]  
DLQIr)   X X X X X X  X  X   (X) (X) [IP_ADDRESS]  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79397] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
 
Screeninga) 
Washouta) 
Baseline/  
Start of treatment  
Treatment 
 
End of treatmentb) 
Primary endpointc) 
SFU phone calls  
SFU site visitd) 
Early IMP 
termination, if 
applicablee) 
Unscheduled. Visitf) 
 
 References (Section 
in protocol)  
 
Visit  1 2 3 4 5 6 7 8 9 10 11 12 13, 14, 15  16    
Week  -4 -1 0 1 2 4 6 8 10 12 14 16 20, 24, 28  32 
Day -28 -7 1 8 15 29 43 57 71 85 99 113 141, 169, 197  225 
Visit window  
(days)g)  NA NA NA ±1 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 
Investigator assessments of safety  
Vital signss) X  X X X X X X X X X X  X (X) (X) 11.4.1  
Physical 
examination  X  X   X  X  X  X  X (X) (X) 11.4.2  
Weight  X           X  X (X) (X) 11.4.3  
ECGt) X  X   X  X  X  X  X (X) (X) 11.4.4  
Clinical c hemistry, 
haematology 
(central laboratory)   X  
X  X X  X  X  X  X (X) (X) 11.4.5  
IgE   X   X      X  X (X) (X) 11.4.5  
Urinalysisu) X  X   X  X  X  X  X (X) (X) 11.4.5  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79398] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
 
Screeninga) 
Washouta) 
Baseline/  
Start of treatment  
Treatment 
 
End of treatmentb) 
Primary endpointc) 
SFU phone calls  
SFU site visitd) 
Early IMP 
termination, if 
applicablee) 
Unscheduled. Visitf) 
 
 References (Section 
in protocol)  
 
Visit  1 2 3 4 5 6 7 8 9 10 11 12 13, 14, 15  16    
Week  -4 -1 0 1 2 4 6 8 10 12 14 16 20, 24, 28  32 
Day -28 -7 1 8 15 29 43 57 71 85 99 113 141, 169, 197  225 
Visit window  
(days)g)  NA NA NA ±1 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±[ADDRESS_79399] 
(females only)l)    X   X  X  X  X  
 X (X) (X) 11.4.5  
ADA    X   X  X  X  X  X (X) (X) 11.4.6  
Adverse events  X X X X X X X X X X X X X X X X 13 
Pharmacokinetic assessment  
PK b lood sample s   X X X X X X X X X X  X (X) (X) 11.5 
Pharmacodynamic assessments  
Blood biomarkers 
(PD se rum sample)    X  X X  X    X   (X) (X) 11.6.2  
Skin swabs    X         X   (X) (X) 11.6.3  
Tape strips    X         X   (X) (X) 11.6.4  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79400] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
 
Screeninga) 
Washouta) 
Baseline/  
Start of treatment  
Treatment 
 
End of treatmentb) 
Primary endpointc) 
SFU phone calls  
SFU site visitd) 
Early IMP 
termination, if 
applicablee) 
Unscheduled. Visitf) 
 
 References (Section 
in protocol)  
 
Visit  1 2 3 4 5 6 7 8 9 10 11 12 13, 14, 15  16    
Week  -4 -1 0 1 2 4 6 8 10 12 14 16 20, 24, 28  32 
Day -28 -7 1 8 15 29 43 57 71 85 99 113 141, 169, 197  225 
Visit window  
(days)g)  NA NA NA ±1 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 
End of treatment/trial  
End-of-treatment 
form             X   X  11.7 
End-of-trial form               X X  11.7 
a) Screening will be performed  up to 4 weeks before the baseline visit and can be  combined with the washout visit  (Visit 2) if needed.  
b) An end-of-treatment form must be completed in the eCRF for all randomised subjects. See Section  11.7 for further details.  
c) Subjects who permanently discontinue IMP treatment prior to Week 16 will be asked to return to the trial site at Week 16 for a primary endpoint (nomin al 
Week  16) visit.  
d) An end -of-trial form must be completed in the eCRF for all randomise d subjects . See Section  11.7 for further details.  
e) Subjects who permanently discontinue IMP prior to Week 16 and subjects who withdraw from the trial will be asked to come to a n early termination visit and 
will be followed up as described in Section 10.3. As an early termination  visit will on ly be performed in case of subjects permanently discontinuing the IMP, 
the visit  has been marked with an  (X).  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79401] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
f) Unscheduled visit(s) between planned visits may be added to the subject’s visit schedule if judged necessary by [CONTACT_093], e.g. , due to an AE, a 
significant change in disease state, or difficulty complying with the clinical trial protocol  requirements. At an unscheduled visit, the investigator should at least 
collect AEs data. Other assessments/procedures to be conducted at an unscheduled visit will be at the discretion of the investi gator.  As unscheduled  visits will 
only be performed i f judged necessary by  [CONTACT_093] , the visits have  been marked with an  (X).  
g) If the date of a trial visit does not conform to the clinical trial protocol, subsequent visits should be planned to maintain  the visit schedule relative to 
randomisation/baseline.  
h) The informed consent form must be signed prior to performing any protocol -related procedures, including but not limited to screening evaluations and washout 
of disallowed medications.  
i) At screening, the demographic data listed in Section 11.2.1  will be recorded. At baseline, only age will be recorded.  
j) In case medical history is incomplete at the screening visit, missing data will be retrieved at Week  0 (baseline).  
k) Mycobacterium tuberculosis  IFN-γ release assay (or a [COMPANY_003] test if it is a requirement from the local health authorities ). 
l) For women of childbearing potential (as defined in inclusion criterion no . 10 and 11, Section 8.2). 
m) In addition to the Q2W dosing schedule, both treatment groups will receive an additional dose of LEO 138559 450  mg or placebo  at Week 1 .  
n) All subjects must use an emollient twice daily (or more  frequently , if needed) for at least 7 days before Day 1 (baseline) and throughout the treatment period 
(until Week 16).  
o) Relevant concomitant medication s/ concurrent procedures  should be included from 3 months prior to screening  until end of trial  (Week 32) . 
p) At Week  32, subjects will be asked to bring the eDiary back to the clinic.  
q) Completion of the eDiary for Worst Daily Pruritus  NRS  will be initiated at least 1 week prior to baseline (Day 1 ). Compliance with the eDiary completion will 
be reviewed by [CONTACT_73279]. Subjects who discontinue IMP but remain in the trial will continue completing the eDiary until the safety 
follow -up visit (Visit 16) . 
r) At the screening visit (at the earliest  Week -4), the subject's eligibility to participate in the trial must be confirmed before any PRO s are completed. PROs will 
be collected in the electronic device at the trial site  and should  be completed before the investigator’s assessment of efficacy.   
s) For the first 3 IMP treatment visits (i.e. , Visits 3, 4, and 5) subjects will be monitored after IMP administration for immediate drug reactions for a minimum of 
1 hour with vital signs taken immediately after IMP administration as well as after 30 minutes (± 5 minutes) and after 1 hour  (± 5 minutes), or until stable, 
whichever is later.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79402] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
t) ECG should be recorded in triplicate for each time point and  will be centrally evaluated . 
u) Urinalysis is performed by a urine dipstick. The analytes listed in Section 11.4.5  will only be  measured if the urine dipstick is abnormal.   
 
Abbreviations : ADA  = anti-drug antibodies; AE = adverse event ; BSA = body surface area;  DLQI  = Dermatology Life Quality Index;  EASI  = Eczema Area 
and Severity Index ; ECG  = electrocardiogram; eCRF = electronic case report  form ; HIV = human immunodeficiency virus; HRQoL = health related quality of 
life; IFN -γ = interferon gamma; IgE = immunoglobulin  E; IMP = investigational medicinal product;  NRS = Numeric  Rating Scale;  PCR  = polymerase chain 
reaction ; PD = pharmacodynamic s; PK = pharmacokinetics; POEM  = Patient -Oriented Eczema Measure ; [COMPANY_003] = purified protein derivative ; PRO = patient -
reported outcome; Q2W = every second  week ; SARS -CoV-2 = severe acute respi[INVESTIGATOR_6507]  2; SFU = safety follow -up; vIGA -
AD = validated Investigator Global Assessment Scale for Atopic Dermatitis .
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79403] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
5 Introduction and trial rationale  
5.1 Atopic dermatitis  
AD is a chronic inflammatory disease characteri sed by [CONTACT_73280], erythematous , and  xerotic 
lesions with exudation  at acute  stages and fissuring and lichenification at chronic  stages. The 
clinical course of AD typi[INVESTIGATOR_73205] a chronic, relapsing -remitt ing patter n with periods of 
worsening (‘flares ’). AD lesions are accompanied by [CONTACT_73281], sleep deprivation, mood changes, and lost productivity (2-4). 
AD is the most common inflammatory skin disorder with a lifetime prevalence of  
15–20% (5). While AD was initially thought to be a disease of  early childhood, more recent 
evidence demonstrates adult annual prevalence rates up to 10%, and 1 in 4 adults with AD 
report adult -onset disease (6, 7).  
AD is a heterogenous disease mediated by v arying degrees of epi[INVESTIGATOR_73206], 
immune cell activation, and microbiome dysbiosis. Epi[INVESTIGATOR_73207] 
(APCs ) and recruit Th2 cells and  innate lymphoid cells (8, 9). These cells amplify the type 2 
immune response by [CONTACT_73282] -4, IL -5, and IL -13 (10-12). As AD progresses from acute to 
chronic, a mixed T -cell infiltrate including Th17 and Th22 cells develops  (13). These  cells 
secrete IL -[ADDRESS_79404] been p urported to play a role in  AD pathogenesis  (14, 
15). Whether IL -22 is a key driver of AD pathog enesis remains unknown.  
Topi[INVESTIGATOR_73208], TCS, TCI, 
and PDE -4 inhibitors  (16). In addition, topi[INVESTIGATOR_73209] (cream) are in development for 
the treatment of AD  (17, 18) and the topi[INVESTIGATOR_73210] b (ointment)  has 
received marketing approval in Japan (19). If disease control cannot be achieved with topi[INVESTIGATOR_73211], pho totherapy can be considered (20). For patients with moderate  to severe AD, 
topi[INVESTIGATOR_73212] o r impractical, and therefore systemic 
therapy is indicated. Systemic non -biologic therapi[INVESTIGATOR_73213], azathioprine, 
methotrexate, and mycophenolate mofetil. Cyclosporine is approved for the treatment of 
severe AD in multiple European countries and Japan. However, its use is limited by [CONTACT_73283] -term therapy (>1 -2 years) is not recommended. In addition, 
azathioprine, methotrexate, and mycophenolate mofetil have demonstrated varying levels of 
efficacy (21, 22) and are used off -label. In 2017, the first biologic was approved for the 
treatment of moderate  to severe AD ( dupi[INVESTIGATOR_12458], anti -IL4Ra mAb) and there are several 
targeted biologic therapi[INVESTIGATOR_73214], lebrikizumab, and 
nemolizumab (23-25), as well as oral JAK inhibitors  (26-28) . Of note , baricitinib  was 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79405] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
recently  approved by [CONTACT_73284] (29), however , its 
position in the treatment paradigm is not ye t fully understood  (30).  
Despi[INVESTIGATOR_73215], approximately 60% of pati ents with AD do not 
achieve clinical remission (i.e. , IGA 0/1, clear/almost clear). Therefore, there is a remaining 
unmet need to develop new therapi[INVESTIGATOR_73216]. Further, it is increasingly 
recogni sed that AD is a phenotypi[INVESTIGATOR_73217]/or combined therapeutic approaches in order to adequately address the 
needs of moderate  to severe AD patients (31, 32). 
5.[ADDRESS_79406]  
Nonclinical  data  
LEO 138559 , original ly known as ARGX -112 (clone ), is a humani sed IgG1 mAb  with 
high affinity for the IL -22R1 chain of the IL-22R, thereby [CONTACT_73285], 
dimeri sation of IL -22R1 with IL -10R2, and downstream signal ling via JAK1-STAT3  (33). 
Given the binding of LEO  138559 to IL -22R1, it is hypothesi sed to prevent not only the 
effects of IL -22 but also partially  and . Further, LEO  138559 does not bind to 
IL-22BP , an endogen ous negative regulator of IL -22, and thereby [CONTACT_73286] -22BP free to 
further inhibit IL -22 cellular activity (34). Therefore, LEO [ADDRESS_79407].   
LEO 138559 has been modified to avoid Fc effector functions (binding of its Fc region to Fc 
receptors on e.g. , effector cells) that can induce unwanted effects of the IMP. It is expected 
that LEO 138559 Q2W will offer an acceptable safety profile in combination with an 
efficacious treatment option for the benefit of patients with  moderate to severe AD.  
Toxicology  
The LEO 138559 nonclinical studies conducted to date ( 4- and 26 -week repeat dose 
toxicology studies in cynomolgus monkeys  with 5 weekly SC or IV doses up to 100  mg/kg) 
showed no signs of local or systemic toxicities in nonhuman primates  (cynomolgus monkeys ).  
The LEO  138559 non clinical  data indicated a toxicity profile that is amenable to clinical 
monitoring, is of low concern for human risk, and provides an approximate -fold margin of 
exposure between the observed NOAELs and the exposure at steady state for 450  mg Q2W 
dosing (planned dosing regimen in LP0145 -1376 ). 
As expected for a m Ab drug, the non clinical  results d id not indicate a need to  perform 
specific clinical trials (typi[INVESTIGATOR_73218]) investigating effects on 
TMF-000616809 - Version 4. 0
CCI
CCI
CCI
CCI
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79408] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
QT prolongation, implication of hepatic or renal impairment and , cytochrome P450 
induction/inhibition potential.  
Based on nonclinical pharm acology an d toxicology studies, LEO [ADDRESS_79409] been identified which are included in the investigator ’s brochure  
(Section  7.3.2 ) (35). 
A detailed overview of nonclinical data on LEO 138559 is available in the current 
investigator ’s brochure (35). 
Clinical data  
LEO  [ADDRESS_79410]-in-human clinical trial : 
LP0145 -1315 . This is a phase 1, randomised, double -blind, placebo -controlled, multi -centre, 
SAD , and  MAD trial to evaluate the safety, tolerability, PK, and PD of LEO 138559 in 
healthy volunteers and subjects with moderate to severe AD.  The trial consists of 2 parts: 
SAD and MAD.  
To date in the LP0145 -[ADDRESS_79411] been ad ministered to healthy 
subjects. LEO 138559 or placebo are administered SC as once -weekly doses in healthy 
subjects (  mg) and in AD patients (  and  mg) for [ADDRESS_79412] been identified at the dose levels tested to date.   
Prior to LP0145 -1315 , there was no clinical experience o f administering of LEO 138559 to 
humans . However, the anti -IL-22 mAb fezakinumab (ILV -094, [COMPANY_007]) was well tolerated 
when IV administered  to AD patients and improved disease score s in patients with severe AD 
after 12  weeks in a phase 2a trial (36). Fezakinumab was also well tolerated in a safety and 
efficacy trial where it was administered SC in rheumatoid arthritis patients on a stable  
background of methotrexate  (37). 
Pharmac okinetics   
Based on the preliminary human PK data, the PK of LEO [ADDRESS_79413] a membrane -bound target, and the TMDD characteristics are also visible in 
the observed human data as it was in the cynomolgus data . 
TMF-000616809 - Version 4. 0
CCI
CCI
CCI
CCI
CCI
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79414] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
After SC administration, LEO 138559 is slowly absorbed with a mean time to maximum 
concentration of approximately  days. After multiple dosing, the elimination half -life was 
observed to be between  days. At and above the exposure level relevant for clinical 
testing (  mg Q2W), the elimination is dominated by [CONTACT_73287]-proportionality is expected at steady state.  The exposure at steady state following 
administration of 450 mg Q2W is expected to result in lower exposure than 450 mg every 
week  for 5  weeks  (the  in  the LP014 5-1315  trial). 
A detailed overview of clinical data on LEO 138559 is available in the current investigator ’s 
brochure (35). 
5.[ADDRESS_79415] via LEO 138559 may be an effective treatment in patients 
with moderate  to severe AD. The primary goal of the PoC trial will be to evaluate whether 
patients with moderate  to severe AD who are treated with LEO 138559 demonstrate  improved 
efficacy compared with placebo . 
5.4 Ethical considerations  
This trial will be conducted in accordance with the ethical principles originating from the 
Declaration of Helsinki (38) and ICH GCP (39) and in compliance with the approved protocol 
and applicable regulatory requirements.  
The trial design is considered scientifically justified and to adhere to ethical standards 
ensuring the rights, safety, and well -being of the subject. The efficacy and safety of 
LEO  [ADDRESS_79416] can discontinue IMP and/or wi thdraw 
from the trial at any time. If a subject is withdrawn from the trial, they will be treated at the 
discretion of the investigator or referred to (an)other physician(s) according to standard 
practice.  
Women who are pregnant (or trying to become pregna nt) and women who are breastfeeding 
will not be included in the trial. Women of childbearing potential must agree to use  a highly 
TMF-000616809 - Version 4. 0
CCI
CCI
CCI
CCI
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79417].    
5.5 Benefit/ risk assessment  
There is a clear unmet need for safe, long -term treatment options for subjects with moderate 
to severe AD. As a novel IL-22R antagonist, LEO [ADDRESS_79418]  AD.  
Risks to  subjects in the trial will be minimi sed by [CONTACT_73288] (Sections 8.1 to 8.3) and by [CONTACT_73289] (Section 4). Discontinuation and 
withdrawal criteria are also in p lace (Section 10.2).  
The subject will be informed that changes to their ongoing AD treatment may be required 
during the screening period up to Visit 6 (Week 4)  and that their condition may worsen as a 
result. To minimi se the negative consequences of this for the subject and ensure subject 
safety, investigators will be asked only to include subjects who are considered able to 
discontinue prohibited medications during the screening period without experiencing 
intolerable worsening of AD.  
The subject will also be informed of the possibility and probability of receiving active or 
placebo treatment. In this trial, approximately 50% of the subjects will receive active 
treatment with LEO [ADDRESS_79419] care.  
After randomi sation and if medically necessary (i.e. , due to worsening of AD or  intolerable 
worsening of AD symptoms), rescue treatment of AD may be provided to the subject after 
Week 4 at the discretion of the investigator. All subjects may receive rescue treatment, 
regardless of t reatment allocation (Section 9.5). The subject will be instructed to inform the 
investigator if their AD significantly worsens at any time during the trial.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79420] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Blood s ampling presents the same low risk as normally associated with this procedure (i.e. 
infection, bleeding into the surrounding tissue, and, very rarely, inflammation of the vein , or 
formation of blood clots). Blood sampling will only be conducted by [CONTACT_73290] d medical 
personnel.  Collection  of tape strip s and skin swab s are non-invasive technique s with no or 
very limited risks  to the subject . 
LEO Pharma has evaluated currently available safety data on LEO [ADDRESS_79421] of LEO 138559 on the immune response was performed in an immune -toxicological 
study in monkeys. The study concluded that KLH -specific antibody responses (IgG and IgM) 
to the first and second immuni sations with KLH occurre d in all animals. Importantly, no 
adverse effect on the ability to mount a humoral primary or memory response was noted in 
animals administered up to 100  mg/kg LEO 138559.  Further, n o indicators of 
immunosuppression (e.g. , haematological  changes, organ wei ghts, infections , and histology) 
were observed in 4 - and 26 -week nonclinical toxicology studies .  
Participation in any clinical trial is currently associated with increased risk and added 
challenges due to the COVID -19 pandemic caused by [CONTACT_7544] -CoV -2. The proposed trial and 
treatment with LEO 138559  are not believed to put subjects with AD under an increased risk 
for viral infections including SARS -CoV -2. However, the risk of exposure to infected people 
cannot be exclud ed as the trial subjects may need to expose themselves to public areas (e.g. , 
commute to the trial site) and have additional human contact (e.g. , with trial site staff).  Both 
EMA (40) and FDA  (41) as well as national health authorities in Europe have issued 
guidelines aiming at providing recommen dations for conducting clinical trials during the 
COVID -[ADDRESS_79422] 
infection with SARS -CoV -2 and to ensure integrity of the trial data (Appendix  9). A number 
of eligibility criteria have been added to reduce the risk of severe SARS -CoV -2 infections  
(Section s 8.1 to 8.3). 
During the trial, the investigators will be trusted to take appropriate action to ensure 
individual subject safety according to the recommendations and preventive measures issued 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79423] safety and the need for 
postponing/cancelling visits during the trial.  
However, safety monitoring is an obligation of LEO Pharma and in case the subject, due to 
local restrictions, is prevented from coming to the trial site, the investigator can convert 
on-site visit s into phone  visits  for the purpose of safety monitoring  (for details refer to 
Appendix  9). The phone  visits  must, however, not be used for the investigator’s assessments 
of efficacy. Other mitigation measures include POEM and DLQI  collected on the web-based 
solution  by [CONTACT_73291]  (see Appendix  3D).  
With the above provisions in place, the risks associated with participating in the trial are 
considered low and outweighed by [CONTACT_73292] a potential future SC treatment option for 
AD. The current benefit -risk profile is therefore deemed in favo ur of conducting the present 
trial. 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79424] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
6 Trial  objectives  and endpoints   
Trial objectives and endpoints are presented in Panel 3. An estimand framework is used for 
the primary endpoint to ensure that occurrence of intercurrent events is taken into account. 
Further details about the estimands and statistical analyses of the endpoints are presented in 
Section 14.3. 
Panel 3: Objectives and endpoints   
Objectives  Endpoints  
Primary objective   
To compare the efficacy of 
LEO  138559 with placebo in subjects 
with moderate  to severe AD.  Primary endpoint  
• Change in Eczema Area and Severity Index (EASI) 
score from baseline to Week 16.  
 
Exploratory  endpoints  (efficacy ) 
• Having a decrease in EASI of at least 50% (EASI 
50) from baseline to Week 16.  
• Having a decrease in EASI of at least 75% (EASI 
75) from baseline to Week 16.  
• Having a decrease in EASI of at least 90% (EASI 
90) from baseline to Week 16.  
• Having vIGA -AD score of 0 (clear) or 1 (almost 
clear) at Week 16.  
• Time to  having a decrease in EASI of at least 50% 
(EASI 50) between baseline and Week 16.  
• Time to having a decrease in EASI of at least 75% 
(EASI 75) between baseline and Week 16. 
• Time to having a decrease in EASI of at least 90% 
(EASI 90) between baseline and Week 16.  
• Time to initiation of TCI or TCS rescue treatment  
between baseline and Week 16.  
 
Exploratory  endpoints  (patient -reported outcomes)  
• Change in Worst Daily Pruritus NRS  (weekly 
average) from baseline to Weeks 1, 2, 4, 8, 12, and 
16. 
• Having a decrease  in Worst Daily Pruritus NRS  
(weekly average) of ≥3 points from baseline at 
Weeks 1, 2, 4, 8, 12, and 16, assessed separately . 
• Time to reduction of Worst Daily Pruritus NRS  
(weekly average) of ≥3 points  between baseline 
and Week 16 . 
• Having a decrease in  Worst Daily Pruritus NRS 
(weekly average) of ≥4 points from baseline at 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79425] Daily 
Pruritus NRS  ≥4 points.  
• Time to reduction of Worst Daily Pruritus NRS  
(weekly average) of ≥[ADDRESS_79426] 
Daily Pruritus NRS  ≥4 points.   
• Change in POEM score from baseline  to Week 16.  
• Change in DLQI from baseline to Week 16.  
Secondary objective   
To compare the safety of LEO 138559 
with placebo in subjects with moderate  
to severe AD.  Secondary endpoint  
• Number of treatment -emergent adverse events 
from baseline to Week [ADDRESS_79427].  
Exploratory  endpoint  (ADA)  
• Having a positive ADA response at Weeks 0, 4, 8, 
12, 16, 32, assessed separately.  
Exploratory objectives   
To evaluate the pharmacokinetics of 
LEO  138559 for 16  weeks in subjects 
with moderate to severe AD  Exploratory endpoint  (pharmacokinetics ) 
• Serum concentration of LEO [ADDRESS_79428] of treatment 
with LEO  138559  compared with 
placebo for 16  weeks on disease 
biomarkers in subjects with moderate 
to severe AD  Exploratory endpoints  (pharmaco dynamics ) 
• Change in expression of AD disease biomarkers in 
serum from baseline to Week 16. 
• Change in expression of AD disease biomarkers in 
skin from baseline to Week 16. 
Abbreviations : AD  = atopic dermatitis ; ADA = anti -drug antibodies;  DLQI = Dermatology Life Quality Index ; 
EASI = Eczema Area and Severity Index; EASI 50 = at least 50% decrease in  EASI  score; EASI 75 = at least 
75% decrease in  EASI score; EASI 90 = at least 90% decrease in EASI score; NRS = numeric rating scale; 
POEM = Patient -Oriented Eczema  
Measure ; TCI = topi[INVESTIGATOR_73199](s) ; TCS = topi[INVESTIGATOR_11977](s) ; vIGA -AD = Validated 
Investigator Global Assessment Scale for Atopic Dermatitis . 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79429] of :  
• A screening period of up to 4 weeks (Week s -4 to 0) including a n applicable  washout 
period of 1 week (Week -1 to 0) . 
• A treatment period of 16 weeks (Week s 0 to 16 ). 
• A follow -up period of 16 weeks  (Weeks 16 to 32) for the assessment of safety and ADA.  
Randomi sation will take place at Week 0. The primary endpoint will be assessed at Week 16. 
The final safety assessments will be conducted at Week 32 (end of trial) . 
The subject ’s visit schedule and the procedures and assessments to be conducted at each visit 
are presented in Section 4. The trial rationale is presented in Sectio n 5.3 and the scientific 
rationale for trial design is presented in Section 12.1. 
Screening period ( between 0 and 4 weeks prior to the baseline visit [Day 1 ]) 
In the screening period, eligibility of the subject  (Sections  8.1 to 8.3) to participate in the trial 
will be evaluated  at a screening visit (Visit 1) . This visit  will be performed up to 4 weeks 
before the baseline visit (Visit 3 ) and can be combined with the washout visit (Visit 2) if 
needed.  
At the washout visit (Visit 2, Week -1), subjects  will stop any treatment with TCS , TCI, 
PDE -4 inhibitors , or other topi[INVESTIGATOR_73200], and start application of an emollient 
to all affected areas of the skin twice daily (or more frequently , if needed) . The daily 
application of the emollient  should  continue  throughout the treatment period.  Moreover, at the 
washout  visit (Visit 2), t he subjects will receive training in completion of an eDiary  and will 
be given an electronic device to record the Worst Daily Pruritus NRS . To complete training of 
the eDiary , and  as an opportunity to fill out Worst Daily Pruritus NRS  before the treatment 
period, subjects will be asked to complete Worst Daily Pruritus NRS  at the visit. Completion 
of the eDiary will be initiated at the latest 1  week prior to the baseline visit ( Visit 3, Week 0 ). 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79430] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Randomi sation (Week  0) 
At baseline ( Visit 3 , Week 0 ), eligible subjects will be randomised 1:1 to 1 of 2 treatment 
groups: LEO 138559 or placebo. Randomisation will be stratified by [CONTACT_22789]. 
One stratum , ‘stratum  A’, will be defined as having  EASI <21 and the other stratum, 
‘stratu m B’, will be defined as having EASI ≥21. IRT will be used to control randomisation 
and stratification factors . 
Treatment period (Week 0 to Week 16)  
In the treatment period, LEO 138559  or placebo injection s will be administered at the site by 
[CONTACT_6624] Q2W  for 16 weeks (Section 9.2). In addition to this Q2W dosing schedule, both 
treatment groups will receive an additional dose of their allocated treatment (LEO [ZIP_CODE] 9 
450 mg or placebo) at Visit 4 (Week 1).  During the treatment  period, the subject will be asked 
to continue applying the emollient twice daily  (or more frequently , if needed) . The subject 
will also be asked to visit the clinic for assessments and procedur es. Final dosing will be 
administered at Week 14, regardless of AD improvement. If medically necessary (i.e.  due to 
worsening of AD or  intolerable AD symptoms), rescue treatment for AD in the form of 
TCS/TCI may be used from Week 4 at the discretion of the investigator.   
Safety follow -up period (Week 16 to Week 32) 
In the safety follow -up period, the subject will stop treatment with LEO [ADDRESS_79431]  will further be assessed at 3 safety f ollow -up phone 
calls (Weeks 20, 24 , and 28) and at a final safety follow -up visit at Week 32. Topi[INVESTIGATOR_73219] -up period.  
7.2 Number of subjects needed  
Based on an anticipated screening failure rate of 35%,  the planned number of subjects to 
screen is set to 80. 
At Week 0 (baseline), a total of 52 subjects will be randomi sed 1:1 to: 
• LEO 1 [ZIP_CODE]  450 mg (26 subjects).  
• Placebo ( 26 subjects).  
Based on an anticipated attrition rate of 30% in both treatment groups, this will provide a total 
of 36 subjects for analysis  (18 subjects per treatment group) . 
The trial will be conducted at approximately 20 sites in Canada, [LOCATION_013], Poland , and  the 
US.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79432] completed all periods of the 
trial including the safety follow -up visit at Week 32 (see Section 11.7 for data to be recorded 
on the end -of-trial form).  
The end of the trial is defined as the date of the last safety follow -up visit (Week 32) for the 
last subject in the trial globally . 
Final data collection for evaluation of the primary endpoint will occur at Week  16. Therefore, 
the primary completion date is defined as t he date of last Week  [ADDRESS_79433] in 
the trial globally.  
 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79434] ’s eligibi lity for the clinical trial must  be verified according to the inclusion and 
exclusion criteria at visits specified in  Section 4. It will be recor ded in the eCRF if the subject 
has met all the inclusion criteria and none of the exclusion criteria.  
Any implementation of national requirements/law for the subject ’s participation in the clinical 
trial will be ensured and described in submission document ation to regulatory authorities and 
IRBs/IECs , as applicable.   
8.[ADDRESS_79435] fulfil all of the following criteria:  
1. Signed and dated informed consent has been obtained prior to any protocol -related 
procedures.  
2. 18-64 years old  (both included ) at screening . 
3. Diagnosis of  AD [as defined by [CONTACT_73278] (1) and Appendix 4] that 
has been present for ≥[ADDRESS_79436] a recent history (within 6 months before screening) of inadequate 
response to treatment with topi[INVESTIGATOR_73201], or for whom topi[INVESTIGATOR_73220].  
• Inadequate response is defined as failure to ac hieve and maintain remission or a 
low disease activity state (comparable to IGA 0=clear to 2=mild) despi[INVESTIGATOR_73221] a daily regimen of TCS of medium to higher potency (±TCI as appropriate), 
applied for at least [ADDRESS_79437] prescribing information (e.g. , 14 days for super  potent TCS), whichever is 
shorter.  
• Subjects with documented systemic treatment  or phototherapy  for AD in the past 
6 months are considered as inadequate responders to topi[INVESTIGATOR_73222].  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79438] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
• Important side effects or safety risks are those that outweigh the potential 
treatment benefits and include intolerance to treatment, hypersensitivity reactions, 
significant skin atrophy, and systemic effects, as assessed by [CONTACT_73293] ’s treating physician.  
5. EASI score ≥12 at screening and ≥16 at baseline .  
6. vIGA -AD score ≥3 at screening and baseline.  
7. Body surface area (BSA) of AD involvement ≥10% at screenin g and baseline.  
8. Worst Daily Pruritus NRS  (weekly average) of ≥3 points at baseline.  
NOTE: The baseline weekly average will be calculated from daily assessments of itch 
severity during the [ADDRESS_79439] agree s to apply an emollient twice daily (or more frequently , if needed) to AD 
lesional and non -lesional skin for at least 7 days before baseline.  
10. A woman of childbearing potential * must have a negative serum pregnancy test at 
screening and a negative urine pregnancy test at baseline.  
11. A wom an of childbearing potential * must use a highly effective ** form of birth 
control throughout the trial and at least for [ADDRESS_79440] administration of IMP.  
* A woman of childbearing potential is defined as a female subject aged ≥12 years old 
or a younger girl who, at the discretion of the investigator, is deemed to be of 
reproductive potential.  A woman is defined as not being of childbearing potential if 
she is postmenopausal (at least 12  months with no menses without an alternative 
medical cause prior to screening), or surgically sterile (hysterectomy, bilateral 
salpi[INVESTIGATOR_1656], or bilateral ooph orectomy).  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79441] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
**A highly effective method of birth control is defined as one which results in a low 
failure rate (less than 1% per year) such as bilateral tubal occlusion, intrauterine 
device (IUD), intrauterine hormone -releasing system (IUS), combined ( oestr ogen - and 
progestogen -containing) hormonal contraception associated with inhibition of 
ovulation (oral, intravaginal, transdermal), progestogen -only hormonal contraception 
associated with inhibition of ovulation (oral, injectable, implantable), sexual 
abstinence (when this is in line with the preferred and usual life style of the subject 
and not just being without a current partner), same -sex partner,  or vasectomised 
partner (given that the subject is monogamous).  
8.[ADDRESS_79442] not enter  the trial if they fulfil any of the following exclusion criteria:  
1. Active dermatologic condition that could confound the diagnosis of AD or interfere 
with assessment of the treatment.  
2. Previously randomised in this clinical trial.  
3. Current participation in any other interventional clinical trial.  
4. Treatment with systemic immunosuppressive /immunomodulating medication , 
immunoglobulin /blood products , or phototherapy within 4 weeks or 5 half -lives prior 
to randomisation , whichever is longer . 
5. Treatment with biologics within 5 half -lives (if known) or 16 weeks prior to 
randomisation, whichever is longer.  
6. Treatment with TCS, TCI, topi[INVESTIGATOR_22732] -4 inhibitor , or other topi[INVESTIGATOR_73223] 1 week prior to randomisation.  
NOTE: Subject  may be rescreened (on ce) if failed for this criterion  (see Section  8.4). 
7. Treatment with a live (attenuated) vaccine within [ADDRESS_79443]. 
NOTE: Subject  may be rescreened (once ) after infection resolves  (see Section  8.4). 
10. Skin infection within 1 week prior to randomisation .  
NOTE: Subject  may be rescreened (once ) after infection resolves  (see Section  8.4). 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79444] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
11. Current or recent (within 2 years prior to randomisation ) gastrointestinal ulcers.  
12. History of any of the following: anaphylaxis, immune complex disease, pancreatic 
disease, inflammatory bowel disease , or known  or suspected history of 
immunosuppressive disorder.  
13. Known or suspected hypersensitivity to any component(s) of the IMP . 
14. Presence of hepatitis B or C infection  at screening. These are  defined as: 1) Positive 
hepatitis C Ab, or 2) Positive HBsAg, or 3) Negativ e anti -HBs Ab AND positive 
anti-HBc Ab. 
15. History of human immunodeficiency virus (HIV) infection or positive HIV serology at 
screening.  
16. Subject has a  positive  or indeterminate  Mycobacterium tuberculosis  IFN-γ release 
assay test  or a positive  purified protein derivative ([COMPANY_003]) test at screening .  
NOTE : The [COMPANY_003] test is only accepted if it is a requirement from local health 
authorities.  
17. Current d iagnos is of diabetes.  
18. Serious heart conditions (e.g. , heart failure, coronary artery disease, congenital heart 
disease, cardiomyopathies, and/or pulmonary hypertension).  
19. Chronic lung diseases (e.g. , chronic obstructive pulmonary disease, idiopathic 
pulmonary fibrosis, and/or cystic fibrosis).  
20. Moderate to sev ere asthma [as defined by G INA guidelines  (42)]. 
21. Obesity (BMI  ≥35). 
22. Subject has laboratory abnormalities  that, in the opi[INVESTIGATOR_871], will 
prevent the subject from completing the trial or interfere with the analysis of results . 
23. Subject is pregnant or lactating . 
24. Subject has a history of chronic alcohol or drug abuse within [ADDRESS_79445] of the trial, or immediat e family members of such individuals.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79446] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
26. Any disorder * at screening and/or baseline , which is not stable in the opi[INVESTIGATOR_1070], and could:  
a. Affect the safety of the subject throughout the trial.  
b. Influence the findings of the trial.  
c. Impede the subject ’s ability to complete the trial.  
*Examples include but are not limited to endocrine, gastrointestinal, hepatic, 
immunological, infectious, metabolic, musculoskeletal, neurological, and major 
physical impairment.  
27. Any significant abnormal finding * at baseline and/or screening  which may  in the 
opi[INVESTIGATOR_871] : 
a. Put the subject at risk because of their participation in the trial.  
b. Influence the results of the trial.  
c. Influence the subject ’s ability to complete the trial.  
*Examples include  clinically significant abnormal vital sign, physical examination, 
ECG, and laboratory result.  
28. Treatment with any non -marketed drug substance (that is, an agent which has not yet 
been made available for clinical use following registration) within the last  [ADDRESS_79447] at screening.  
NOTE : Subject may be rescreened (once ) if failed for this criterion (see Section  8.4). 
8.[ADDRESS_79448] identification number  
Trial participation begins once writt en informed consent is obtained  (refer to Append ix 3B  for 
details on the informed consent process ). Once informed consent is obtained, a 10-digit 
subject identification number (subject  ID xxxx -xxxx-xx) will be assigned by a central IR T 
system . The date of first screening activity could be on the same day or a later date than the 
informed consent was signed. The subject ID will be used to identify the subject during the 
screening process and throughout trial participation, if applicable . Subjects who have given 
written informed consent to participate in the trial and who have been assigned a subject  ID 
are considered ‘screened ’ subjects . 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79449] been randomised or not (scree ning log). This log will be anonymous and will include the 
reason(s) for not entering the trial, if applicable, or the allocated s ubject  ID. In addition, the 
investigator will maintain a log of all consented subjects at the trial site (subject identification 
list). This log will include each subject ’s identity, date of consent , and corresponding 
subject  ID so that any subject may be identified if required for any reason. The subject 
identification list  must not be copi[INVESTIGATOR_73224] .  
Screen ing failures  
Screen failures are defined as subjects who consent to participate in the trial but are not 
subsequently randomly assig ned to trial treatment. A minimal set of screen failure information 
is required to ensure transparent reporting of screen failure subjects to meet the CONSORT 
publishing requirements (43) and to respond to queries from regulatory authorities. As a 
minimum, the following data will be collected in the eCRF for screen failures:  
• Date of informed consent(s).  
• Date of screening failure . 
• Reason for screen failure.  
a. Failure to meet eligibility crite ria and which eligibility criterion(ia) was (were) not 
met.  
b. Lost to follow -up. 
c. Withdrawal by [CONTACT_1130].  
d. Other  (if other, a specification should be provided).   
• Demographics  (full date of birth [day, month, and year], only month and year, or only 
year, as per  local legislation, age, sex, race, ethnicity as per local legislation).  
• Any adverse events (AEs) and serious AEs (SAEs).  
 
Any SAE will require expedited reporting as described in Section  13.7. 
Rescreening of screening failures (subjects who did not meet the eligibility criteria for 
participation in the trial) is not allowed  except in specific situations  as descri bed below .  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79450] not meeting the 
eligibility criteria (e.g. , delayed test results or temporary site closure due to the COVID -19 
pandemic), rescreening may be permitted. In addition , rescreening may be permitted (once ) if 
an infection resolve s after initially not having met exclusion  criteria no. 9 (active chronic or 
acute infection requiring systemic treatment ), no. 10 (skin infection ), or no. 30 (positive 
SARS -CoV-[ADDRESS_79451])  or if the subject failed exclusion criterion no. 6 (treatment with TCS, 
TCI, or topi[INVESTIGATOR_22732] -4 inhibitor , or other topi[INVESTIGATOR_73200] ). Rescreening  will 
require approval by [CONTACT_1142] ’s medical expert [INVESTIGATOR_73370].  In all cases, rescreening will only be permitted  if the duration of the 
screening period does not exceed [ADDRESS_79452] description  
LEO  138559  is a human recombinant m Ab of the IgG 1 subclass that specifically binds to 
human IL-22R1 and inhibits the ligand IL-22 from binding to it . It is presented as a 
lyophilised powder for reconstitution ( using 1.0  mL sterili sed water ) and injection . 
LEO 138559  and placebo will be packag ed in individually numbered kits. Refer to Panel 4 for 
further details.  
Panel 4: Identification of investigational medicinal products  
Investigational 
medicinal 
product  
 Dosage form  Volume to be 
SC inject ed Active 
ingredient and 
concentration  Pack size  
 Source  
 
LEO 138559  Lyophilised powder for 
reconstitution ( using 
1.0 mL sterilised water ) 
adding up to a volume of 
1.2 mL/vial  ( vials of 
 mL each) LEO  138559, 
 mg/mL 
(following 
reconstitution)   mg/vial LEO  Pharma  
Placebo  Solution for SC injection 
(contains 1.2  mL/vial)  mL (  vials of  
 mL each)  Not applicable  1.2 mL/vial LEO  Pharma  
Note:  To ensure  that 1.0 mL ca n be withdraw n by a syringe, there will be  a small overfill in the placebo vial and in the active 
IMP vial after reconstitut ion, of approximately 0.2 mL  per vial .  
Abbreviation:  SC = subcutaneous (ly). 
 
TMF-000616809 - Version 4. 0
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79453] according to the schedule of trial procedures  
(Section  4). Dispensing of the IMP will be handled by [CONTACT_73294]. The IRT system will 
assign the required kit number(s) for each subject at each dispensing visit.  
The first day of dosing is considered Day 1 (Week 0 ). Each subject will receive  SC 
injections (each  mL) of  mg LEO 138559  or placebo to receive a total dose of 
450 mg LEO  138559  or placebo (  mL). In addition to this Q2W dosing  schedule , both 
treatment groups will receive an additional dose of their allocated treatment ( LEO 138559 
450 mg or placebo ) at Visit 4 ( Week 1). During the treatment period, final dosing will be 
administered at Week  [ADDRESS_79454] from placebo (see Section 9.3.1  for blindi ng details). The IMP must be 
injected SC in the upper legs (thighs), stomach area (abdomen) or in the upper, outer arm  but 
should not be given into areas where the skin is tender, bruised, red, hard, thick, scaly, or 
affected by [CONTACT_22802]. The anatomical location  of the injection , and if it was on the right or left side,  
must be recorded in the source documents at each treatment visit and recorded  in the eCRF.  
At each treatment visit, the  injections of IMP must be administered within a maximum of 
10 minutes. The  injections of IMP should be administered in the same injection site area 
(e.g. upper right arm) separated by [CONTACT_2669] [ADDRESS_79455] receives IMP at a different anatomical site at each treatment visit. If for some 
reason the injection site was not rotated, this should be document ed, and a reason should be 
recorded in the eCRF .    
If any issues with the IMP (e.g. , damaged kit or vial/syringe) or a malfunction during 
administration  should arise , the unblinded CRA sho uld be contact [INVESTIGATOR_530], and  the issue sho uld be 
document ed. 
Further details on IMP preparation and administration will be  provided in an instruction for 
use and trial product handling manual . IMP administration must be carried out according to 
these instructions.  
TMF-000616809 - Version 4. 0
CCI
CCI
CCI
CCI
CCI
CCI
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79456] 3 IMP treatment  visits (i.e., Visits  3, 4, and 5 ), subjects  will be monitored after 
IMP administration for immediate drug reactions for a minimum of 1 hour with vital signs  
taken immediately after IMP administration as well as after  30 minutes (± 5 minutes ) and 
after 1 hour  (± 5 minutes) , or until stable, whicheve r is later. Vital signs will be documented in 
the eCRF.  
As with any antibody, allergic reactions to dose administration are possible. The World 
Allergy Organi sation has categorised anaphylaxis into 2 subgroups: allergic anaphylaxis 
(mediated by [CONTACT_73295]) and nonallergic anaphylaxis (which has a 
nonimmunologic cause) (44). The clinical criteria for defining anaphylaxis for this trial are 
listed  in Appendix  5 and (45). Appropriate drugs, such as epi[INVESTIGATOR_238], antihistamines, 
corticosteroids, etc., and medical equipment to treat acute anaphylactic reactions must be 
immediately available at trial sites, and trial personnel should be trained to recognise and 
respond to anaphylaxis according to local guidelines.  
If an anaphylactic reaction occurs, a blood sample will be drawn from the subject as soon as 
possible after the event, at 60 minutes ± 30 minutes after the event, and at discharge for 
analysis of serum tryptase at the central laboratory.  
Conditions requiring IMP administration rescheduling   
If any of the following should occur, the investigator should reschedule the visit and IMP 
should not be administered until the rescheduled visit:  
• The subject has an intercurrent illness that in the opi[INVESTIGATOR_73225] (e.g. , viral illnesses).  
• The subject is febrile (defined as ≥38°C; ≥100.4 °F) within 72 hours prior to IMP 
administration.  
If the trial  visit cannot be rescheduled in order to maintain minimum of 7 days  to subsequent 
dose, the sponsor ’s medical expert [INVESTIGATOR_73371][INVESTIGATOR_530].  
Overdose is specified in Section  13.6.[ADDRESS_79457] any specific treatment 
recommendations in relation to overdose. The investigator will use clinical judg ement  to treat 
any overdose if necessary.  
9.3 Treatment assignment  
Subjects who comply with all the eligibility criteria (Sections 8.1, 8.2, and 8.3) will be 
randomised at baseline (Day 1) to receive treatment with either LEO 138559  450 mg Q2W or 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376 Date: 31-Jan-2022  Version: 4.[ADDRESS_79458] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
placebo  Q2W . Treatment assignment will be pre -planned according to a computer generated 
randomisation schedule in a 1:1 ratio ( LEO 138559  : placebo) stratified by  [CONTACT_73296] ; one stratum , ‘stratum A’, will be defined as having EASI <21 and the other stratum, 
‘stratum B’, will be defined  as having EASI ≥21.  
IRT will be used to control randomisation and stratification factors, along with IMP supply 
chain  and expi[INVESTIGATOR_73226].  
9.3.[ADDRESS_79459] nor any of the investigator s or 
LEO Pharma staff (except unblinded CRAs ) who are involved in the clinical evaluation and 
monitoring  of the subjects will be aware of the treatment received.  
IMP will be prepared, handled , and administered by a qualified, unblinded HCP at the site 
who will not be involved in the management of trial subjects and who will not perform any of 
the assessments.  
In the event that the treatment allocation for a subject becomes known  to the investigator or 
other trial staff involved in the management of trial subjects, LEO Pharma must be notified 
immediately.  
Should an issue arise with the IMP (e.g. , damaged kit or syringe that has been assigned to a 
subject prior to administration, or any other unexpected event with the kit or syringe [e.g. a 
malfunction during IMP administration]), the unblinded HCP at the site will contact [CONTACT_73297].  
The trial site will maintain a writt en plan (site blinding plan) detailing which staff members 
are blinded/unblinded and the process of IMP administration used to maintain the blind.  
9.3.[ADDRESS_79460] ’s safety. An emergency unblinding request can be 
made by [CONTACT_473], HCPs who are not members of the trial s taff, or authorised LEO 
Pharma personnel.  
Provisions are in place for 24-hour emergency unblinding of individual subject treatment. If 
emergency unblinding is required, the investigator  can unblind a subject ’s treatment in the 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79461] access to the 
IRT (e.g., a physician at an emergency room ), a local contact [CONTACT_73298] (see Append ix 3B ) to be used if the 
investigator or delegated site staff cannot be reached . The requester will provide the trial ID 
and subject  ID to the emergency unblinding CRO who will immediately reveal the individual 
treatment allocation.  
The emergency unblinding CRO will clarify that the requester requires immediate unblinding 
without further medical consultation. Should the requester wish to discuss whether unblinding 
is necessary, the  emergency  unblinding  CRO will provide the requester with the LEO Pharma 
24/[ADDRESS_79462](s)  if it is deemed necessary, including for 
regulatory purposes in relation to reporting of S[LOCATION_003]Rs.  
9.4 Background treatment  (emollients)  
All subjects must use an emollient twice daily (or more  frequently , if needed ) for at least 
7 days before Day 1  (baseline) and throug hout the treatment period ( until Week 16). Subjects 
should use the same emollient  throughout the trial .  
The emollient should preferably not contain additives such as ceramide, hyaluronic acid, or 
urea. To ensure use of a suitable emollient, the investigator should provide guidance to the 
subject as to which locally available emollient  to use.  
The function of the emollient is to:  
• Keep the subject ’s skin well moisturi sed in the absence of systemic and/or topi[INVESTIGATOR_73227](s) in the washout  period (Week -1 to Week 0).  
• Act as a complement to systemic treatment with the IMP (standard of care) and keep the 
subject ’s skin well moisturi sed in the treatment period (Week 0 to Week 16).  
Reporting in eCRF  
It will be recorded in the eCRF if background treatment (emollient) has been used  daily ; if 
not, a reason should be provided.  
9.5 Rescue treatment  
If medically necessary (i.e. , due to worsening of AD or  intolerable AD symptoms), rescue 
treatment for AD in the form of TCS/TCI may be prescribed to trial subjects and used from 
Week 4 at the discretion of the investigator. It is recommended that the inv estigator start s with 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79463] potent TCS for the face (e.g. , hydrocortisone 2.5% cream/ointment) and 
moderately potent TCS for the body (e.g. , triamcinolone acetonide 0.1% cream/ointment).  
If rescue treatment with TCS/TCI is initiated after Week [ADDRESS_79464] receives  the following treatment:  
• Rescue treatment with any TCS/TCI before Week 4 . 
• Super potent TCS (e.g., clobetasol propi[INVESTIGATOR_16847] 0.05% cream) between Week -1 and 
Week  16. 
• Systemic rescue treatment (besides systemic antihistamines and/or anti -infectives) at any 
point during the trial between Week -4 (or from 5 half -lives of Week 0, whichever is 
longer) and Week 16.  
Investigators should make every attempt to conduct efficacy and safety assessments (for 
example disease severity scores, safety labs) immediately before administering any rescue 
treatment. An unscheduled visit may be used for this purpose, if necessar y. 
During the safety follow -up period (Week s 16 to 32), topi[INVESTIGATOR_8588] (including TCS and TCI) 
may be prescribed to control disease activity at the discretion of the investigator and will not 
be considered as rescue treatment . Any medication taken by [CONTACT_73299] -up 
period will be  reported as concomitant medication using the eCRF.  
Reporting in eCRF  
It will be recorded in the eCRF if and what rescue  treatment  has been used.  
9.[ADDRESS_79465] ’s medical record and the eCRF along with  
details such as : 
• Medication name  [CONTACT_73378]  (generic or brand name) . 
• Whether the medication or therapy is a rescue treatment  for AD. 
• Indication . 
• Start and stop date of administration  (it will also be recorded if the medication is 
ongoing ).  
• Dosage information , including dose  per administration , unit, and frequency . 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79466] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
• Route of  administration : oral, topi[INVESTIGATOR_2855], SC, transdermal, intraocular, intramuscular, 
respi[INVESTIGATOR_696] (inhalation), intralesional, intraperitoneal, nasal, vaginal, rectal, IV, or other (if 
other, a specification must be provided).  
For topi[INVESTIGATOR_12969], the dosage fo rm (cream, lotion, ointment, other) and the potency  
will also be recorded .  
For topi[INVESTIGATOR_2855], SC, transdermal, intramuscular, and intralesional treatments, the location of 
administration including laterality will also be recorde d (e.g., left upper arm).  
Similarly, a ny concurrent procedure conducted within [ADDRESS_79467] ’s medical record and the eCRF  with details such as : 
• Procedure name .  
• Body location (upper limb, lower limb, trunk, head ).  
• Indication.   
• Start and stop date (it will also be recorded if the procedure is ongoing).  
It should be included whether the procedure is inside the area of injection or the area of an AD 
lesion.  
Investigators may prescribe concomitant medications or treatments to provid e adequate 
supportive care as deemed necessary, except for medications listed in Section  9.7. The 
sponsor ’s medical expert [INVESTIGATOR_73371][CONTACT_26237].  
The following concomitant medications are permitted during the trial : 
• Paracetamol use (maximum 2  g/day).  
• Concomitant therapi[INVESTIGATOR_73228] -term treatment of pre -existing conditions 
can continue during the trial provided they are in accordance with the exclusion 
criteria (see  Section 8.3). 
• Systemic antihistamines  and/or anti-infectives . 
• Emollients allowed during the treatment period . 
For AD patients with mild chronic asthma  (42) or mild allergic rhinitis , use of inhaled 
corticosteroid s up to and  including 500 µg beclometasone (or equivalent) per day is 
acceptable.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79468] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
9.7 Prohibited medication  and procedures  
Prohibited  medications and/or procedures are listed in Panel 5. Details regarding prohibited 
medications and/or procedures prior to screening and during wash out(s) are described in 
Section 8.3. 
If prohibited medications are used during the trial, they must be recorded as concomitant 
medication in the eCRF (Secti on 9.6). 
Panel 5: Prohibited medication (s) and/ or procedure (s) 
Medication  or procedure  Prohibited from  Prohibited to  
TCS or TCI (other than those 
permitted as rescue treatment ). Washout (Week -1). Week 16 . 
Topi[INVESTIGATOR_22732] -4 inhibitors . Washout (Week -1). Week 16 . 
Other topi[INVESTIGATOR_73229]/moisturisers (other 
than the ones allowed during 
treatment period) used for the 
treatment of AD . Washout (Week -1). Week 16 . 
Use of UVA , UVB, PUVA, 
other phototherapy , or tanning 
beds.  Week -4 prior to randomisation . Week 16 . 
Immunoglobulin or blood 
products.  Week -4 or 5 half -lives  prior to 
randomisation , whichever is 
longer . Safety follow -up (Week 32) . 
Systemic corticosteroids 
(excluding inhaled or intra -nasal 
steroids).  Week -4 prior to randomisation . Safety follow -up (Week 32) . 
Systemic 
immunosuppressive/immuno - 
modulating medication 
(excluding systemic  
antihistamines).  Week -4 or 5 half -lives  prior to 
randomisation , whichever is 
longer .  Safety follow -up (Week 32) . 
Biologics . Week -16 or 5 half -lives  prior to 
randomisation , whichever is 
longer . Safety follow -up (Week 32).  
Allergen immunotherapy.  Week -4 prior to randomisation . Safety follow -up (Week 32) . 
Live (attenuated) vaccine.  Week -12 prior to 
randomisation . Safety follow -up (Week 32) . 
Abbreviations:  AD = atopic dermatitis; PDE -4 = phosphodiesterase -4; PUVA = psoralen ultraviolet A ; TCI = 
topi[INVESTIGATOR_73199] (s); TCS = topi[INVESTIGATOR_11977] (s); UVA = ultraviolet A; UVB =  ultraviolet B . 
The sponsor ’s medical expert [INVESTIGATOR_73372] a subject receives any of these prohibited 
medications during the trial.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79469] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
As described in Section 9.5, TCI and TCS used as rescue treatment for worsening of AD or 
intolerable AD symptoms are allowed  from Week 4. 
9.8 Treatment logistics and a ccountability  
9.8.1 Labelling and p ackaging of trial products  
IMP will be packed open  label in individually numbered kits . 
Primary and secondary packaging materials ( vial and outer carton, respectively) will be 
individually labelled.  
The labelling of IMPs will be in accordance with the EU guidelines for Good Manufac turing 
Practices for Medicinal Products for Human and Veterinary use, Annex 13 (46), local 
regulations, and trial requirements. Label text will be translated into local languages as 
required.   
9.8.[ADDRESS_79470] be stored at 2 to 8°C at the site. The temperature during storage must be 
monitored by a calibrated, stationary , and  continuously  monitoring system. Minimum 
requirement is a calibrated min/max thermometer.   
A temperature log must be kept to document the storage within the right temperature interval. 
Storage facilities should be checked at least every working day.  
Storage of IMP may be delegated, e.g. , to a hospi[INVESTIGATOR_4601], as locally applicable.  
Note that in the cases listed below, site staff should not use the affected IMP and should 
immediately contact [CONTACT_73300]:  
• Temperature excursion upon receipt o r during storage at the trial site.  
• Damaged kit upon receipt.  
• Damaged vial. 
Damaged IMP should be documented via IR T (refer to the IR T quick reference guide for 
further details). Damaged IMP should not be used.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79471] be recorded in the eCRF.  
 
Reporting in eCRF  
The following data will be recorded in the eCRF:  
Did the subject comply with the IMP dosing schedule (yes, no); If no, a reason will be given. 
It will also be recorded how much IMP the subject received (partial dose, no dose, and the 
total number of IMP applications missed since last visit ). 
• Primary reason for non -compliance – lack of time, adverse event, other (if other, a 
specification should be provided).  
• Date and time of IMP administration  (stated for each of the  injections) . 
• Site of IMP injecti on: For the site (upper leg [thigh ], stomach area [abdomen ] or in 
the upper, outer arm ) the laterality should be specified (right or left).  
9.8.[ADDRESS_79472] destruction  
Used IMP (i.e. , empty vials) and unused IMP must be returned to the CMO for destruction. 
Used IMP and unused IMP that is no longer available for dispensation (e.g. , expi[INVESTIGATOR_73230]-000616809 - Version 4. 0
CCI
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79473] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
damaged IMP) can be returned on an on going  basis throughout the trial. Unused IMP (i.e. , 
IMP th at is still available for dispensation) can be returned for destruction after the last dosing 
visit of the last subject at the site.  
Syringes used for administration of IMP can be destroyed at site according to local procedures 
in compliance with local re gulations.  
9.[ADDRESS_79474] completed the trial, the 
subjects will be treated at the investigator ’s discretion or referred to other physician(s) 
according to standard practice.  
9.[ADDRESS_79475] complaints  
Any defects or issues with the IMP (e.g., inadequate labelling)  must be reported to Global 
Safety at LEO Pharma on the trial -specific (paper) complaint form within [ADDRESS_79476] 
knowledge.  
Critical complaints (defined as any defect or issue that has or potentially could have a serious 
impact for the subject [ e.g., SAE or large particles in the vial]) must be reported to Global 
Safety, LEO Pharma within [ADDRESS_79477] or issue, including 
whether it led to an AE. (S)AEs which occur due to a defect or issue with the IMP will be 
reported by [CONTACT_73301] 13.[ADDRESS_79478] be stored at labelled 
conditions unless otherwise instructed; the trial site will be notified whether the IMP needs to 
be returned for further investigation or may be destroyed.  
Global Safety, LEO Pharma contact [CONTACT_73302]:  
Fax number: [PHONE_1767]  2468  
E-mail address: drug.safety@leo -pharma.com  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79479] may withdraw from the trial (prior to first dose or during the treatment period) or 
permanently discontinue trial treatment at any time if the subject, the investigator, or 
LEO  Pharma considers that it is not in the subject ’s best interest to continue.  
A subje ct who withdraws from the trial is a subject who stops treatment with the IMP and all 
further protocol defined trial activities. A subject who permanently discontinues IMP is a 
subject who, although they stop treatment with the IMP, agree to their follow -up as described 
in Section 10.3. Early termination assessments to be conducted for both events are described 
in Section 10.3. 
Subjects who withdraw from the trial and subjects who permanently discontinue IMP will not 
be replaced.  
If a subject withdraws from the trial, they may request destruct ion of any samples taken and 
not tested . The investigator must document this in the subject ’s medical record  and inform 
LEO Pharma . 
10.2 Reasons for discontinuation of IMP  
10.2.1  Reasons for permanent discontinuation of IMP  
 Subjects will permanently disco ntinue  IMP in the event of:  
• Withdrawal of consent . 
• An AE that, in the opi[INVESTIGATOR_73231] ’s medical expert, 
contraindicates further dosing.  
• Initiation of systemic rescue treatment of AD  (besides systemic antihistamines  
and/or anti -infectives ) at any point during the trial between Week 0 and 16 , rescue 
treatment before Week 4, and/or super potent TCS between Week -1 and Week 16 . 
• Initiation of prohibited medication which cannot be safely replaced by [CONTACT_73303]-prohibited medications.  
• Evidence of pregnancy , or if the subject is noncompliant with the contraception 
requirements (see Section 8). 
• Other reasons, at the discretion of the investigator . If other, a specification should 
be provided.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79480] be recorded in the medical records and on the 
end-of-treatment form in the eCRF where the following options are  available:  
• Pregnancy . 
• Adverse event  (if adverse event, a specification must be provided).  
• Lack of efficacy . 
• Withdrawal by [CONTACT_1130] . 
• Lost to follow -up. 
• Other  (if other, a specification should be provided).  
In case the primary reason is adverse event, the AE in question will be linked to the 
permanent discontinuation of IMP. To support the statistical analysis, i t will also be recorded 
if the permanent discontinuation of IMP was due to the COVID -19 pandemic.  
10.2.2  Reasons for temporary discontinuation of IMP   
IMP dosing may be temporarily suspended in the event of:  
• COVID -[ADDRESS_79481] be discussed 
with sponsor ’s medica l expert. However, the investigator  may suspend trial treatment at any 
time, even without consultation with sponsor ’s medical expert [INVESTIGATOR_73373] ’s best interest. I n such 
cases, sponsor ’s medical expert [INVESTIGATOR_73374].   
10.[ADDRESS_79482] administration of IMP and return to the trial site 
for additional visits as indicated below. See the schedule of trial procedures (Section  4) for 
data to be collected at these visits. Subjects who discontinue IMP but remain in the trial will 
continue completing the eDiary until the safety follow -up visit (Visit 16) . The investigator 
will review any AEs which will be followe d up according to Section  13.7, if the subject 
agrees.  
Subjects who permanently discontinue IMP will be asked to attend:  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022 Version: 4.[ADDRESS_79483] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
• An e arly termination visit  as soon as possible after last dose of IMP.  
• The primary endpoint visit (16 weeks after randomi sation).  
• A safety follow -up visit ( [ADDRESS_79484] administration of IMP).  
Details on data to be recorded in the eCRF for subjects who permanently discontinue  IMP can 
be found in Section 11.7. 
Withdrawal from trial  
Subjects who withdraw /are withdrawn  from the trial prior to first dose of IMP 
(randomisation) will be considered screening failur es. 
Subjects who withdraw from the trial for any reason should attend an early termination visit 
as soon as possible after last administration of IMP . Assessments/procedures to be conducted 
at this visit a re listed in the schedule of trial procedures  (Section  4). If the subject agrees , the 
investigator will review any AEs which will be followed up acc ording to Section  13.7. 
Details on data to be recorded in the eCRF for subjects who withdraw from the trial can be 
found in Section 11.7. 
10.[ADDRESS_79485] fails to return to the trial site for a required 
visit:  
• The trial site must attempt to contact [CONTACT_73304].  
• Before a subject is deemed lost to follow -up, the investigator or designee must make 
every effort  to regain contact [CONTACT_1155] (where possible, [ADDRESS_79486] ’s last known mailing address or local 
equivalent method[s]). These contact [CONTACT_9300] ’s 
medical re cord.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79487] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
• Should the subject continue to be unreachable, they will be considered to have 
withdrawn from the trial with a primary reason of lost to follow -up. 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79488] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
11 Trial assessments  and procedures  
11.1 Overview  
Assessments and procedures to be conducted at each visit  are listed in the schedule of trial 
procedures (Section 4) and will be  conducted in the order presented in Panel 6. PROs to be 
completed at the trial site and investigator assessments of efficacy should  be conducted at the 
same visit.   
Panel 6: Sequence of assessments   
 
a At the screening visit (at the earliest Week -4), the subject’s eligibility to participate in the trial must be 
confirmed before any PROs are completed. PROs will be completed either in the eDiary or on an electronic 
device at the trial site.  
b Laboratory assessments include PK and PD samples. PD samples include s erum biomarkers, skin swabs , and 
tape strips . 
c For the first 3 IMP treatment  visits (i.e. , Visits  3, 4, and 5) subjects  will be monitored after IMP administration 
for immediate drug reactions for a minimum of 1 hour with vital signs taken immediately after IMP 
administration as well as after 30 minutes (± 5 minutes) and after 1 hour (± 5 minutes), or until stable, 
whichever is later.  
 
Subjects participating in the trial will be under careful supervision of a qualif ied principal 
investigator [INVESTIGATOR_73232] a dermatologist  or an allergist . Investigators must be physicians and 
have experience in treating AD as well as documented experience with and/or training in the 
assessments used in this  trial. All dermato logic assessments must be performed by a  Patient -reported 
outcomesa
Investigator assessments
Safety and laboratory 
assessmentsb
Administration of IMPc
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79489] or a n adequately qualified medical doctor  (defined as someone with at least 
[ADDRESS_79490] graduate experience ).  
AEs must be assessed by a physician (Section  13.2). 
To reduce  inter-rater variability, t he same investigator  should , whenever possible , perform all 
the efficacy assessments  for a given subject throughout the entire trial period.  
The investigators performing the assessments must not be involved in the administration of 
IMP (Section  9.3.1 ).  
11.2 Assessments performed only at screening/baseline  
11.2.1  Demographics  
The following demographic data will be recorded  at screening  (Section 4): 
• Full date of birth (day, month, and year) or partial date of birth (only month and 
year, or only year), as per local legislation.  
• Age (as on the day informed consent is signed, if full date of birth cannot be 
collected due to local legislation).  
• Sex: female, male . 
• Race: American Indian or Alaska native, Asian, Black  or African American, native 
Hawaiian  or other Pacific islander, White, other (if other, a specification should be 
provided ). 
• Ethnic origin (self -reported by [CONTACT_423] , Hispanic or Latino, not Hispanic or 
Latino ), if allowe d by [CONTACT_73305] .  
At baseline, only age will be recorded (Section 4). 
11.2.2  Body assessment  (height ) 
Height will be recorded according to the schedule of trial procedure (Section 4).  
The subject ’s height (without shoes) will be measured.   
11.2.3  Medical history  
Medical history will be recorded according to the schedule of trial procedures (Section 4). 
Relevant past and concurrent medical history must be recorded including all past and current 
skin disease history :  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79491] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
• Atopy history:  
- Age at first onset of AD. 
- Previous AD treatments (e.g., dupi[INVESTIGATOR_12458], cyclosporine,  etc). 
- Asthma . 
- Food allergy . 
- Hay fever . 
• Other medical and surgical history including concurrent diagnoses  within the previous 
12 months . For each condition, surgical procedure, or diagnosis, the start and stop dates 
will be recorded. It will also be recorded if the condition or diagnosis is ongoing.  
Relevant medical history also includes diseases which are specifically listed as exclusion 
criteria and diseases for which treatments are listed as exclusion criteria or prohibite d 
medications . 
11.2.4  Other assessments  
The following tests will be conducted according to the schedule of trial procedures 
(Section  4): 
• Hepatitis B virus testing ( for more detail, see Panel  10). 
• Hepatitis C virus antibody . 
• HIV antibodies . 
• Tuberculosis (Mycobacterium tuberculosis  IFN-γ release assay [or a [COMPANY_003] test  if a 
requirement from the local health authorities ]). 
• SARS -CoV-2 (PCR ). 
11.3 Efficacy assessments  
11.3.1  Eczema Area and Severity Index  (EASI)  
EASI will be assessed by [CONTACT_73306] 
(Section 4). At an unscheduled visit, it will be at the discretion of the investigator if EASI  
should be assessed.  
EASI is a validated measure used in clinical practice and clinical trials to assess the severity 
and exten t of AD (47). The as sessment will be based on the condition of the disease at the 
time of evaluation and not in relation to the condition at a previous visit. To reduce 
inter-assessor variability, the same investigator should, whenever possible, conduct all EASI 
assessments for a given subject during the entire trial.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79492] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
EASI is a composite score ranging from 0 to 72 with higher scores indicating a more severe 
or more extensive condition. The score will be calculated as described in Panel 7. Briefly, the 
investigator will assess the severity of 4 AD disease characteristics (erythema, 
induration/papulation, excoriation, and lichenification) on the 4 body regions (head/neck, 
trunk, upper extremities, and lower extremities). Severity will  be assessed using the severity 
score scale presented in Panel 8. For each body region, a severity sum score will be calculated 
and multiplied by [CONTACT_73307] ( Panel 8) and a weighting factor. The EASI score equals the 
sum of scores obtained for each body region ( Panel 7). 
Reporting in eCRF  
The body region, severity of the disease characteristics (erythema, induration/papulation, 
excoriation, and lichenification), and the area score will be recorded in the eCRF.  Refer to 
Appendix  3D for principles for data entry in the eCRF.  
Panel 7: Calculation of the Eczema Area and Severity Index  
Body region  
Erythema  
Induration/ 
papulation  
Excoriation  
Lichen ification  
Area score  
Weighting 
factor  
Score  
Head/neck  (SS   +     SS   +     SS   +     SS) ×  AS  × 0.1   
Trunk  (SS   +     SS   +     SS   +     SS) ×  AS  × 0.3   
Upper extremities  (SS   +     SS   +     SS   +     SS) ×  AS  × 0.2   
Lower extremities  (SS   +     SS   +     SS   +     SS) ×  AS  × 0.4   
The EASI score is the sum of scores of the 4  body regions   
(Range 
0-72) 
Abbreviations : AS = area score; EASI = Eczema Area and Severity Index; SS = severity score.  
Modified from  (48). 
Panel 8: Eczema Area and Severity Index severity score scale and area score scale  
Severity score scale a  Area score scale  
0 None/absent   0 0% affected area  
1 Mild   1 1% to 9% affected area  
2 Moderate   2 10% to 29% affected area  
3 Severe   3 30% to 49% affected area  
a Half-scores (0.5, 1.5, 2.5) are allowed.   4 50% to 69% affected area  
 5 70% to 89% affected area  
 6 90% to 100% affected area 
 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79493] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
11.3.2  Validated Investigator Global Assessment Scale for Atopic Dermatitis 
(vIGA -AD) 
vIGA -AD will be assessed by [CONTACT_73306] 
(Section 4). At an unscheduled visit, it will be at the discretion of the investigator if the 
vIGA -AD should be assessed.  
The vIGA -AD is an instrument used in clinical trials to assess the subject ’s glo bal disease 
severity and is based on a 5 -point scale ranging from 0 (clear) to 4 (severe) ( Panel 9) (49). 
The assessment will be based on the condition of the disease at the time of evaluation and not 
in relation to the condition at a previous visit.  
Reporting in eCRF  
The disease severity assessment score will be recorded in the eCRF.  Refer to Appendix  3D for 
principles for data entry in the eCRF.  
Panel 9: Validated Investigator Global Assessment Scale for Atopic Dermatitis  
Score  Morphological description  
0 - Clear  No inflammatory signs of atopic dermatitis (no erythema, no 
induration/papulation, no lichenification, no oozing/crusting). Post -
inflammatory hyperpi[INVESTIGATOR_22758]/or hypopi[INVESTIGATOR_22765].  
[ADDRESS_79494] clear  Barely perceptible erythema, and barely perceptible induration/papulation, 
and/or minimal lichenification. No oozing or crusting.  
2 - Mild  Slight but definite erythema (pi[INVESTIGATOR_8745]), slight but definite induration/papulation, 
and/or slight but definite lic henification. No oozing or crusting.  
3 - Moderate  Clearly perceptible erythema (dull red), clearly perceptible 
induration/papulation, and/or clearly perceptible lichenification. Oozing and 
crusting may be present.  
4 - Severe  Marked erythema (deep or brig ht red), marked induration/papulation, and/or 
marked lichenification. Disease is widespread in extent. Oozing or crusting 
may be present.  
 
11.3.3  Body surface area involvement  
The total BSA score will be assessed according to the schedule of procedures (Section 4). 
The investigator will assess the total AD involvement for the whole body, i.e. , head/neck, 
upper extremities, trunk, genitalia, and lower extremities, as a percentage of the total BSA. As 
a guidance for this estimate, the surface of a full, flat palm (including the 5 fingers) of an 
adult subject corresponds to approximately 1% of the  total BSA.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79495] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
11.3.4   Patient -reported outcomes  
[IP_ADDRESS]  Overview  
During the trial each subject should  make individual assessments relating to their perception 
of their disease and quality of life. These should  be performed independently of the 
investigator and prior to the  investigator performing his/her efficacy assessments. At the 
screening visit  (at the ea rliest Week -4), the subject ’s eligibility to participate in the trial needs 
to be established before the PROs can be completed.  
The subject will be asked to complete the following PROs according to the schedule of trial 
procedures (Section  4). 
• Worst Daily Pruritus NRS .  
• POEM .  
• DLQI. 
Worst Daily Pruritus NRS  will be completed  daily  in an eDiary . At Week -[ADDRESS_79496] visit in t he trial.  
POEM and DLQI  will be completed in an electronic device by [CONTACT_73308]  (Section  4). At an unscheduled visit, it 
will be at the discretion of the investigator if POEM and/or DLQI  should be assessed.  
[IP_ADDRESS]  Worst Daily Pruritus NRS  
Subjects will assess their worst itch severity ov er the past 24 hours using an 11 -point NRS 
(‘Worst Daily Pruritus NRS ’) with 0 indicating ‘no itch ’ and 10 indicating ‘worst itch 
imaginable ’. Subjects will complete the Worst Daily Pruritus NRS as part of an eDiary each 
day from Week -1 until Week 32. 
[IP_ADDRESS]  Patient-Oriented E czema Measure  (POEM)  
The POEM is a validated questionnaire used to assess disease symptoms in AD patients in 
both clinical practice and clinical trials  (50). The tool consists of 7  items each addressing a 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79497] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
specific symptom (itching, sleep, bleeding, weepi[INVESTIGATOR_007], cracking, flaking, and dryness). Subject s 
will score how often they have experienced each symptom over the previous week on a 
5-point categorical response scale (0 = ‘no days ’; 1 = ‘1 to 2 days ’; 2 = ‘3 to 4 days ’; 3 = ‘5 to 
6 days’; 4 = ‘ every day ’). The total score is the sum of the 7  items (range 0 to 28) and reflects 
disease -related morbidity; a high score is indicative of a worse disease severity.  
[IP_ADDRESS]  Dermatology  Life Quality Index  (DLQI)  
The DLQI is a validated questionnaire with content specific to those with dermatology 
conditions  (51). It consists of [ADDRESS_79498] ’s perception of the impact of 
their skin disease on different aspects of their quality of life over the last week such as 
dermatology -related symptoms and feelings, daily activities, leisure, work or school, personal 
relationships, and the t reatment . Each item is scored on a 4 -point Likert scale (0  = ‘not at all 
⁄not relevant ’; 1 = ‘a little ’; 2 = ‘a lot’; 3 = ‘very much ’). The total score is the sum of the 
10 items (0 to 30); a high score is indicative of a poor quality of life.  
11.4 Safety ass essments  
11.4.1  Vital signs 
Vital signs (blood pressure, pulse, and body temperature) will be assessed according to the 
schedule of trial procedures (Section  4). At an unscheduled visit, it will be at the discretion of 
the investigator if vital signs should be assessed.  
For the first 3 IMP treatment visits (i.e. , Visits  3, 4, and 5) subjects will b e monitored after 
IMP administration for immediate drug reactions for a minimum of 1 hour with vital signs 
taken immediately after IMP administration as well as after 30 minutes (± 5 minutes) and 
after 1 hour (± 5 minutes), or until stable, whichever is la ter.  
Vital signs (blood pressure, pulse, and body temperature) will be assessed  following at least 
[ADDRESS_79499] presents with an abnormal vital sign, the measurement of the 
vital sign can be repeated approximately 2–[ADDRESS_79500] measurement verifies the second (normal) value, the first measurement 
should be considered false and the third m easurement should be recorded in the eCRF. If the 
third measurement confirms the first measurement (abnormal), the second measurement 
should be considered false and the third measurement should be recorded in the eCRF. Only 
the last measurement considered true should be recorded in the eCRF.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79501] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
In case of a clinically significant abnormal vital sign at screening and/or baseline, it will be at 
the discretion of the investigator if the subject should be included in the trial in accordance 
with exclusion criterion no. 27. During the trial, if a subject presents with a clinically 
significant abnormal vital sign, the investigator must take appropriate action, at their 
discretion.  
Reporting in eCRF  
Vital signs will  be recorded in the eCRF and if not measured, a reason should be provided.  
Clinically significant abnormal vital signs at screening and baseline  will be documented as 
medical history in the eCRF. At subsequent visits, any clinically significant deteriorati on of a 
pre-existing condition as well as any new clinically significant sign, symptom, or illness 
occurring after randomisation will be reported as an AE in accordance with Section  13.3. 
Refer to Appendix  3D for principles for data entry in the eCRF.  
11.4.[ADDRESS_79502] including general appearance, regional lymph nodes , 
and dermatologic examination of the skin  will be performed according to the schedule of trial 
procedures (Section  4). At an unscheduled visit, it will be at the discretion of the investigator 
if a physical e xamination  should be performed .  
In case of a clinically significant abnormal finding during physica l examination at screening 
and/or baseline, it will be at the discretion of the investigator if the subject should be included 
in the trial in accordance with exclusion  criterion no. 27. During the trial, if a subject presents 
with a clinically significant abnormal finding during physical examination, the investigator 
must take appropriate action, at their discretion.  
Reporting in eCRF  
It will be recorded in the eCRF if a physical examination was conducted. If not, a reason 
should be provided. The investigator ’s evaluation of the physical examination (‘normal ’, 
‘abnormal, not clinically significant ’, ‘abnormal, clinically significant ’) will also be recorded.  
Clinically significant abnormal findings during physical examination at screening and 
baseline will be documented as medical history in the eCRF. At subsequent visits, any new 
clinically significant abnormal findings, symptoms, or il lnesses, as well as any clinically 
significant deterioration of a pre -existing condition after randomi sation will be reported as an 
AE as described in Section  13.3. 
Refer to Appendix  3D for principles for data entry in the eCRF.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79503] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
11.4.3  Weight  
Weight will be recorded according to the schedule of trial procedure s (Section 4). The 
subject ’s weight (in indoor clothing and without shoes) will be measured.  At an unscheduled 
visit, it will be at the discretion of the investigator if weig ht should be measured.  
11.4.[ADDRESS_79504] be measured according to the schedule of trial procedure s in (Section 4). At an 
unscheduled visit, it will be at the discretion of the investigator if an ECG should be 
measured.  
At each visit, the individual  measurements  as well as the average of [ADDRESS_79505] evaluate all abnormal ECG  results  (‘clinically significant ’ or ‘not 
clinically significant ’) and sign and date when the evaluation is performed. The investigator 
has the final decision on the clinical significance of ECG abnormalities.  
If a result is abnormal at the screening or baseline visit and considered by t he investigator to 
be clinically significant, it will be up to the investigator ’s discretion to decide if the subject 
should be enro lled into the trial (respecting exclusion criteria no. 18 and 27). If a subject with 
an abnormal and clinically significant ECG result is enrolled, the investigator should provide 
a justification in the medical record.  
During the trial if a subject present s with a clinically significant abnormal ECG or a clinically 
significant abnormal change in ECG from baseline, the ECG should be repeated. If the ECG 
or change in ECG is confirmed clinically signific antly abnormal, the subject  must 
permanently discontinue IMP , and  be withdrawn from the trial. In such case, the subject 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79506] ’s ECG returns to a state similar to that of 
screening/baseline at the discretion of the investiga tor. 
The collection and transmission of ECG data will be described in a separate ECG manual.  
Reporting in eCRF  
It must be recorded in the eCRF if an ECG was measured. If not, a reason must be provided. 
The date of ECG measurement must be recorded. In case of a suspected abnormal ECG, the 
action taken with the subject, if any, must be recorded. The  investigator ’s assessment of ECG 
result (‘normal ’, ‘abnormal, not clinically significant ’, ‘abnormal, clinically significant ’) must 
also be recorded in the eCRF.  
Clinically significant abnormal ECG findings at screening and baseline before first dose of 
IMP will be documented as medical history in the eCRF. At subsequent visits, any new 
clinically significant abnormal ECG finding, symptoms, or illnesses, as well as  any clinically 
significant deterioration of a pre -existing condition after randomi sation will be reported as an 
AE as described in Section 13.3. 
Refer to Appendix  3D for principles for data entry in the eCRF.  
11.4.5  Laboratory  testing  
[IP_ADDRESS]  Overview  
Blood and urine  samples will be collected according to the schedule of trial procedures 
(Section  4) and the evaluations listed in  Panel  10 will be conducted by [CONTACT_2237].  
At an unscheduled visit, it will be at the discretion of the investigator if sample s should be  
collected . 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79507] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Panel  10: Clinical laboratory tests   
Clinical c hemistry  Haematology  
Sodium  
Potassium  
Creatinine  
Urea nitrogen  
Calcium  
Alkaline phosphatase  
Aspartate aminotransferase (AST)  
Alanine aminotransferase (ALT)  
Gamma glutamyl transferase  
Bilirubin1 
(Direct bilirubin )1 
(Indirect bilirubin)1 
Cholesterol  
LDL cholesterol  
HDL cholesterol  
Triglycerides  
Glucose (non -fasting)  
Albumin  
Protein  
Tryptase2 
Lactate dehydrogenase  
C-reactive protein  Haematocrit  
Haemoglobin  
Leukocytes  
Neutrophils   
Neutrophils/leukocytes5 
Lymphocytes  
Lymphocytes/leukocytes5 
Monocytes  
Monocytes/leukocytes5 
Eosinophils  
Eosinophils/leukocytes5 
Basophils  
Basophils/leukocytes5 
Thrombocytes  
Serology  Tuberculosis test6 
Hepatitis B virus surface antigen3 
Hepatitis B virus surface antibody3 
Hepatitis B virus core antibody3 
Hepatitis C virus antibody3 
HIV-[ADDRESS_79508]  
SARS -CoV -2 (PCR)3 
Urinalysis4 Serum pregnancy test7  
Protein  
Glucose  
Ketones  
Occult blood  
Leukocytes  
Nitrite  β-human chorionic gonadotropin  
1) If bilirubin is above upper limit of normal, direct and indirect bilirubin will also be measured.  
2) In case of reactions to SC IMP administration, tryptase can be tested at the discretion of the investigator.  
3) Conducted  at screening only.  
4) The analytes listed will only be measured if the urine dipstick is abnormal.  
5) The symbol ‘/’included in the table  represents ‘a ratio’ . 
6) Conducted at screening only . 
7) Only women of childbearing potential . 
Abbreviations:  HDL  = high density lipoprotein; HIV  = human immunodeficiency virus; IMP = investigational medic ine 
product; LDL  = low density lipoprotein ; PCR  = polymerase chain reaction ; SARS -CoV -2 = severe acute respi[INVESTIGATOR_11520]  2; SC = subcutaneous . 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79509] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
[IP_ADDRESS]  Investigator evaluation of laboratory samples  
Laboratory samples sent to the central laboratory  
Clinical  chemistry, haematology, urinalysis (if applicable), serology, and serum pregnancy 
tests will be analysed by a central laboratory which will provide results to the trial sites.  
Laboratory parameters will be classified as low, normal, or high, depending on whether the 
value is below, within, or above the reference range. The investigator must evaluate all results 
outside the reference range (clinically significant or not clinically significant) and sign and 
date their evaluation which will be archived in the  investigator ’s trial file.   
In case of an abnormal clinically significant laboratory result at screening and/or baseline, it 
will be at the discretion of the investigator if the subject should be randomi sed in the trial in 
accordance with exclusion criter ion no. 22. During the trial, if a subject presents with an 
abnormal clinically significant laboratory result, the investigator must take appropriate action, 
at thei r discretion.   
In case additional analys es are needed to support the interpretation of the initial test results for 
hepatitis B, hepatitis C, or HIV , these will be conducted by [CONTACT_2237], as 
applicable. Subjects with a positive serology , tuberculosis , or SARS -CoV-[ADDRESS_79510] not be included in the trial ( inclusion criteri on no. 10 and 
exclusion crit erion no. 23). 
Instruction for collection, processing, storage, and shipment of laboratory samples, as well as 
laboratory contact [CONTACT_73309] a separate laboratory 
manual.  
Laboratory t ests performed at the trial site  
Urine samples will be tested at the trial site with a dipstick according to the schedule of trial 
procedures (Section  4). At an unscheduled visit, it will be at the discretion of the investigator 
if urine sample s should be collected.  
If a dipstick shows any abnormal reading, a urine sample must always be co llected and sent to 
the central laboratory for further analysis, regardless of causality or investigator ’s assessment 
of significance.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79511] at Week 0 (baseline) must not be randomised in 
the trial (inclusion criterion no. 10 and exclusion criterion no. 23). The test will be repeated 
every [ADDRESS_79512].  
Reporting in eCRF  
It will be recorded in the eCRF if a blood sample was taken. If not, a reason should be 
provided. The investigator ’s assessment of the results (‘normal ’, ‘abnormal, not clinically 
significant ’, ‘abnormal, clinically significant ’) will also be recorded.  
It will be recorded in the eCRF if a urine sample was tested with a dipstick. If not, a reason 
should be provided. It will be recorded if the urine sample was sent to the central laboratory 
for further analysis (urinaly sis). In case urinalysis is conducted, the investigator ’s assessment 
of the results (‘normal ’, ‘abnormal, not clinically significant ’, ‘abnormal, clinically 
significant ’) will also be recorded.  
It will be recorded in the eCRF if the subject is a woman of c hildbearing potential and if a 
urine pregnancy test was conducted. If not, a reason should be provided. The date and 
outcome (‘positive ’, ‘negative ’) of the urine pregnancy test will also be recorded.  
Clinically significant abnormal laboratory results at s creening and baseline will be 
documented as medical history in the eCRF. At subsequent visits, any new clinically 
significant abnormal laboratory results, symptoms, or illnesses, as well as any clinically 
significant deterioration of a pre -existing conditi on after randomi sation will be reported as an 
AE as described in Sectio n 13.3. 
Refer to Appendix  3D for principles for data entry in the eCRF.  
11.4.6  Anti -drug antibodies measurements  
Blood samples will be collected to determine ADA levels at pre -determined time points 
according to the schedule of t rial procedures (Section  4). At an unscheduled visit, it will be at 
the discretion of the investigator if a blood sample to determine ADA levels sho uld be 
collected .  
Serum samples for determination of presence or absence of ADA will be analysed by a 
laboratory using a validated bioanalytical method. A tiered testing scheme will be employed,  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79513] major market ( EU, US, and JP ) or until 10 years after final 
CTR – whichever comes last.  
Reporting in eCRF  
It will be recorded in the eCRF if a n ADA blood sample was taken. If not, a reason should be 
provided.  Refer to Appendix  3D for principles for data entry in the eCRF.  
11.5 Pharmacokinetic assessments  
11.5.1  Blood sampling for analysis of  PK 
Blood samples for PK assessments will be collected at the time points specified in the 
schedule of trial procedures (Section  4). At an unscheduled visit, it will be at the discretion of 
the investigator if a blood sample to determine PK should be collected.  
Serum samples for determination of LEO 138559 concentrations will be analysed by a  
laboratory using a validated bioanalytical method . 
Instructions for collection, handling, and shipment of PK samples will be provided in a 
separate la boratory manual.  
Reporting in eCRF  
It will be recorded in the eCRF if the PK sample was taken; if not, a reason will be provided. 
Refer to Appendix  3D for principles for data entry in the eCRF.  
11.6 Pharmacodynamic s assessments  
11.6.1   Overview  
Biomarker expression in blood and skin (skin swabs and tape strips) will be measured to 
evaluate treatment effect of LEO  138559  on disease biomarkers and biomarkers related to the 
mechanism of action of LEO  138559  as presented in Sections 11.6.2 , 11.6.3 , and 11.6.4 . 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79514] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
 
The biomarker assessments are considered exploratory. A summary of the results will be 
included in the CTR if the results are available in time for this. Th e full 
pharmacodynamics/biomarker results will be reported in an addendum to the CTR.  
11.6.2  Blood  biomarkers  
Serum samples for biomarker analyses will be collected according to the schedule of trial 
procedures (Section 4). At an unscheduled visit, it will be at the discretion of the investigator 
if a blood sample should be collected  to determine blood biomarkers .  
The serum biomarkers to be analysed include, but are not limited to  
.  
Collection, handling, and shipment instructions for serum samples will be provided in a 
separate laboratory manual.  
Serum biom arker data will be described in a separate report appended to the CTR.  
Reporting in eCRF  
It will be recorded in the eCRF if PD blood  samples were taken. If not, a reason should be 
provided.   
Refer to Appendix  3D for principles for data entry in the eCRF . 
11.6.3  Skin swabs  
Skin swabs will be taken according to the schedule of trial procedures (Section  4). At an 
unscheduled visit, it will be at the discretion of the investigator if skin swabs should be taken .  
Skin swab s from both lesion al and non -lesional skin  will be performed to measure the 
abundance  of S. aureus  colonisation as well as for broad microbiome profiling based on 16  S 
rRNA  sequencing  at baseline  and Week 16. Subjects will be asked not to shower, bathe , or 
wash in general within 12 hours prior to the baseline and Week 16 visit s. 
S. aureus  colonisation will be analysed by [CONTACT_62865]. In addition, the skin microbiome may be 
characterised using next -generation sequencing.  
Collection, handling, and shipment instructions for skin swabs  are provided in a laboratory 
manual.  
Results from skin swabs  will be described in a separate report appended to the CTR.  
TMF-000616809 - Version 4. 0
CCI
CCI
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79515] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Reporting in eCRF  
It will be recorded in the eCRF if skin swabs  were taken and from which body location (volar 
arm, elbow pit , trunk, lower limbs, other) it was taken. If skin swabs  were not taken, a reason 
should be provided.   
Refer to Appendix  3D for principles for data entry in the eCRF.  
11.6.4  Tape strip s  
Tape strippi[INVESTIGATOR_73233] (Section  4). At 
an unscheduled visit, it will be at the discretion of the investigator if tape strip pi[INVESTIGATOR_73234] .  
Non-invasive tape strippi[INVESTIGATOR_73235]. At 
baseline, the assessment will be done in 2 areas: in a representative lesional area and in a 
non-lesional area which is anatomically similar to the lesional area. If an anatomically similar 
non-lesional area cannot be found, the volar forearm may be used instead. At the 
end-of-treatment  visit (or early IMP termination  visit, if applicable)  both the original lesional 
and a non -lesional area will  be sampled . Note that the lesion  sample  at the end-of-treatment  
(or early IMP termination  visit, if applicable)  should be taken from the original lesional area,  
even  if this lesion clears during the trial.   
Subjects will be instructed not to apply any emollients for at least 2 hours prior to visits that 
include tape strippi[INVESTIGATOR_007].  
Collection, handling, and shipment instructions for tape strips  samples are provided in a 
laboratory manual.  
Reporting in eCRF  
It will be recorded in the eCRF if the tape strips w ere collected and from which body 
locations (volar arm, lower limbs, trunk, other).  
Refer to Appendix  3D for principles for data entry in the eCRF.  
11.[ADDRESS_79516] administration  of IMP. This form will also be completed for subjects who 
permanently discontinue IMP and subjects who withdraw from trial (see Section  10.3 for 
early termination assessments) . 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79517] be recorded ( see Section  10.2.1 ).  
End-of-trial form  
At their last visit in the trial, a n end -of-trial form must be completed in the eCRF for all  
random ised subjects . The following data will be collected:  
• Did the subject c omplete the trial  (Section 7.3). If not, it will be recorded if the reason was 
due to the COVID -19 pandemic.  
• Date of last contact.  
• Primary reason for withdrawal from trial (death, pregnancy, adverse event, lack of 
efficacy, withdrawal by [CONTACT_1130], lost to follow -up, or other [if other, a specification should 
be provided]).   
• If the subject attended the primary endpoint visit (Week 16). I f not, the primary reason for 
not attending the visit (death, pregnancy, adverse event, lack of efficacy, withdrawal by 
[CONTACT_1130], lost to follow -up, or other [if other, a specification should be provided]).  
• If the subject attended the safety follow -up visit  (Week 32). If not, the primary reason for 
not attending the visit (see reasons above) should be provided.  
The end -of-trial form will be completed when the subject has had their last visit (that is, the 
follow -up visit at Week  32, or early termination visi t, or primary endpoint visit ). 
11.8 Estimate of total blood volume collected  
Blood samples will be drawn for haematology, biochemistry, serology, PK, PD, ADA, and 
safety assess ments . The total volume of blood to be drawn is approximately 200 mL. If 
additional blood samples are required, the amount of blood drawn may be more than this 
stated value; however, the total volume of blood drawn will be less than that taken during a 
blood donation (approximately 500  mL).  
11.9 Storage of biological samples  
Primary samples (set A samples) for PK will be discarded by [CONTACT_73310] (set B samples) stored at the central 
laboratory  will be retained no longer than 12 months after completion of the CTR.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79518] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Primary s amples (set A samples)  for ADA  evaluation will be discarded by [CONTACT_73311] (set B samples) stored at the central 
laboratory  will be retained until approval in first major market (US , EU, and JP) or  until 10 
years after final CTR  – whichever comes last. Any B  samples  that have been sent to the 
bioanalytical lab will also be discarded upon finalisation of the CTR. The B samples stored at 
the central laboratory will be transferred to a central archiv e facility  for long -term storage 
upon finalisation of the CTR . 
Biobank  
This protocol includes the collection and analysis of different biological samples. If consent is 
given by [CONTACT_423], LEO Pharma will store serum , skin swab , and tape str ip samples 
collected in a biobank established by [CONTACT_73312] ([LOCATION_013]) . The biobanked  biological samples will be used for future research 
performed by [CONTACT_73313] . Donation of the samples for future research is voluntary and 
subjects must give their written consent to confirm donation and storage and the terms 
associated herewith. The samples will be transferred from the relevant laboratory to the 
biobank. The samp les will be labelled with the trial ID, subject ID, and the sample date to 
protect the privacy of the subjects and to allow continued blinding for future analyses. The 
samples in this trial will be stored in the biobank for a maximum of 15 years after CTR  
finalisation , and will the n be destroyed . 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79519] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
12 Scientific rationale for trial design and a ppropriateness of assessments  
12.1 Scientific rationale for trial design  
The overall trial design is presented in Section 7.1 and illustrated in Section 3.  
The trial is designed to evaluate the efficacy and safety of SC admini stered LEO 1 [ZIP_CODE] 
450 mg Q2W compared with placebo Q2W in adults with moderate to severe AD . The trial 
design is considered appropriate to evaluate the trial objectives  (Section 6). 
Population  
The most important inclusion criterion for participation in the trial is an established diagnosis 
of AD (as defined by [CONTACT_73314]  (1) with a history of AD of at least 1 year 
prior to screening ), to ensure correct diagnosis and rule out differential diagnosis 
(Section  8.2). The AAD Consensus  Criteria are utilised in clinical trials and in clinical 
practice for the diagnosis of AD. The AAD Consensus Criteria are based on the long standing 
Hanifin and Rajka criteria  (52) but are updated to emphasi se both childhood and adult aspects 
of AD. 
Another prereq uisite for participation in the trial is a recent (within 6 months prior to the 
screening visit ) documented history of inadequate response to topi[INVESTIGATOR_73236] 
a subject for whom topi[INVESTIGATOR_73237], to ensure that the s ubject is 
candidate for the treatment.  
The other eligibility criteria have been chosen to ensure inclusion of the targeted patient 
population and safety of the subjects and to minimi se factors which could interfere with the 
efficacy and safety assessments  (Sections 8.2 and 8.3). 
Treatment and t reatment groups  
Based on PK, PD, and safety results of the FiM trial with LEO 138559 (LP 0145 -1315 ), the 
dose regimen LEO 1 [ZIP_CODE]  450 mg Q2W  was selected for investigation in this trial.  
In addition to the Q2W dosing schedule, a n additional dose of IMP will be given to the 
subjects at Week  1 to reach steady state exposure early in the treatment period . According to a 
PK model developed based on preliminary data from the FiM trial, the additional dose given 
at Week  1 should allow 75% of steady state exposure to be reached already after 3  weeks of 
treatment . 
The placebo control group will serve as reference to evaluate the efficacy and safety of 
LEO  138559. The use of a placebo control group allows for an evaluation of similarity to the 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79520] long enough to allow complete washout of any systemic AD 
treatment by [CONTACT_10585] 0 (baseline) but should not exceed [ADDRESS_79521], as established by [CONTACT_73315], has not significantly changed by  [CONTACT_10585] 0 
(Section 7.1). 
The 1-week washout  period is considered an appropriate length to ensure washout of any 
topi[INVESTIGATOR_73238] (TCS/TCI ) and esta blish a baseline for AD symptoms. In this period, the 
subject should apply a background treatment (emollient) on lesional and non -lesional skin at 
least twice daily for at least 7 consecutive days prior to baseline to keep their skin well 
moisturi sed in th e absence of systemic and/or topi[INVESTIGATOR_73238](s) (Section 7.1). 
AD is a chronic condition with a waxing and waning course. Subjects with moderate to severe 
AD oft en experience multiple flares during the course of a year and therefore a [ADDRESS_79522] will be asked to continue applying an emollient twice daily 
(or more frequently , if needed ) as a complement to the systemic t reatment (standard of care) 
and to keep their skin well moisturi sed (Section 7.1). 
After last dose of IMP, the 16-week safety follow -up period is considered an appro priate 
length before the last safety assessments are conducted (Section 7.1). 
Mitigation of bias  
The combination of randomi sation  and blinding ( Section 9.3.1 ) minimi ses the likelihood of 
allocation bias. The risk of allocation bias is further reduced through the use of central 
randomi sation . The use of randomi sation  also ensures that baseline facto rs will not be 
confounded with treatment. Randomi sation  within the strata defined by [CONTACT_73296] (‘stratum A ’ [EASI <21] or ‘stratum B ’ [EASI ≥21]) will limit any potential 
imbalance in the allocation of subjects across baseline disease sever ity.  
Endpoints and estimands  
The endpoints have been selected to evaluate the efficacy of LEO 138559 in improving the 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79523] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
severity and extent of AD, including objective signs of the disease, subjective symptoms (e.g. , 
itch), as well as HRQoL.  
Change in EASI s core from baseline to Week 16 has been chosen as primary endpoint 
because EASI allows capturing change in disease on a continuous scale with a degree of 
precision making it a suitable tool for modelling the exposure -response relationship of 
LEO  138559 (53). 
The primary estimand addressing the primary endpoint follows a hypothetical  strategy which 
attempts to quantify the effect of treatment, in the hypothetical situation, where one or more 
intercurrent events (initiat ion of rescue treatment or permanent discontinuation of IMP)  do not 
occur .   
12.2 Appropriateness of assessments  
Efficacy assessments  
EASI  and vIGA -AD are validated measures used in clinical practice and clinical trials by 
[CONTACT_73316]/or exten t of AD (see Sections 11.3.1  and 11.3.2 )  
(47-49). 
PROs  
A range of validated PROs will be used to assess subject perception of AD independently of 
the investigator or trial staff. The PROs have been selected to assess the key symptoms of AD 
(including itch ) and HRQoL (11.3.4 ). 
Safety assessments  
Standard clinical methods of subject evaluations, such as AE monitoring (Section 13), vital 
signs, physical examinations, ECG, laboratory testing including pregnancy testing , and ADA  
will be used to assess subject safety  (Section  11.4). Given some large proteins may cause 
indirect adverse cardiac effects upon long term exposure, data on ECG will be collected and 
evaluated  (11.4.4 ). Data on ADA will be collected in order to evaluate the potential 
immunogenicity of LEO 138559  (11.4.6 ). 
One AESI of lower respi[INVESTIGATOR_73239]-[ADDRESS_79524] defence of the lung and induce expression of epi[INVESTIGATOR_73240]  (13.6.1 ). Therefore, when blocking IL -22R, there is a potential for 
increased risk of infection. However, no SAEs were reported in the FiM trial ( LP0145 -1315 ) 
nor in subjects with AD treated with a mAb targeting IL‑22 (fezakinumab)  (36). Further,  
IL-22R is expressed on epi[INVESTIGATOR_73241], so immune cell responses to 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79525] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
infections are preserve d. For further information please refer to the current investigator ’s 
brochure (35). 
Pharmacokinetic assessments  
Serum  concentration of LEO 1 [ZIP_CODE]  will be measured to  further  characterise the PK  of 
LEO  138559 in subjects with moderate to severe  AD (Section  11.5). The serum 
concentrations will be summarised and reported in the CTR  as well as subjected to population 
PK analysis and reported separately , and may be used in  an exploratory exposure -response 
analysis to support dose selection in future clinical trials.  
Pharmacodynamics assessments  
Biomarkers will be evaluated in blood and skin of subjects to assess 1) target engagement in 
the skin, 2) the molecular response of  LEO [ADDRESS_79526], and 3) to identify sub -populations of AD 
patients with increased response to treatment.  
Serum samples from all subjects will be collected for assessment of PD markers in the blood. 
Serum samples will be analysed for IL -[ADDRESS_79527] microbiome profiling based on 16  S rRNA 
sequencing.  
Transcriptome profiling of tape strips will be used to further elucidate the pathophysiological 
mechanisms of AD and  to expand our understanding of the compound MoA. Biomarkers in 
tape strips will be assessed by [CONTACT_73317].   
 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79528] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
13 Adverse events  
13.1 Definition and classification  of adverse events  
Adverse events ( AEs) and serious adverse events (SAEs) are defined in  Appendix [ADDRESS_79529] has signed 
the ICF until completion of the clinical trial (all trial periods including safety follow -up visit 
at Week 32, see Section  7.3). 
AEs must be assessed by a physician . In the US only, certain AE assessments can be 
delegated to  investigators with other qualifications . However , the diagnosis, seriousness, and 
causality of the AEs must be assessed by a physician.  
At all visits, the subject will be asked a non -leading question by [CONTACT_73318], 
for example : “How have y ou felt since I saw you last?” No specific symptoms should  be 
asked for. It is important that the investigator  also observes the subject for any changes not 
reported by [CONTACT_73319].  
Principles  for data entry in the eCRF are descri bed in Sections 11.4.[ADDRESS_79530] be recorded on the AE form 
of the eCRF and should be described in the following manner:  
The AE term  must  be in precise English medical terminology ( that is, not necessarily the exact 
words used by [CONTACT_423]). Whenever possible, a specific diagnosis should be stated ( for 
example  ‘allergic contact [CONTACT_8748] ’). 
The duration  of the AE must be reported by [CONTACT_73320] (if the 
event is ongoing  it will also be recorded ). In addition, it will be recorded if th e AE started 
prior to first administration of IMP.  
AEs must be classified in terms of severity, causality, and outcome according to the 
definitions in Appendix 2. 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79531] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Action taken with IMP:  any action taken with IMP as a consequence of the AE must be 
recorded in the eCRF (dose not changed,  drug interrupted, drug discontinued , not applicable, 
unknow n). 
Other action taken : any other action taken as a result of the AE must be recorded (none, 
concomitant medication, concurrent procedure).  
It must be recorded in the eCRF if the AE led to permanent discontinuation of IMP and/or 
withdrawal from trial.  
13.4 Reporting of s erious adverse events  
The criteria that define an AE as serious ( that is , an SAE) are defined in Appendix [ADDRESS_79532] be reported to LEO Pharma on the (paper) SAE form within [ADDRESS_79533] 
knowledge. This repo rt should contain an assessment of available information on seriousness, 
severity, causal relationship to the IMP or trial procedure, the action taken, the outcome to 
date, and a narrative description of the course of the event.  
By [CONTACT_73321] S AE form, the investigator acknowledges that he/she is aware of 
the SAE and has assessed the causal relationship of the IMP(s) and any of the other 
medications to the SAE.  
The actual reporter, if not the investigator, should also sign and date the SAE report.  
The completed SAE form must be faxed or scanned and e -mailed to Global Safety at 
LEO  Pharma using the e -mail address or fax number below:  
Global Safety at LEO  Pharma  
E-mail address: drug.safety@leo -pharma.com  
Fax number: [PHONE_1768]  
If relevant,  the investigator will enclose other information with the SAE form, such as 
anonymised reports of diagnostic procedures, hospi[INVESTIGATOR_1097], autopsy reports, etc.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79534] 
by [CONTACT_3719] e -mail (see contact [CONTACT_73322]).  
The investigator must notify the local IRB(s)/IEC(s) of SAEs, as required by [CONTACT_73323].  
SAEs occurring after the completion of the clinical trial should not be routinely sought or 
recorded. However, such events should be reported to Global Safety at LEO  Pharma (see 
contact [CONTACT_73322] ) if the investigator becomes aware of them.  
13.4.2  LEO  Pharma reporting responsibilities  
Global Safety at LEO Pharma is responsible for assessing whether or not an SAE is expected. 
The relevant reference safety information document  for this clinical trial is  the investigator ’s 
brochure Section 7. 4, edition 4.0 and subsequent updates  (35).  
Global Safety at LEO Pharma will notify the regulatory authorities and concerned 
investigators of SAEs according to the current applicable legislation for the concerned 
countries.  
The IRB(s)/IEC(s) will be notified of SAEs according to the current applicable legislation for 
the concerned countries.  
For all non -US countries, the following reporting requirements apply: all SAEs which are 
assessed as causally related to the IMP(s) by [CONTACT_73324] (54), 
and which are unexpected ( suspected, unexpected serious adverse reactions [S[LOCATION_003]Rs]), are 
subject to expedited reporting to regulatory authorities, IEC(s)/IRB(s)  according to the current 
applicable legislation in the concerned countries. Investigators will be notified of the evolving 
safety profile of the IMP on an ongoing basis.  
For the US, the following reporting requirements apply: all SAEs which are assessed as 
causally related to the IMP(s) by [CONTACT_73313]  (55, 56) and which are unexpected ( serious 
and unexpected suspected adverse reactions [IND safety report]) are subject to expedited 
reporting to regulatory au thorities  and IRB(s) . Investigators will be notified of the evolving 
safety profile of the IMP on an ongoing basis . 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79535] knowledge using the (paper) 
pregnancy form (part  I). All pregnancies must be followed up until delivery or terminati on 
and final outcome must be reported on the (paper) pregnancy form (part  II) within [ADDRESS_79536] immediately discontinue IMP permanently and be withdrawn from the 
trial (Sections  10.2.1  and 10.3). 
13.[ADDRESS_79537] results, as appropriate. An AES I may be serious or non -serious. Serious AESIs require 
expedited reporting as described in Section 13.4.  
Panel 11: Adverse  events of special interest  
AESI  Additional data to be recorded  Data collection method  
Lower respi[INVESTIGATOR_54582]  • Infectious cause.  
• COVID -[ADDRESS_79538] performed in relation to 
event.  
• Known risk factors.  
• Smoking.  eCRF  
Abbreviation s: AESI = adverse events of special interest ; eCRF = electroni c case report form; COVID -19 = 
coronavirus disease [ADDRESS_79539] receiving a dose of IMP in excess of that specified in this 
protocol.  
The term ‘overdose ’ including a specification of why it occurred (accidental or intentional) 
must be recorded on the AE form of the eCRF. In addition, AEs originating from overdose 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79540] be recorded as separate events. If the AE originating from the overdos e qualifies as an 
SAE, expedited reporting is required (Section 13.4). 
LEO Pharma does not recommend specific treatment for an overdose. The investigator will 
use clinical judgement  to treat any overdose if necessary.  
13.6.[ADDRESS_79541] occurred should be recorded based on investigator jud gement. Treatment 
non-compliance (incl. missed doses) where no clinical consequence occurred or could have 
occurred should not be recorded as medication errors. See Section 9.8.[ADDRESS_79542] be recorded as separate events . If the AE 
originating from the medication error qualifies as an SAE, expedited reporting is required 
(Section 13.4). 
13.6.[ADDRESS_79543] other than defined in the protocol.  
Misuse refers to situations where the IMP is intentionally and inappropriately used for 
therapeutic purposes not in accordance with the  protocol.  
Abuse refers to intentional use of an IMP for what could be considered desirable 
non-therapeutic effects (e.g. , sedative, stimulant, euphoric effects).  
Misuse and abuse must be recorded on the AE form in the eCRF. In addition, any clinical 
conse quences of misuse/abuse must be recorded as separate AEs on the AE form. If the AE 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79544] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
originating from the misuse or abuse qualifies as an SAE, expedited reporting is required  
(Section 13.4). 
13.6.5  Aggravation of condition  
Any clinically significant aggravation/exacerbation/worsening of any medical condition(s) 
(including the trial disease), compared with screening, must be reported as an (S)AE in 
accordance with Sections  13.3 and 13.4. 
13.7 Follow -up for final outcome of adverse events  
During the trial, the investigator should follow -up for final outcome on all AEs (including 
SAEs). Once a subject leaves the clinical trial, the investigator should  follow -up on the 
outcome of all non -serious AEs classified as of possibly or probably related to the IMP for 
[ADDRESS_79545] cannot be expected to recover during the trial or the safety follow -up periods, for 
example chronic or stabilised conditions, the final outcome should be reported as ‘recovering ’ 
or ‘not recovered ’ as per the investigator ’s discretion . In additi on, a statement that the SAE 
has stabilised or is chronic should be added to the narrative description of the SAE on the 
SAE form.  
13.8 Handling of an urgent safety measure  
An urgent safety measure is a measure taken to implement an action/protocol deviation under 
an emergency. This is defined as “…the occurrence of any new event relating to the conduct 
of the trial or the development of the investigational medicinal product where that new event 
is likely to affect the safety of the subjects, the sponsor and the investigator shall take 
appropriate urgent safety measures to protect the subjects against any immediate 
hazard. ” (57). 
If the investigator becomes aware of information that requires an immediate change in a 
clinical tr ial procedure or a temporary halt of the clinical trial to protect clinical trial subjects 
from any immediate hazard to their health and safety, the investigator can do so without prior 
approval from LEO  Pharma , regulatory authorities, or IRBs/IECs.  
The investigator must immediately inform LEO Pharma – by [CONTACT_73325] – of this change in a clinical trial procedure or of the temporary 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79546] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
halt; the investigator will provide full details of the information and th e decision making 
process leading to the implementation of the urgent safety measure.  
LEO Pharma must act immediately upon receipt of the urgent safety measure notification in 
accordance with internal procedures and local legislation . 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79547] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
14 Statistical m ethods  
14.1 Sample size 
At baseline , a total of 52 subjects will be randomi sed 1:1: 
• 26 subjects to LEO 1 [ZIP_CODE]  450 mg Q2W . 
• [ADDRESS_79548] for pairwise consideration of 2 treatment groups  
based  on the following assumptions : 
Treatment  Expected reduction in EASI (SD)*  Attrition rate  
LEO  138559  22.9 (13) 30% 
Placebo  7.3 (18)  30% 
*Expected reduction in EASI for LEO  138559  is based on results from an upadacitini b phase 2b trial (28), and 
for placebo , the expected reduction is based on  a dupi[INVESTIGATOR_73242] 2b trial (58). 
With a significance level of 5% , [ADDRESS_79549] 80% to detect a difference between the 2 treatment groups. Assuming a 
maximum attrition rate of 30%, 26 subjects in each treatment group should be randomised 
into the trial.  
Assuming a screen ing failure rate of 35%, the planned number of subjects to screen is set to 
80. 
14.2 Trial analysis sets 
All screened subjects will be accounted for in the CTR.  
All subjects randomised  and exposed  to IMP  will be included in the full analysis set ( FAS) 
and will be analysed for efficacy. Exclusions from the FAS can be considered in special cases 
as described in ICH E9, Section 5.2.1., Full Analysis Set. If it is decided to exclude a  subject 
from the FAS, a justification addressing ICH E9 will be given.  
A safety analysis set (SAF)  will be defined as all subjects who will be exposed to  IMP.   
A PK analysis set will be defined as all subjects who will be exposed  to LEO 138559  and 
provide samples for measuring  serum concentrations  of LEO 138559 .  
The decisions regarding inclusion/exclusion of subjects or subject data from the trial analysis 
sets will be documented in the analysis set definition document before breaking the 
randomisation code . 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79550] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
14.3 Statistical analysis  
14.3.1  General principles  
All significance tests will be two -sided using the 5% significance level. All confidence 
intervals will be presented with 95% degree of confidence, unless otherwise specified. 
Efficacy analyses will be based on the FAS, and safety analys es will be based on the safety 
analysis set.  PK analysis  will be based on the PK analysis set.  
If not mentioned otherwise, endpoints will be summarised descriptively at each visit by 
[CONTACT_3148]. For endpoints evaluated over time, plots will be made to explo re the trajector ies 
with time.  
An observed cases approach will be used for tabulations of data by [CONTACT_765] (that is, involving 
only those subjects who attended each specific visit). For categorical endpoints , the number of 
subjects not attending each specific visit will also be  provided . 
Categorical data will be summarised by [CONTACT_1570] , using the number and percentage of 
subjects in each category. Continuous data will be summarised using the mean, median, 
standard deviation (SD), 1st quartile, 3rd quartile, minimum, and maximum values. 
Additionally, geometric mean and coefficient of variation (CV) will be provided for the PK 
endpoint.   
In general, for endpoints evaluated as change from baseline and/or where a  baseline 
adjustment is applied, baseline is defined as assessments conducted  at the randomisation visit 
(Visit 3), if not otherwise stated. If the information  is not available at the randomisation visit 
but at the (re)screening visit (Visit 1) then this w ill be used instead.  
All the analyses specified in the protocol will be reviewed in relation to the blinded data 
actually obtained, and the statistical analysis plan will be finali sed before breaking the 
randomi sation code.  
Any changes from the statistic al analyses planned in this clinical trial protocol will be 
described and justified in a protocol amendment, the statistical analysis plan , and/or in the 
CTR, dependent on the type of change.  
14.3.2  Handling of missing values  
The methods for handling of missing values for the primary endpoint  are described in 
Section  14.3.8 . 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79551] will be used , subjects with missing data 
will be considered as non -responders and their missing values will be imputed using NRI.  
14.3.3  Handling of intercurrent events related to  the COVID -19 pandemic  
As the implications of the COVID -19 pandemic might, extraordinarily, influence trial events 
and data in manners not foreseen by [CONTACT_73326], this section introduces the 
statistical considerations for handling of intercurrent events related to the pandemic for the 
primary endpoint.  
A supplementary estimand, ‘pandemic -modified composite ’, is introduced for analysis of the 
primary endpoint to address permanent discontinuation of IMP due to the pandemic as an 
intercurrent event. Details are desc ribed in Section  14.3.8 . 
Interruption of IMP administration during the treatment period (Week s 0–16) is not 
considered as an intercurrent event  if only 1 full dose (450 mg)  is missed . Observed data from 
subjects missing more than one dose will be ‘treated as missing ’. The causal relationship of 
permanent discontinuation of IMP related to the pandemic will be recorded in the eCRF.  
Handling of data affected by  [CONTACT_73327]-19 pandemic  
As a consequence of the pandemic and associated local preventive measures, subjects may 
miss an entire visit.  At scheduled visits, it will be recorded in the eCRF whether data are 
missing due to the pandemic.  
Observed data after permanent discontinuation of IMP related to the pandemic will be ‘treated 
as missing ’ and imputed assuming MAR. Similarly, missing data and/or initiation of rescue 
treatment  related to the pandemic will be imputed assuming MAR.  
It should be noted that a subject may have missing data related to the pandemic, even though 
the subject has not experienced an intercurrent event related to the pandemic.  
An overview of how observed and missing data will be handled according to the intercurrent 
events and their relatedness to  the pandemic is presented in  Section 14.3.7 . For the primary 
analysis of estimands , details of the analysis are described in Section 14.3.8 . 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79552] disposition summary table will be made including information of number of 
subjects who w ere screened, randomised, exposed  and who  completed  the trial, permanently 
discontinued IMP, and /or were  withdraw n from the trial (by [CONTACT_73328]).  
14.3.5  Demographics and other baseline characteristics  
Descriptive statistics of demographics and other baseline characteristics will be presented for 
all randomi sed subjects and by [CONTACT_1570]. Presentations of date of birth , age, sex, 
ethnicity, race , and baseline EASI score by [CONTACT_73329] .  
Other baseline characteristics include height, weight, BMI , duration of AD , concurrent 
diagnoses (from medical history and indications for concomitant medication), concomitant 
medication, and previous AD treatments.  
14.3.[ADDRESS_79553] to follow -up, or permanently 
discontinue IMP, their cumulated dose will be calc ulated up until the time of 
withdrawal/permanent discontinuation of IMP/loss to follow -up. 
Treatment compliance will be presented for the safety analysis set per treatment group as the 
percentages of missed IMP doses.  
14.3.7  Testing strategy  
This is a phase 2 a trial with the primary objective to investigate efficacy of LEO 138559 . For 
the primary endpoint, change in EASI score  from baseline to Week 16 , the statistical analysis 
will be controlled by 2-sided  alpha value of 5%. There will be no adjustment for the multiple 
testing of primary and secondary endpoints, all p -values will be considered nominal.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79554] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
14.3.8   Analysis of primary endpoint  
A primary and 3 supplementary estimands will be defined for the primary endpoint to ensure 
that occurrence of intercurrent events is taken into account  (Panel 12).
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79555] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Panel 12: Objective and estimands for primary endpoint   
Objective  Estimands  Endpoint  
 Estimand type 
(Primary/  
Supplementary)  Comparison 
groups  Interpretation of endpoint  Intercurrent events and strategy  Population 
level 
summary   
Primary 
objective  
To 
compare 
the 
efficacy of 
LEO 
138559 
with 
placebo in 
subjects 
with 
moderate  
to severe 
AD. Primary  Dose of 
LEO  138559 
450 mg Q2W 
vs. placebo . Change in EASI from baseline to Week  16 as 
if all subjects adhered to the treatment 
regimen, i.e. , they did not permanently 
discontinue IMP and did not use rescue 
treatment  before Week  16 (Section [IP_ADDRESS] ). Events: Permanent discontinuation 
of IMP, initiation of rescue 
treatment  
Strategy: ‘Hypothetical’ . Difference 
in mean 
change in 
EASI 
from 
baseline to 
Week  16. Primary 
endpoint  
Change in  
EASI 
score from 
baseline to 
Week 16.  
First 
supplementary  Change in EASI from baseline to Week  16 
without intercurrent events  (Section  [IP_ADDRESS] ). Events: Permanent discontinuation 
of IMP, initiation of rescue  
treatment  
Strategy: ‘Composite’ . 
Second  
supplementary  Change in EASI from baseline to Week  16 
without intercurrent events and as if 
COVID -19 pandemic did not happen  
(Section  [IP_ADDRESS] ). Events: Permanent discontinuation 
of IMP due to 
non-pandemic -related factors, 
permanent discontinuation of IMP 
due to pandemic -related factors, 
initiation of rescue treatment  
Strategy: ‘Pand emic -modified 
composite’ . 
Third  
supplementary  Change in EASI from baseline to Week  16 
regardless of intercurrent events  
(Section  [IP_ADDRESS] ). Events: Pe rmanent discontinuation 
of IMP, initiation of rescue 
treatment  
Strategy: ‘Treatment policy’ . 
Abbreviations : AD = atopic dermatitis; COVID -19 = coronavirus disease 2019; EASI = Eczema Area and Severity Index; IMP = investigational medicinal 
product; Q 2W = every second  week . 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79556] the interpretation of the estimated 
treatment effects:  
• Initiation of rescue treatment: This event occurs when a subject initiates rescue treatment. 
This event is disallowed during the first [ADDRESS_79557] will be withdrawn from the trial.  
• Permanent discontinuation of IMP independent of the COVID -19 pandemic: This event 
occurs when a subject permanently discontinues IMP  independe ntly of the pandemic . This 
event can occur at the subject's own initiative, at the discretion of the investigator or the 
sponsor, or if the subject is lost to follow -up. The timing of the event will be taken as the 
date of permanent discontinuation of IMP recorded in the eCRF .  
• Permanent discontinuation of IMP due to the COVID -19 pandemic: This event occurs 
when a subject permanently discontinues IMP due to circumstances related to the 
pandemic; not attributed to lack of efficacy or randomised treatment features considered 
unacceptable by [CONTACT_423].  
Depending on the estimand strategy selected, the occurrence of an intercurrent event may be 
ignored, lead to the exclusion of data observed after the occurrence of the event, be accounted  
for in the definition of a composite endpo int, or restrict the relevant observation window to 
the time prior to the occurrence of the intercurrent event  as described below.  
[IP_ADDRESS]  Primary estimand  
The primary estimand will use a hypothetical strategy  which attempts to quantify the effect of 
treatment, i n the hypothetical situation, where one or more intercurrent events do not occur. In 
this context, an intercurrent event refers to a post -randomi sation event that either precludes 
the existence of or affects the interpretation of the measurements of the en dpoint e.g. , 
permanent discontinuation of IMP.  
This primary estimand evaluates the treatment difference in change in EASI score from 
baseline to Week 16 as if all subjects adhered to the treatment regimen, i.e. , they did not 
discontinue IMP permanently an d no rescue treatment was made available before Week 16. 
Data collected after permanent discontinuation of IMP or after initiation of rescue treatment 
will not be included in the analysis , but will be ‘treated as missing ’ and imputed assuming 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79558] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
MAR . Similar ly, for subjects who experience a pandemic -related intercurrent event prior to 
Week  16, observed data at Week  16 will be ‘treated as missing ’ and imputed assuming MAR.  
If data is missing at Week  16 due to a non -pandemic -related intercurrent event, the data will 
be imputed using MI (100  iterations) assuming MAR within each treatment group  and 
whether the subject has experienced a non -pandemic -related intercurrent event. Within a 
given treatment group, observed data from su bjects not experiencing an intercurrent event 
will be used to impute missing data for subjects who experience an intercurrent event.  
Missing data or data ‘treated as missing ’ at Week [ADDRESS_79559] not 
experienced an intercurrent event.   
For each of the 100  complete datasets, the change in EASI score from baseline to Week 16 
will be analy sed using an ANCOVA model adjusted for treatment, region,  baseline E ASI 
score , and baseline disease severity . The pooled estimate of the difference in the LS -mean 
change from baseline, along with the associated 95%  CIs and nominal p -values will be 
presented based on applying Rubin ’s rules to the estimates and standard erro rs from the 
ANCOV A analysis of the imputed datasets.  
[IP_ADDRESS].[ADDRESS_79560] missing data . The estimates will be 
presented with nominal p -values and 95% CI at each visit.  
[IP_ADDRESS]  First supplementary estimand  
A first supplementary estimand will use  composite strategy  to handle intercurrent events. A 
composite strategy accounts for the occurrence of intercurrent events, through the definition 
of a suitable composite endpoint, whose components include the aforementioned intercurrent 
events, as well as the endpoint of interest.  
The first supplementary  estimand for the primary endpoint is the treatment difference in 
change in EASI score from baseline to Week 16 as if initiation of rescue treatment or  
permanent discontinuation of IMP  did not happen . For s ubjects who received rescue treatment 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79561] and do not 
experience an intercurrent event prior to this visit will be imputed as LOCF.  
The change in EASI score from baseline to Week 16 will be analy sed using an ANCOV A 
model adjusted for treatment , region, bas eline EASI score, and baseline disease severity . The 
difference in the LS -mean change from baseline between the treatment groups will be 
presented alo ng with the corresponding 95%  CI and nominal p -value . 
[IP_ADDRESS].[ADDRESS_79562] and do not experience an 
intercurrent event prior to this visit will be imputed as WOCF. The same ANCOV A model 
described for the primary analysis of the primary estimand wil l be used.  
[IP_ADDRESS]   Second supplementary estimand  
A second supplementary estimand will use a  pandemic -modified composite strategy . The 
strategy follows a composite strategy for intercurrent events independent of the COVID -[ADDRESS_79563], observed data after the event will be ‘treated as missing ’ and imputed 
assuming MAR.  
For imputation purposes, data available from all subjects will be used, but excluding 
individual subject data captured after the intercurr ent events.  
The procedure for imputing values will be implemented in a 2 -step procedure, where all 
missing or ‘treated as missing ’ data related to pandemic will be imputed using MI (100 
iterations) assuming MAR within treatment groups. Once the [ADDRESS_79564] 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79565] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
been generated by [CONTACT_51866], LOCF imputation of relevant data points not affected by [CONTACT_73330].  
For each of the 100 complete datasets, the change in EASI score from baseline to Week 16 
will be analy sed using an  ANCOVA model including treatment,  region, and baseline disease 
severity as factors and adjusting for baseline EASI score as covariate. The pooled estimate of 
the difference in the LS -mean change from baseline, along with the associat ed 95%  CIs and 
nominal p -values will be presented based on applying Rubin ’s rules to the estimates and 
standard errors from the aforementioned ANCOVA analysis of the imputed datasets .  
[IP_ADDRESS]  Third  supplementary estimand  
A third  supplementary estimand will use a  treatment policy strategy  which attempts to 
quantify the effect of the decision to treat subjects with the randomised  treatment, thus 
ignoring the occurrence of intercurrent events. Data collected for the primary endpoint  are 
used regardless of whether an intercurrent event (independent of the pandemic) occurred. 
Data collected after an event related to the pandemic will be ‘treated as missing ’ and imputed 
assuming MAR.  
This supplementary estimand will evaluate the treatment difference in change in EASI sco re 
from baseline to Week  16 regardless of permanent discontinuation of IMP or initiation of 
rescue treatment and as if the COVID -19 pandemic did not happen. Observed data will be 
used in the analysis, including the data observed after the occurrence of non -pandemic -related 
intercurrent events. For subjects who experience a pandemic -related intercurrent event prior 
to Week  16, observed data at Week  16 will be ‘treated as missing ’ and imputed assuming 
MAR.  
If data is missing at Week  16 due to a non -pandemic -related intercurrent event, the data will 
be imputed using MI (100  iterations) assuming MAR within each treatment group  and 
whether the subject has experienced a non -pandemic -related intercurrent event. Within a 
given treatment group, observed data from sub jects not experiencing an intercurrent event 
will be used to impute missing data for subjects who experience an intercurrent event.  
Missing data or data ‘treated as missing ’ at Week [ADDRESS_79566] not 
experienced an intercurrent event.   
For each of the 100  complete datasets, the change in EASI score from baseline to Week 16 
will be analy sed using an ANCOVA model adjusted for treatment, region,  baseline EA SI 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79567] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
score , and baseline disease severity . The pooled estimate of the difference in the LS -mean 
change from baseline, along with the associated 95%  CIs and nominal p -values will be 
presented based on applying Rubin ’s rules to the estimates and standard errors from the 
ANCOV A analysis of the imputed datasets . 
Panel 13 presents an overview of how observed and missing data will be handled according to 
the intercurrent ev ents for the analyses of estimands.  
 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79568] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Panel 13: Handling of intercurrent events and analyses of estimands for the primary endpoint   
Events  Data observed or 
missing  Estimand strategy  
Primary:  
‘Hypothetical’   
 First supplementary:  
‘Composite ’ Second  supplementary:  
‘Pandemic modified 
composite’   Third  supplementary:  
‘Treatment policy’   
Initiation of rescue 
treatmenta Observed  MI (MAR)  LOCF  LOCF  Used  
Missing  MI (MAR)  LOCF  LOCF  MI (MAR)  
Permanent 
discontinuation of IMP 
independent of  the 
pandemic  Observed  MI (MAR)  LOCF  LOCF  Used  
Missing  MI (MAR)  LOCF  LOCF  MI (MAR)  
Permanent 
discontinuation of IMP 
related to  the pandemic  Observed  Treated as missing, 
MI (MAR)  LOCF  Treated as missing,  
MI (MAR)  Treated as missing,  
MI (MAR)  
Missing  MI (MAR)  LOCF  MI (MAR)  MI (MAR)  
No intercurrent events  Observed  Used  Used  Used  Used  
Missing 
independent of  
the pandemic  MI (MAR)  LOCF  LOCF  MI (MAR)  
Missing related 
to the pandemic  MI (MAR)  LOCF  MI (MAR)  MI (MAR)  
Abbreviations:  COVID -19 = coronavirus disease 2019; IMP  = investigational medicinal product; LOCF= last observation carried forward;  
MAR  = missing at random; MI  = multiple imputation.  
a Initiation of rescue treatment is considered an intercurrent event regardless of the relatedness to the COVID -19 pandemic.
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date : 31-Jan-2022  Version: 4.[ADDRESS_79569] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
14.3.9  Analysis of secondary endpoint  
Analysis of the secondary endpoint  
• Number of treatment -emergent adverse events from baseline to Week [ADDRESS_79570].  
is described in Section [IP_ADDRESS]  in details.  
14.3.10  Analysis of explorator y efficacy  endpoints  
Binary endpoints  
The following endpoints;  
• Having a decrease in EASI of at least 50% (EASI 50) from baseline to Week 16.  
• Having a decrease in EASI of at least 75% (EASI 75) from baseline to Week 16.  
• Having a decrease in EASI of at least  90% (EASI 90) from baseline to Week 16.  
• Having vIGA -AD of 0 (clear) or 1 (almost clear) at Week 16.  
will be analy sed using  CMH test stratified by [CONTACT_73331]. Subjects 
who received rescue treatment prior to the Week  [ADDRESS_79571] missing data will be considered as non -responders.  Additionally, responder rates will be 
summari sed descriptively at each visit by [CONTACT_1570] . 
Time -to-event endpoint s  
The endpoint s; 
• Time to having a decrease in EASI of at least 50% (EASI 50) between baseline and 
Week  16. 
• Time to having a decrease in EASI of at least 75% (EASI 75) between baseline and 
Week  16. 
• Time to having a decrease in EASI of at least 90% (EASI 90) between baseline and 
Week  16. 
• Time to initiat ion of TCI or TCS rescue treatment  between  baseline and Week 16.  
will be analy sed according to Gray’s test, stratified by [CONTACT_73331] . 
Gray ’s test accounts for the occurrence of the competing risks, permanent discontinuation of 
IMP and initiation of rescue treatment . Inference will be based on the estimated cumulative 
incidence of achieving the endpoint  derived from the Aalen -Johansen estimator. The 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date : 31-Jan-2022  Version: 4.[ADDRESS_79572] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
estimated cumulative incidence functions will be presented by [CONTACT_73332] 
95% confidence bands.  
14.3.11  Analysis of p atient -reported outcomes  
Continuous endpoints  
The following endpoints;  
• Change in Worst Daily Pruritus NRS  (weekly average)  from baseline to Weeks 1, 2, 4, 8, 
12, and 16 . 
• Change in POEM score from baseline to Week 16. 
• Change in DLQI from baseline to Week 16.   
will be summari sed descriptively at each visit by [CONTACT_73333] a 
MMRM model including treatment, visit, interaction between treatment and visit, region  and 
baseline disease severity as factors and adjusting for baseline value for the endpoint of interest 
as covariate. The model will use an unstructured covariance matrix, Kenward  Roger 
approximation to estimate denominator degrees of freedom. For these en dpoints, data 
collected after permanent discontinuation of IMP or after initiation of rescue treatment  will 
not be included in the analysis but will be ‘treated as missing ’. This model assumes that data 
is missing at random within each treatment group. The  estimates will be presented with 
nominal p -values and 95% CI at each visit.  
Binary endpoint s 
The following endpoint s; 
• Having a de crease in  Worst Daily Pruritus NRS  (weekly average) of ≥3 points from 
baseline at Weeks 1, 2, 4, 8, 12, and 16 , assessed separately . 
• Having a decrease in Worst Daily Pruritus NRS  (weekly average) of ≥[ADDRESS_79573] Daily Pruritus NRS  ≥[ADDRESS_79574] described in Section 14.3.10  for binary endpoints.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date : 31-Jan-2022  Version: 4.[ADDRESS_79575] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Time -to-event endpoint s  
The endpoints;  
• Time to reduction of Worst Daily Pruritus NRS  (weekly average) of ≥3 points  between 
baseline and Week 16 . 
• Time to reduction of Worst Daily Pruritus NRS  (weekly average) of ≥[ADDRESS_79576] Daily Pruritus NRS  ≥4 
points.  
will be summari sed descriptively at each visit by [CONTACT_73334] 14.3.10  for time-to-event endpoints.  
14.3.12  Analysis of pharmacodynamics  
For t he following endpoints ; 
• Change in expression of AD disease biomarkers in serum from baseline to Week 16 . 
• Change in expression of AD disease biomarkers in skin from baseline to Week 16 . 
explorative analyses will be performed for the total population as well as by [CONTACT_73296] . 
A summary of the results will be included in the CTR if the results are available in time for 
this. The full set of biomarker results will be reported in an addendum to the CTR.  
14.3.13  Exploratory analyses  
Descriptive statistics of BSA score (absolute and change from baseline) will be summari sed at 
each visit by [CONTACT_1570] . Additional exploratory analyses will be described in the SAP 
and will be performed if deemed necessary.   
14.3.14  Analysis of safety  
The analysis of safety will be based on the safety analysis set . 
[IP_ADDRESS]  Adverse events  
AEs will be coded during the course of the trial according to the MedDRA. AEs will be 
presented by [CONTACT_73335].  
Treatment -emergent AEs will be summarised; however, all AEs recorded during the course of 
the trial will be included in subject data listings.  Treatment -emergent and non -treatment -
emergent AEs will be listed separately.  An event will be considered treatment -emergent if 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date : 31-Jan-2022  Version: 4.[ADDRESS_79577] 1  event, the number of events, and the event rate per 
100 patient years o f observation time.  
Related AEs are defined as AEs for which the investigator has not described the causal 
relationship to IMP as ‘not related ’.  
An overall summary of the number of events and the number (percentage) of subjects with 
any treatment -emergen t AEs, deaths, SAEs,  AESI s, permanent  discontinuations from IMP , 
and/or withdrawals from the trial due to AEs, treatment -related AEs, mild and moderate AEs , 
and severe AEs will be presented.  
Tabulations by [CONTACT_73336], SAEs, related AEs, 
AESIs, and AEs leading to withdrawal from trial and/or permanent discontinuation of IMP. In 
addition, all AEs will be presented by [CONTACT_73337], respectively.  
The number of AEs and number of subjects with each type of AEs will be tabulated  by 
[CONTACT_73338] 16 , from baseline to Week 32 , and  from Week 17 to 
Week 32 .  
SAEs will be evaluated separately and a narrative will be given.  AESIs will be tabulated and 
listed by [CONTACT_1570], no narratives will be given except if these are serious.   
AEs leading to withdrawal from trial and/or permanent discontinuation of IMP will be  
tabulated and listed . The detailed listing will provide an overview of the individual cases and 
include the age a nd sex of the subject, treatment received at the time of AE onset, the AE 
preferred and reported terms, causality and severity of the AE, the action taken with the IMP, 
AE outcome, start and stop date of AE, duration of AE, and number of days since first a nd last 
IMP administration. No narratives will be given.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date : 31-Jan-2022  Version: 4.[ADDRESS_79578] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
[IP_ADDRESS]  Vital signs and p hysical examination  
The change in vital signs (blood pressure, pulse, and body temperature) from baseline to each 
relevant visit will be summari sed by [CONTACT_73339], standard deviation (SD), 
median, minimum and maximum values for the safety analysis set.  
Subjects with abnormal, clinically significant physical findings will be listed. Furthermore, a 
shift table for physical findings showing the change from baseline to W eek 16 in clinical 
assessments (normal; abnormal, not clinically significant; abnormal, clinically significant) 
will be performed.  
[IP_ADDRESS]  ECG  
The change in ECG  from baseline to each visit will be summari sed by [CONTACT_73340], SD, median, minimum and maxi mum values for the safety analysis set.  
Subjects with abnormal, clinically significant ECG  will be listed. Furthermore, a shift table 
for ECG  showing the change from baseline to Week 16 in clinical assessments (normal; 
abnormal, not clinically significant;  abnormal, clinically significant) will be performed.  
[IP_ADDRESS]  Clinical laboratory evaluation  
The change in each of the laboratory parameters from baseline to each visit will be 
summari sed by [CONTACT_73339], SD, median, minimum and maximum values for the 
safety analysis set.  
Laboratory parameters will be classified as ‘low’, ‘normal ’, or ‘high’, depending on whether 
the value is below, within, or above the reference range, respectively. A shift table will be 
produced showing the categories at baseline agai nst those at the end of treatment. Subjects 
with laboratory parameters outside the reference range will be listed.  
[IP_ADDRESS]  Anti -drug antibodies  
For t he endpoint  
• Having a positive ADA response at Weeks 0, 4, 8, 12, 16, 32 , assessed separately . 
the ADA status (posit ive v s. negative) at each assessment time point  will be summarised by 
[CONTACT_1570]. If considered relevant, descriptive statistics including number of subjects, 
mean, SD, median, and range of the actual ADA titres by [CONTACT_73341]. The ADA status across the trial for each subject (positive v s. negative) will also be 
classified and summarised by [CONTACT_1570].  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date : 31-Jan-2022  Version: 4.[ADDRESS_79579] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
The association of ADA status across the trial (positive vs. negative) with AEs/SAEs may be 
evaluated. In addition,  the association of ADA titres (≥ median titre in positive subjects versus 
< median titre) with AE s/SAEs may be evaluated for ADA  positive treated subjects only. The 
ADA  positive subjects across the trial may also be divided into persistent positive versus  
transient positive. A subject will be considered as persistent positive if he/she has positive 
ADA for at least [ADDRESS_79580] will be 
considered as transient ADA positive. The associations between ADA and  AEs/SAEs may be 
summarised for both persistent positive subjects versus transient positives subjects.  
For subjects who develop ADA, the change in EASI at end of treatment will be listed.  
For ADA, all subjects with titre information will be listed.  Graph ical presentations may be 
performed.  
14.3.15  Analysis of p harmacokinetic s  
The endpoint  
• Serum concentration of LEO [ADDRESS_79581] ’s 
Week 16 visit. The CTR will include all data from the trial including data from the safety 
follow -up period.  
A written plan (trial blinding plan) detailing the blinded/unblinded staff for the interim 
analysis will be prepared before FSFV . 
 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date : 31-Jan-2022  Version: 4.[ADDRESS_79582] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
15 References  
1. Eichenfield LF. Consensus guidelines in diagnosis and treatment of atopic dermatitis. 
Allergy. 2004;[ADDRESS_79583] 78 :86-92. 
 
2. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev 
Dis Primers. 2018;4(1) :1-20. 
 
3. Dalgard FJ, Gieler U, Tomas -Aragones L, Lien L, Poot F, Jemec GBE, Misery L, 
Szabo C, Linder D, Sampogna F, et al. The psychological burden of skin diseases: a 
cross -sectional multicenter study among dermatological out -patients in [ADDRESS_79584] Dermatol. 2015;135(4) :984-991. 
 
4. Kiebert G, Sorensen SV , Revicki D, Fagan SC, Doyle JJ, Cohen J, Fivenson D. Atopic 
dermatitis is associated with a decrement in health -related quality of life. Int J 
Dermatol. 2002;41(3) :151-158. 
 
5. Deckers IA , McLean S, Linssen S, Mommers M, van Schayck CP, Sheikh A. 
Investigating international time trends in the incidence and prevalence of atopic 
eczema 1990 -2010: a systematic review of epi[INVESTIGATOR_9037]. PLoS One. 
2012;7(7) :e39803.  
 
6. Abuabara K, Yu AM, Okhovat JP, Allen IE, Langan SM. The prevalence of atopic 
dermatitis beyond childhood: A systematic review and meta -analysis of longitudinal 
studies. Allergy. 2018;73(3) :696-704. 
 
7. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations w ith asthma and 
other health and demographic factors: a US population -based study. J Allergy Clin 
Immunol. 2013;132(5) :[ADDRESS_79585], McKenzie AN, et al. A role for IL -25 and IL -33-driven type -2 
innate lymphoid cells in atopic dermatitis. J Exp Med. 2013;210(13) :[ADDRESS_79586] G, Homey B, Gilliet M, Ho S, 
Antonenko S, Lauerma A, et al. Human epi[INVESTIGATOR_73243]. Nat Immunol. 2002;3(7) :673-680. 
 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date : 31-Jan-2022  Version: 4.[ADDRESS_79587] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
10. Mashiko S, Mehta H, Bissonnette R, Sarfati M. Increased frequencies of basophils, 
type 2 innate lymphoid cells and Th2 cells in skin of patients with  atopic dermatitis 
but not psoriasis. Journal of Dermatological Science. 2017;88(2) :167-174. 
 
11. Brüggen MC, Bauer WM, Reininger B, Clim E, Captarencu C, Steiner GE, Brunner 
PM, Meier B, French LE, Stingl G. In Situ Mappi[INVESTIGATOR_73244]: Evidence for Remarkable Differences between Normal and Inflamed 
Skin. J Invest Dermatol. 2016;136(12) :2396 -2405.  
 
12. Maggi L, Montaini G, Mazzoni A, Rossettini B, Capone M, Rossi MC, Santarlasci V , 
Liotta F, Rossi O, Gallo O, et al. Human circula ting group 2 innate lymphoid cells can 
express CD154 and promote IgE production. J Allergy Clin Immunol. 
2017;139(3) :964-976.e964.  
 
13. Gittler JK, Shemer A, Suarez -Farinas M, Fuentes -Duculan J, Gulewicz KJ, Wang CQ, 
Mitsui H, Cardinale I, de Guzman Strong  C, Krueger JG, Guttman -Yassky E. 
Progressive activation of T(H)2/T(H)22 cytokines and selective epi[INVESTIGATOR_73245]. J Allergy Clin Immunol. 
2012;130(6) :1344 -1354.  
 
14. Nograles KE, Zaba LC, Shemer A, Fuentes -Duculan J, Cardinale I, Kikuchi T, Ramon 
M, Bergman R, Krueger JG, Guttman -Yassky E. IL -22-producing "T22" T cells 
account for upregulated IL -22 in atopic dermatitis despi[INVESTIGATOR_73246] -17-producing 
TH17 T cells. J Allergy Clin Immunol. 2009;123(6) :1244 -1252 e1242.  
 
15. Suarez -Farinas M, Dhingra N, Gittler J, Shemer A, Cardinale I, de Guzman Strong C, 
Krueger JG, Guttman -Yassky E. Intrinsic atopic dermatitis shows similar TH2 and 
higher TH17 immune activation compared with extrinsic atopic dermatitis . J Allergy 
Clin Immunol. 2013;132(2) :361-370. 
 
16. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, 
Bergman JN, Chamlin SL, Cohen DE, Cooper KD, et al. Guidelines of care for the 
management of atopic dermatitis: section 2. Manageme nt and treatment of atopic 
dermatitis with topi[INVESTIGATOR_12491]. J Am Acad Dermatol. 2014;71(1) :116-132. 
 
17. Kim BS, Howell MD, Sun K, Papp K, Nasir A, Kuligowski ME, Investigators IS. 
Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibito r) or 
triamcinolone cream. Journal of Allergy and Clinical Immunology. 2020;145(2) :572-
582. 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date : 31-Jan-2022  Version: 4.[ADDRESS_79588] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
 
18. Nakagawa H, Nemoto O, Igarashi A, Saeki H, Kaino H, Nagata T. Delgocitinib 
ointment, a topi[INVESTIGATOR_73247], in adult patients with moderate to sever e 
atopic dermatitis: A phase 3, randomized, double -blind, vehicle -controlled study and 
an open -label, long -term extension study. J Am Acad Dermatol. 2020;82(4) :823-831. 
 
19. Japan Tobacco Inc. Japan Tobacco delgocitinib (Corectim®) PMDA approval 
(30200AMX00046000). 2020.  
 
20. Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, Chamlin 
SL, Cooper KD, Feldman SR, Hanifin JM, et al. Guidelines of care for the 
manage ment of atopic dermatitis: section 3. Management and treatment with 
phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2) :327-349. 
 
21. Haeck IM, Knol MJ, Ten Berge O, van Velsen SG, de Bruin -Weller MS, Bruijnzeel -
Koomen CA. Enteric -coated mycop henolate sodium versus cyclosporin A as long -
term treatment in adult patients with severe atopic dermatitis: a randomized controlled 
trial. J Am Acad Dermatol. 2011;64(6) :1074 -1084.  
 
22. Schram ME, Roekevisch E, Leeflang MM, Bos JD, Schmitt J, Spuls PI. A randomized 
trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin 
Immunol. 2011;128(2) :353-359. 
 
23. Guttman -Yassky E. Lebrikizumab, a High -Affinity IL -13 Inhibitor, Improves Clinical 
Manifestations in Moderate -to-Severe Atopic Dermatitis: Primary Results From a 
Randomized, Double -Blinded, Placebo -Controlled, Dose -Ranging, Phase 2b Study. 
2019.  
 
24. Kabashima K, Furue M, Hanifin JM, Pulka G, Wollenberg A, Galus R, Etoh T, Mihara 
R, Nakano M, Ruzicka T. Nemolizumab in patients wit h moderate -to-severe atopic 
dermatitis: Randomized, phase II, long -term extension study. J Allergy Clin Immunol. 
2018;142(4) :1121 -1130.e1127.  
 
25. Wollenberg A, Howell MD, Guttman -Yassky E, Silverberg JI, Kell C, Ranade K, 
Moate R, van der Merwe R. Treatme nt of atopic dermatitis with tralokinumab, an anti -
IL-13 mAb. J Allergy Clin Immunol. 2019;143(1) :135-141. 
 
26. Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, Biswas P, 
Valdez H, DiBonaventura M, Nduaka C, Rojo R. Efficacy and Safety  of Abrocitinib in 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date : 31-Jan-2022  Version: 4.[ADDRESS_79589] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Patients With Moderate -to-Severe Atopic Dermatitis: A Randomized Clinical Trial. 
JAMA Dermatology. 2020;156(8) :863-873. 
 
27. Guttman -Yassky E, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R, de la 
Peña A, Nunes FP, Janes J, Gam alo M, et al. Baricitinib in adult patients with 
moderate -to-severe atopic dermatitis: a phase 2 parallel, double -blinded, randomized 
placebo -controlled multiple -dose study. J Am Acad Dermatol. 2018;S0190 -
9622(18) :[ZIP_CODE] -[ZIP_CODE].  
 
28. Guttman -Yassky E, Thaçi D, Pangan AL, Hong HC, Papp KA, Reich K, Beck LA, 
Mohamed MF, Othman AA, Anderson JK, et al. Upadacitinib in adults with moderate 
to severe atopic dermatitis: 16 -week results from a randomized, placebo -controlled 
trial. J Allergy Clin Immunol. 2020;145(3) :877-884. 
 
29. European Medicines Agency. Baricitinib; assessment report (EMA/[ZIP_CODE]/2017 and 
EMEA/H/C/004085/0000). 2016.  
 
30. Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, 
King BA, Thyssen JP, Silverberg JI, Bieber T, et al . Baricitinib in patients with 
moderate -to-severe atopic dermatitis and inadequate response to topi[INVESTIGATOR_030]: results from two randomized monotherapy phase III trials. Br J 
Dermatol. 2020;183(2) :242-255. 
 
31. Thijs JL, Strickland I, Bruijnzeel -Koomen C, Nierkens S, Giovannone B, Csomor E, 
Sellman BR, Mustelin T, Sleeman MA, de Bruin -Weller MS, et al. Moving toward 
endotypes in atopic dermatitis: Identification of patient clusters based on serum 
biomarker analysis. J Allergy Clin Immunol. 2017;140( 3):730-737. 
 
32. Bieber T, D'Erme AM, Akdis CA, Traidl -Hoffmann C, Lauener R, Schäppi G, Schmid -
Grendelmeier P. Clinical phenotypes and endophenotypes of atopic dermatitis: Where 
are we, and where should we go? J Allergy Clin Immunol. 2017;139(4s) :S58-s64. 
 
33. Wolk K, Witte E, Witte K, Warszawska K, Sabat R. Biology of interleukin -22. Semin 
Immunopathol. 2010;32(1) :17-31. 
 
34. Kotenko SV , Izotova LS, Mirochnitchenko OV , Esterova E, Dickensheets H, Donnelly 
RP, Pestka S. Identification, cloning, and characterization of a novel soluble receptor 
that binds IL -22 and neutralizes its activity. J Immunol. 2001;166(12) :7096 -7103.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date : 31-Jan-2022  Version: 4.[ADDRESS_79590] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
 
35. LEO Pharma A/S. Investigator's Brochure, LEO [ADDRESS_79591] 
LP0145 (edition 4.0). 2021.  
 
36. Guttman -Yassky E, Khattri S, Brunner P, Neumann A, Malik K, Fuentes -Duculan J, 
Garcet S, Suarez -Farinas M, Lebwohl M, Krueger J. 313 A pathogenic role for 
Th22/IL -22 in atopic dermatitis is established by a placebo -controlled trial with an anti 
IL-22/ILV -094 mAb. J ournal of Investigative Dermatology. 2017;137(5) :S53. 
 
37. [COMPANY_007] INC. Protocol (3199K1 -2001 (B1981001)); A Randomized, Parallel, Double -
Blind, Placebo -Controlled Study to Evaluate the Efficacy and Safety of ILV -094 
Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis on a 
Stable Background of Methotrexate. 2015.  
 
38. WMA. World Medical Association. Declaration of Helsinki – ethical principles for 
medical research involving human subjects. Amended by [CONTACT_941] 64th WMA General 
Assembly, Fortal eza, Brazil. 2013.  
 
39. ICH. International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use: Integrated Addendum to ICH E6(R1): Guideline for 
Good Clinical Practice. (E6)(R2), Step 4; 09 -Nov. 2016.  
 
40. EMA. European Me dicines Agency. Guidance on the Management of Clinical Trials 
during the COVID -19 (Coronavirus) Pandemic. Version 3. 2020.  
 
41. FDA. FDA Guidance on Conduct of Clinical Trials of Medical Products during 
COVID -19 Public Health Emergency. 2020.  
 
42. Global I nitiative for Asthma. Global Strategy for Asthma Management and 
Prevention. 2020.  
 
43. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for 
reporting parallel group randomised trials. BMC Med. 2010;8 :18. 
 
44. Johansson SG, Bieber T , Dahl R, Friedmann PS, Lanier BQ, Lockey RF, Motala C, 
Ortega Martell JA, Platts -Mills TA, Ring J, et al. Revised nomenclature for allergy for 
global use: Report of the Nomenclature Review Committee of the World Allergy 
Organization, October 2003. J Aller gy Clin Immunol. 2004;113(5) :832-836. 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date : 31-Jan-2022  Version: 4.[ADDRESS_79592] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
 
45. Sampson HA, Muñoz -Furlong A, Campbell RL, Adkinson NF, Bock SA, Branum A, 
Brown SG, Camargo CA, Cydulka R, Galli SJ, et al. Second symposium on the 
definition and management of anaphylaxis: summary report --Second National Institute 
of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. 
J Allergy Clin Immunol. 2006;117(2) :391-397. 
 
46. European Commission. EudraLex: The Rules Governing Medicinal Products in the 
European Union. Guidelines for good manufacturing practices for medicinal products 
for human and veterinary use. 2010;V olume 4.  
 
47. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area 
and severity index (EASI): assessment of reliability in atopic dermat itis. EASI 
Evaluator Group. Exp Dermatol. 2001;10(1) :11-18. 
 
48. HOME. Harmonising Outcome Measures for Eczema. Eczema Area and Severity 
Index (EASI) case report form. Aged 8 and over. 2017.  
 
49. Eli Lilly and Company. Validated Investigator Global Assessm ent scale for Atopic 
Dermatitis. vIGA -AD™. 2017.  
 
50. Charman CR, Venn AJ, Williams HC. The patient -oriented eczema measure: 
development and initial validation of a new tool for measuring atopic eczema severity 
from the patients' perspective. Arch Dermatol . 2004;140(12) :1513 -1519.  
 
51. Finlay AY , Khan GK. Dermatology Life Quality Index (DLQI) --a simple practical 
measure for routine clinical use. Clin Exp Dermatol. 1994;19(3) :210-216. 
 
52. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta D erm Venereol. 
1980;60(92) :44-47. 
 
53. Barbier N, Paul C, Luger T, Allen R, De Prost Y , Papp K, Eichenfield LF, Cherill R, 
Hanifin J. Validation of the Eczema Area and Severity Index for atopic dermatitis in a 
cohort of 1550 patients from the pi[INVESTIGATOR_031] c ream 1% randomized controlled 
clinical trials programme. Br J Dermatol. 2004;150(1) :96-102. 
 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date : 31-Jan-2022  Version: 4.[ADDRESS_79593] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
54. ICH. International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use. Integrated addendum to ICH E6(R1): Guideline for 
good  clinical practice E6(R2). 2016.  
 
55. FDA. The Food and Drug Administration. Guidance for Industry and Investigators. 
Safety Reporting Requirements for INDs and BA/BE Studies. 2012.  
 
56. FDA. The Food and Drug Administration. Guidance for Clinical Investig ators, 
Sponsors, and IRBs. Adverse Event Reporting to IRBs - Improving Human Subject 
Protection. 2009.  
 
57. European Parliament Union, European CoT. Directive 2001/20/EC of the European 
Parliament and of the Council of [ADDRESS_79594] of clinical trials on medicinal 
products for human use. 2001.  
 
58. Thaci D, Simpson EL, Beck LA, Bieber T, Blau velt A, Papp K, Soong W, Worm M, 
Szepi[INVESTIGATOR_22938], Sofen H, et al. Efficacy and safety of dupi[INVESTIGATOR_73248] -to-severe atopic dermatitis inadequately controlled by [CONTACT_12523][INVESTIGATOR_12969]: a 
randomised, placebo -controlled, dose -ranging phase 2b tr ial. Lancet. 
2016;387([ZIP_CODE]) :40-52. 
 
59. Ge M, Durham LK, Meyer RD, Xie W, Thomas N. Covariate -Adjusted Difference in 
Proportions from Clinical Trials Using Logistic Regression and Weighted Risk 
Differences. Drug Information Journal. 2011;45(4) :481-493. 
 
60. ICH. International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use: Clinical Safety Data Management. Definitions and 
Standards for Expected Reporting (E2A), Step 4; [ADDRESS_79595]. 1994.  
 
61. CIOMS. International Ethical G uidelines for Health -related Research Involving 
Humans. Council for International Organizations of Medical Sciences. 4th. Geneva. 
2016.  
 
62. EFPIA. European Federation of Pharmaceutical Industries and Associations. 
Principles for Responsible Clinical Trial  Data Sharing. 2013.  
 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date : 31-Jan-2022  Version: 4.[ADDRESS_79596] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Appendix 1: Definitions of adverse events and serious adverse events  
Adverse event definition  
An AE is defined as any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product and which does not necessarily have a causal 
relationship with this treatment. An AE can therefore be any unfavourable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (in vestigational) product, whether or not related to the medicinal 
(investigational) product.  (60) 
This definition includes:  
• Accidental injuries.  
• Events related to trial procedures.  
• Reasons for any unfavourable and unplanned change in medication (drug and/or dose).  
• Clinically significant worsening of pre -existing conditions.  
• Reasons for admission to hospi[INVESTIGATOR_73249] *.  
• AEs commonly observed  and AEs anticipated based on the pharmaco logical effect of the 
IMP.  
• Any laboratory abnormality assessed as clinically significant by [CONTACT_093] (see 
Section 11.4.5. 2). 
Serious adver se event definition  
An SAE is any untoward medical occurrence that:  
• Results in death.  
• Is life -threatening – at risk of death at the time of the SAE (not an event that 
hypothetically might have caused death if more severe).  
• Requires inpatient hospi[INVESTIGATOR_15574] *.  
• Results in persistent or significant disability  or incapacity.  
• Is a congenital anomaly  or birth defect.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date : 31-Jan-2022  Version: 4.[ADDRESS_79597] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
• Is a medically important condition. Events that may not be immediately life -threatening or 
result in death or hospi[INVESTIGATOR_73250]. Examples 
are intensive treatment in an emergency room or at home for allergic bronchospasm , blood 
dyscrasias , and convulsions that do not result in hospi[INVESTIGATOR_11956], development of drug 
dependency , or drug abuse.  
*Hospi[INVESTIGATOR_73251].  
Hospi[INVESTIGATOR_73252] a pre -existing condition which did not worsen from 
the subject consented to trial participation is not considered an AE and should therefore not be 
reported as AE or SAE, even if not planned before consent to trial participation.  
Hospi[INVESTIGATOR_73253] E. 
Hospi[INVESTIGATOR_73254].  
Complications that occur during hospi[INVESTIGATOR_73255]. If a complication prolongs 
hospi[INVESTIGATOR_73256], the event is an SAE.  
When in dou bt as to whether hospi[INVESTIGATOR_73257], the AE should be considered serious.  
Definition of  adverse events of special intere st 
An AESI  (serious or non -serious) is one of scientific and medical concerns specific to the 
sponsor's product or programme, for which ongoing monitoring may be appropriate. Such an 
event might warrant further investigation in order to characterise and understand it. 
Depending on the nature of the event rapid communication by [CONTACT_73342]/or from the sponsor t o other parties (e.g. , regulators) might also be warranted.   
AESIs are described in Section s 13.6.1 . 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date : 31-Jan-2022  Version: 4.[ADDRESS_79598] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Appendix 2: Classification of adverse events  
Severity  
The severity  of the AE should be described in terms of mild, moderate , or severe according to 
the investigator ’s clinical judgement.  
Mild  An AE that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual 
activities of daily living.  
Moderate  An AE that is usually alleviated with additional specific thera peutic 
intervention. The event interferes with usual activities of daily living, 
causing discomfort but poses no significant or permanent risk of harm to the 
subject.  
Severe  An AE that interrupts usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention.  
If the severity of an AE worsens, a new AE should be recorded.  
Causality  
The causal relation  of the AE to the use of the IMP should be described in terms of probably, 
possibly, or not rel ated according to the investigator ’s clinical judgement.  
Probably 
related  Follows a reasonable temporal sequence from administration of the IMP.  
 
Could not be reasonably explained by [CONTACT_423] ’s clinical state, 
environmental or toxic factors or other th erapi[INVESTIGATOR_73258].  
 
Follows a known pattern of response to the IMP.  
 
Disappears or decreases on cessation or reduction in dose of the IMP.  
 
Reappears or worsens upon re -challenge.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date : 31-Jan-2022  Version: 4.[ADDRESS_79599] ’s clinical state, 
environmental or toxic factors or other therapi[INVESTIGATOR_73258].  
 
Follows a known pattern of response to the IMP.  
Not related  
 Does not follow a reasonable temporal sequence from administration of the 
IMP.  
 
Is better explained by [CONTACT_73343] ’s clinical state, 
environmental or toxic factors or other therapi[INVESTIGATOR_73258].  
 
Does not reappear or worsen upon re-challenge.  
 
Does not follow a known pattern of response to the IMP.  
 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date : 31-Jan-2022  Version: 4.[ADDRESS_79600] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Outcome  
The outcome  of the event according to the investigator ’s clinical judgement should be 
classified using the categories below.  
Recovered/  
resolved  The event has stopped. The stop date of the event must be recorded.  
Recovering/  
resolving  The subject is clearly recovering from an event. The event is not yet 
completely resolved.  
Not 
recovered/  
not resolved  Event is still ongoing.  
Recovered/    
resolved with 
sequelae  The event  has reached a state where no further changes are expected and the 
residual symptoms are assumed to persist. An example is hemiparesis after 
stroke.  
 
The stop date of the event must be recorded. In case of a SAE, the sequelae 
should be specified.  
Fatal  The subject has died as a consequence of the event. Date of death is recorded 
as stop date for the AE.  
Unknown  Unknown to investigator, e.g. , subject lost to follow -up. 
 
LEO Pharma definitions versus CDISC definitions  
Note that as per the above definition, LEO Pharma uses “recovered/resolved ” only if an event 
has actually stopped. According to the CDISC definition, the category “recovered/resolved ” 
also includes events which have improved. However, following the LEO Pharma definitions 
above, such an improved event will instead be classified as “not recovered/not resolved ” or 
“recovering/resolving ”. 
Similarly, it should be noted that as per the above definition, LEO Pharma uses 
“recovered/resolved with sequelae ” only if a n event has reached a state where the residual 
symptoms are assumed to persist. According to CDISC, an event is considered “with 
sequelae ”, if it has “retained pathological conditions ”. Consequently, it is likely that some of 
the events classified by [CONTACT_73344] “recovered/resolved with sequelae ” 
could have been classified with the outcome “recovered/resolved ” according to the CDISC 
definition.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date : 31-Jan-2022  Version: 4.[ADDRESS_79601] cannot be expected to recover 
during the trial or the safety follow -up periods, for example chronic illnesses, the final 
outcome should be reported as ‘recovering ’ or ‘not recovered ’ as per the investigators 
discretion ; in addition, a statement that the SAE has stabilised or is chronic should be added 
to the narrative description of the SAE on the SAE form.   
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79602] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Appendix 3: Trial governance considerations  
Appendix 3A: Regulatory and ethical considerations  
This trial will be conducted in accordance with the protocol and with the following:  
• Consensus ethical principles derived from international guidelines including the 
current version of the Declaration of Helsinki (38) and Council for International 
Organi sations of Medical Sciences (CIOMS) International Ethical Guidel ines (61). 
• Current version of applica ble International Council for Harmonisation Good Clinical 
Practice ( ICH GCP) Guidelines (54). 
• EU Genera l Data Protection Regulation 2016/679 of 27  April  2016.  
• Applicable laws and regulations.  
The appropriate regulatory authority(ies) must be notified of/approve the clinical trial as 
required.  
Any documents that the IRB/IEC may need to fulfil its responsibilities (such as the trial 
protocol, protocol amendments, investigator ’s brochure [as applicable], subject information 
sheet , and  informed consent form [s], or advertisements) will be submitted to the IRB/IEC. 
These documents must be reviewed and approved by [CONTACT_1201]/IEC before the trial is initiated.  
Any amendments to the protocol must be approved by/receive favourable opi[INVESTIGATOR_73259]/IECs, as required, prior to implementation.  
The principal investigator [INVESTIGATOR_1318] b e responsible for the following, if required by [CONTACT_71882]:  
• Providing written summaries of the status of the trial to the IRB/IEC annually or more 
frequently in accordance with the requirements, policies, and procedures established 
by [CONTACT_1201]/IEC.  
• Notifying the local IRB/IEC of SAEs or other significant safety findings as required 
by [CONTACT_1744]/IEC procedures.  
• Providing oversight of the conduct of the trial at the trial site and ensuring adherence 
to applicable national and international legislation.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79603] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Append ix 3B: Informed consent process  
Subjects will receive written and verbal information concerning the clinical trial. This 
information will emphasise that participation in the clinical trial is voluntary and that the 
subject may withdraw from the clinical t rial at any time and for any reason. All subjects will 
be given an opportunity to ask questions and will be given sufficient time to consider before 
consenting.  
The subject ’s signed and dated informed consent to participate in the clinical trial will be 
obtained prior to any clinical trial -related procedure being carried out in accordance with 
ICH GCP and all applicable laws and regulations.  The authorised person obtaining the 
informed consent must also sign the ICF.  
Subjects will be re -consented to the mos t current version of the ICF(s) during their 
participation in the trial, if required.  
A copy of the ICF(s) must be provided to the subject.  
Subject card  
At screening, subjects will be provided with a card stating that they are participating in a 
clinical  trial and which contains contact [CONTACT_49761](es) and telephone number(s) of relevant trial 
site staff including the number for the investigator in case of emergency situations. The 
subject card also includes a local telephone number for the emergency unblindi ng CRO to be 
used if the investigator or delegated site staff cannot be reached or if unblinding in the IRT 
cannot be performed.  
Appendix 3C: Subject and data confidentiality  
This clinical trial protocol as well as all other information, data, and results relating to this 
clinical trial and/or to the IMP is confidential information of LEO Pharma and shall not be 
used by [CONTACT_73345].  
The investigator agrees that LEO Pharma may use any and all information, data , and results 
from this clinical trial in connection with the development of the IMPs and, therefore, may 
disclose and/or transfer information, data and/or results to other investigators, regulatory 
authorities , and/or  commercial partners.  
Trial subjects will be assigned a unique identifier (subject  ID) by [CONTACT_73313] . Any subject’s 
records or datasets that are transferred to LEO  Pharma  will contain the identifier only; subject 
names or any information which would make the subject identifiable will not be t ransferred.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79604] be informed and consent to that their medical records may be examined by 
[CONTACT_73346] , 
by [CONTACT_6667]/IEC members, and by [CONTACT_6668].  
Trial subjects must be informed that LEO Pharma might keep their trial -related data for as  
long as they are useful for developi[INVESTIGATOR_73260].  
Processing of personal data  
This protocol specifies the personal data on trial subjects (for example race, ethnicity, age, 
gender, health condition, medical history, test results, etc.) which shall be collected as part of 
the clinical trial and processed during and after trial completion.  
Personal data collected as part of the clinical trial will be transferred to/from the 
institution/investigator, LEO  Pharma , and  third parties acting on behalf of LEO  Pharma . 
Processing of personal data on behalf of LEO Pharma requires a written agreement between 
LEO  Pharma  and the relevant party which covers collection, processing , and  transfer of 
personal data in the clinical trial  as well as reporting obligations in the event of any data 
breach . In certain cases,  an agreement on transfer of personal data may also be required.  
Investigators and LEO  Pharma  must ensure that collection, processing , and transfer of 
personal data are in compliance with applicable legislation on data protection and privacy, 
including but not limited to the EU General Data Privacy Regulation.  
Subjects will be asked to consent to the collection, processing,  and transfer of their personal 
data to EU and non -EU countries for the purpose of conducting the clinical trial, research and 
development of new or existing products/services, improving existing products/services, 
applying for marketing authorisations for products/serv ices, marketing of products/services , 
and other related activities.  
LEO Pharma has obtained the necessary authorisations for the processing of personal data 
collected in the trial.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79605] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Appendix  3D: Record keepi[INVESTIGATOR_007], quality control, and data handling  
Source data  at trial sites  
For all data recorded, the source document must be defined in a source document agreement 
or similar document at each trial site. There must only be [ADDRESS_79606] ’s medical record or other 
defined document normally used at the trial site. Source data not normally collected as a 
routine part of the clinical practice at the site may be entered on a worksheet. Clinical 
assessments/safety evalua tions must be signed and dated by [CONTACT_73347].  
If the worksheet does not become part of the subject ’s medical record, the following should as 
a minimum be added to the subject ’s medical record:  
• Subject ID.  
• A statement from the investigator to verify that each of the eligibility criteria were met 
and documented.  
• Randomisation code number . 
• The fact that the subject is participating in a clinical trial in AD including treatment with 
LEO 138559  or placebo  for 16 weeks. 
• Other relevan t medical information.  
Trial monitoring  
During the course of the trial, CRA(s) (blinded and unblinded ) will visit the trial site. These 
visits have the following objectives: (i) to continually verify source data to confirm that data 
entered into the eCRF b y authorised site personnel are accurate, complete, and verifiable from 
source documents; (ii) to confirm that the safety and rights of subjects are being protected; 
and (iii) to confirm that the trial is being conducted in accordance with the currently ap proved 
protocol and any other trial agreements, ICH GCP, and all applicable regulatory requirements.  
The monitoring will be performed in a systematic, prioritised, risk -based approach, and as a 
combination of on -site, remote, and centralised monitoring. Fo r more details, please refer to 
the trial specific monitoring guideline and data review plan . 
In addition to on -site monitoring, pre -specified trial data will undergo central monitoring as 
specified in the trial ’s data review plan.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79607] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
In order to perform thei r role effectively, CRAs (blinded or unblinded) and persons involved 
in quality assurance and inspections will need direct access  to source data, for example, 
medical records, laboratory reports, appointment books, etc. based on the assignment . If the 
electronic medical record does not have a visible audit trail, the investigator must provide the 
appli cable CRA (blinded or unblinded) with signed and dated printouts. In addition, relevant 
site staff should be available for discussions at monitorin g visits and between monitoring 
visits (e.g. , by [CONTACT_756]).  
Protocol compliance  
Protocol deviations will be documented and notified to the investigator. Protocol deviations 
will be assessed by [CONTACT_73348].  
Sponsor audits, IRB/IEC review, and regulatory agency inspections  
The clinical trial will be subject to audits conducted by [CONTACT_73349]/IECs. Audits and inspections may 
take place during or  after the trial. The investigator and the site staff as well as LEO Pharma 
staff have an obligation to cooperate and assist in audits and inspections. This includes giving 
auditors and inspectors direct access to all source documents and other documents a t the trial 
site relevant to the clinical trial. This includes permission to examine, verify , and  reproduce 
any records and reports that are important to the evaluation of the trial.  
If the trial site is contact[CONTACT_73350] , LEO Pharma must be 
notified immediately.  
Data handling  
Data will be collected by [CONTACT_73351] (e.g. , laboratory data). The investigator or staff authorised by [CONTACT_73352] s. Data recorded in the eCRF will be accessible 
to the trial site and LEO Pharma personnel immediately after entry. The eCRF must be 
maintained in an up -to-date state by [CONTACT_73353].  
The investigator must verify the correctness of the data entered by [CONTACT_73354]. This signature [CONTACT_73379] . Any correction(s) made by [CONTACT_73355]. Changes to data already 
approved will require re -signature [CONTACT_3265] [CONTACT_093]. The person making the change to th e 
data, and the date, time , and  reason for the change will be identified in the audit trail.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79608] data should be entered into the eCRF no later than 5  working days after each visit, 
unless a different deadline is stated in the clinical trial agreement. Queries for discrepant data 
will be generated automatically by [CONTACT_73356]  
(blinded or unblinded) , sponsor ’s medical expert, or the data manager. All queries will be 
raised electronically within the electronic da ta capture system. This systematic validation will 
ensure that a clean and consistent database is provided for the statistical analysis.  
An ePRO solution will be used to capture patient -reported data (data from questionnaires 
completed at the trial site an d eDiary data). By [CONTACT_73357], data will be available 
immediately after data entry and available for the blinded CRAs  and site personnel, including 
the investigator, with reader access only. The ePRO system is a separate application from the 
eCRF a nd data captured from the eCRF and the ePRO will be stored on different servers 
during data capture. Data from both systems will be included in the final trial database.  
External data transfers from vendors to LEO Pharma will be transmitted and handled via  a 
secure file transfer protocol  site.  
Transmissions of data are documented in more detail in a data flow plan which is part of the 
trial master file.  
Software used  
CDISC controlled terminology version 06‑Nov‑[ADDRESS_79609] data tabulation model (SDTM) version 1.[ADDRESS_79610] make arrangements to store the essential trial 
documents, including the investigator tr ial file (54). Essential trial documents must be stored 
until LEO Pharma informs the investigator that the documents are no longer to be retained, or 
longer if required by [CONTACT_427].  
In addition, the investigator is responsible for the archiving of all relevant source documents 
so that the trial data can be compared against source data after the com pletion of the trial (for 
example in case of an inspection from regulatory authorities).  
The investigator is required to ensure the continued storage of the documents even if the 
investigator leaves the trial site or retires before the end of the required storage period.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79611] be done in accordance 
with local regulatory requirements.  
For archiving purposes, each investigator will be supplied with an electronic copy of the 
eCRFs and ePRO data for all screened subjects at the trial site. Thi s is done after completion 
of the trial and before access to the eCRF/ePRO is revoked. Audit trail information will be 
included. eCRFs and ePRO data must be available for inspection by [CONTACT_73358] , from regulatory authorities  and/or IRBs/ IECs.  
Appendix 3E: Registration, reporting , and publication policy  
Trial disclosure  
LEO Pharma is committed to be transparent with respect to its clinical trials.  
Basic information of this clinical trial will be registered in the global data registry, 
www.ClinicalTrials.gov before the first subject enters into the trial. The trial may also become 
registered in other online data registries, according to applicable law and regulations.   
Results of this clinical trial will be posted on leopharmatrials.com  in accordance with our 
Position on Public Access to Clinical Trial Information  within approximately [ADDRESS_79612], a poster/presentation for a congress, or 
any openly a ccessible material.  
A primary publication including the primary results of the trial (i.e. the results of the primary 
endpoint[s])  may be submitted for peer-reviewed publication within  12 months of database 
lock. In such case, LEO Pharma would be responsible  for this publication. All authors (trial 
responsible employees and/or applicable investigators and advisors) must fulfil  the criteria for 
authorship from the International Committee of Medical Journal Editors (ICMJE).  
The investigators may reach out to LE O Pharma to publish results that are not included in the 
primary publication. The investigator and LEO Pharma should agree on terms for data sharing 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79613] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
and collaboration on such publications, as well as timing for release of the publication(s). In 
all cases, LEO Pharma retains the right to review and comment on the draft publication in due 
time before submission, but the investigator is not required to revise the draft accordingly, 
unless it discloses company confidential information or protected personal info rmation, or 
may compromise intellectual property rights of LEO Pharma.  
LEO Pharma may give researchers outside LEO Pharma access to anonymised data from this 
trial for further research according to the principles outlined by [CONTACT_73359] (EFPIA)  (62). In that case, the researchers are 
obliged to attempt publication of the results obtained fr om their analyses.  
LEO Pharma follows Good Publication Practice (GPP3) standards and the recommendations 
from ICMJE.  
Appendix 3F: Insurance  
LEO Pharma has taken out relevant insurances covering the subjects in the present clinical 
trial in accordance with applicable laws and regulations.  
Appendix 3G: Financial disclosure  
Investigators will provide LEO Pharma  with sufficient, accurate financial information as 
requested to allow LEO Pharma  to submit complete and accurate financial certification or 
disclosure statements to the appropriate regulatory authorities. Investigators are responsible 
for providing information on financial interests during the course of the clinical trial and for 
1 year after completion of the clinical trial, or for a longer period of ti me if required by [CONTACT_71882].  
Appendix 3H: Committee structure  
Not applicable  
Appendix 3I: Trial and trial site closure  
Premature termination of trial or trial site  
LEO  Pharma , the investigator, the IRB/IECs or competent authorities may decide to st op the 
clinical trial, part of the trial , or a trial site at any time, but agreement on procedures to be 
followed must be obtained.  
If a clinical trial is suspended or prematurely terminated, the investigator must inform the 
subjects promptly and ensure ap propriate therapy and follow -up. As specified by [CONTACT_73360]-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79614] promptly inform IRB/IECs 
and provide a detailed written explanation. Relevant competent authorities must be informed.  
The trial must be  terminated if the perception of the benefit/risk ratio (judged from clinical 
signs and symptoms, [S]AEs, and/or remarkable safety laboratory changes) becomes 
unfavourable for the continuation of the trial.  
Reasons for the early closure of a trial site by [CONTACT_73361]:  
• Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC 
or local health authorities, LEO Pharma  procedures, or GCP guidelines.  
• Inadequate recruitment of subjects by [CONTACT_093].  
Completion of trial  
Investigators will be informed when subject recruitment is to cease. Screening activities will 
be stopped at a trial site when the total requested number of subjects for the clinical trial has 
been obtained , irrespective of the specific site ’s planned inclusion number.  
Trial sites will be closed upon trial completion. LEO Pharma will undertake arrangements for 
the collection and disposal of any unused trial material that the investigator is not required to 
keep in his/her files. A trial site is considered closed when all required documents and trial 
supplies have been collected and a trial site closure visit has been performed.  
When the randomisation code has been broken, the investigators will receive inform ation 
about the treatment allocation for the subjects randomised at their respective sites and will be 
asked to record this in the subject ’s medical record.  
Appendix 3J: Responsibilities  
The signatory investigator is responsible for the approval of the cli nical trial protocol and 
the CTR on behalf of all clinical trial investigators and as agreed to in a signatory investigator 
agreement.  
The national coordinating investigators  are responsible for national issues relating to the 
clinical trial as agreed to i n a national coordinating investigator [INVESTIGATOR_73261].  
Each participating investigator  is responsible for all aspects of the clinical trial conduct at 
his/her trial site as agreed to in a clinical trial agreement.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79615] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Appendix 4: AAD Consensus Criteria for the diagnosis of AD 
From Eichenfield, L. F. (2004). "Consensus guidelines in diagnosis and treatment of atopic 
dermatitis." Allergy 59(s78): [ADDRESS_79616] viewed as a syndrome. Clinical findings that define this syndrome and clinical 
criteria of AD inc lude the following:  
A. Essential features (must be present):  
1. Pruritus  
2. Eczema (acute, subacute, chronic)  
a) Typi[INVESTIGATOR_73262] -specific patterns*  
b) Chronic or relapsing history  
*Patterns include: (i) facial, neck, and extensor involvement in infants and children; (ii) 
current or prior flexural lesions in any age group; (iii) sparing of groin and axillary regions.  
B. Important features (seen in most cases, adding support to the diagnosis)  
1. Early age at onset  
2. Atopy  
a. Personal and/or family history  
b. IgE reactivity  
3. Xerosis  
C. Associated features (these clinical associations help to suggest the diagnosis of AD but 
are too nonspecific to be used for defining or detecting AD for research or 
epi[INVESTIGATOR_29820]):  
1. Atypi[INVESTIGATOR_73263] (e.g. , facial pallor, white der mographism, delayed 
blanch response)  
2. Keratosis pi[INVESTIGATOR_22785]/hyperlinear palms/ichthyosis  
3. Ocular/periorbital changes  
4. Other regional findings (e.g. , perioral changes/periauricular lesions)  
5. Perifollicular accentuation/lichenification/prurigo lesions  
TMF-000616809 - Version 4. 0
Trial ID: LP01 45-1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79617] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Exclusionary conditions: It should be noted that a diagnosis of AD depends on excluding 
conditions such as scabies, seborrheic dermatitis, allergic contact [CONTACT_8748], ichthyoses, 
cutaneous lymphoma, psoriasis, and immune deficiency diseases.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79618] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Appendix  5: Guidance for anaphylaxis diagnosis  
From Sampson HA, Muñoz -Furlong A, Campbell RL, Adkinson FN Jr, Bock SA, Branum A, 
et al. Second symposium on the definition and management of anaphylaxis: Summary report -
- Second National Institute of Allergy and Infectious Diseases/ Food Allergy and Anaphylaxis 
Network symposium. J Allergy Clin Immunol. 2006;117(2):391 -397. 
The National Institute of Allergy and Infectious Diseases (NIAID) and Food Allergy and 
Anaphylaxis Network Guidance for Anaphylaxis Diagnosis (FAAN) define anaphyl axis as a 
serious allergic reaction that is rapid in onset and may cause death. They recogni se 
3 categories of anaphylaxis, with criteria designated to capture from 80% of cases 
(category  1) to >95% of all cases of anaphylaxis (for all 3 categories).  
Clinical criteria for diagnosing anaphylaxis  
Anaphylaxis is highly likely when any one of the following 3 criteria are fulfilled:  
1) Acute onset of an illness (minutes to several hours) with involvement of the skin, 
mucosal tissue, or both (e .g., generali sed hive s, pruritus or flushing, swollen lips -
tongue -uvula)  
AND AT LEAST ONE OF THE FOLLOWING:  
• Respi[INVESTIGATOR_7798] (e .g., dyspn oea, wheeze -bronchospasm, stridor, 
reduced peak expi[INVESTIGATOR_10229] [PEF], hypoxemia).  
• Reduced blood pressure (BP) or associated symptoms of end -organ 
dysfunction (e .g., hypotonia [collapse], syncope, incontinence).  
2) Two or more of the following that occur rapi[INVESTIGATOR_17176] a likely  allergen for 
that patient (minutes to several hours):  
• Involvement of the skin -mucosal tissue (e .g., generalised hives, itch -flush, 
swollen lips -tongue -uvula).  
• Respi[INVESTIGATOR_7798] (e .g., dyspn oea, wheeze -bronchospasm, stridor, 
reduced PEF, hypoxemia).  
• Reduced BP or associated symptoms (e .g., hypotonia [collapse], syncope, 
incontinence).  
• Persistent gastroi ntestinal symptoms (e .g., crampy abdominal pain, vomiting).  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79619] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
3) Reduced BP after exposure to known  allergen for that patient (minutes to several 
hours):  
• Infants and children: low systolic BP (age specific) or greater than 30% 
decrease in systolic BP . 
• Adults: systolic BP of less than 90  mm Hg or greater than 30% decrease from 
that person ’s baseline . 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79620] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Appendix 6: Country -specific requirements   
Not ap plicable  
 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79621] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Appendix  7: Short version and justification for  eligibility criteria  
Inclusion criteria  
No. Short version   Justification  
1 Signed and dated informed consent has been obtained prior to any 
protocol -related procedures.  To ensure compliance with Declaration of Helsinki (38) and GCP . 
2 18-64 years old (both included) at screening . To ensure only adults are included given the early stage of 
development. Subjects older than 65 years  are excluded to ensure safety 
of subjects by [CONTACT_73362] -19 infection.  
3 Diagnosis of AD [as defined by [CONTACT_73278] (1) 
and Appendix 4] that has been present for ≥[ADDRESS_79622] a recent  history (within 6 months before  
screening) of inadequate response to treatment with topi[INVESTIGATOR_73264] , or for whom topi[INVESTIGATOR_73265].  To ensure that the subject is a candidate for systemic treatment with 
LEO  138559 . 
5 EASI score ≥1 2 at screening and ≥[ADDRESS_79623] has a severity of disease that makes 
assessment of improvement possible . 
6 vIGA -AD score ≥[ADDRESS_79624] has a severity of disease that makes 
assessment of improvement possible . 
7 Body surface area (BSA) of AD involvement ≥10% at screening 
and baseline.  To ensure that the subject has a BSA involvement that makes 
assessmen t of improvement possible . 
[ADDRESS_79625] Daily Pruritus NRS  (weekly  average) of ≥[ADDRESS_79626] agrees to apply an  emollient twice daily (or more 
frequently , if needed) to AD lesional and non -lesional  skin for at 
least [ADDRESS_79627] of care therapy.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376 Date: 31-Jan-2022  Version: 4.[ADDRESS_79628] at 
baseline.  For the safety of the unborn/newborn child.  
[ADDRESS_79629] administration of IMP.  For the safety of the unborn/newborn child.  
 
  
Exclusion criteria  
No. Short version   Justification  
[ADDRESS_79630] entries.  
3 Current participation in any other interventional clinical trial.  To ensure safety of subjects and ensure lack of confounding of 
measurements (e.g. , efficacy, PK, and PD).  
4 Treatment with systemic  immunosuppressive/immunomodulating 
medication, immunoglobulin/blood products, or phototherap y 
within 4 weeks or 5 half -lives prior to randomisation, whichever is 
longer.  To not interfere with efficacy assessments . 
5 Treatment with biologics within 5 half -lives (if known) or 
16 weeks prior to randomisation, whichever is longer.  To not interfere with efficacy assessments . 
6 Treatment with TCS, TCI, topi[INVESTIGATOR_22732] -4 inhibitor , or other 
topi[INVESTIGATOR_73266] 1 week prior to 
randomisation.  To not interfere with efficacy assessments . 
7 Treatment with a live (attenuated) vaccine within [ADDRESS_79631] with this.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79632].  To ensure safety of subjects given  the potential increased risk of 
infections of the skin with LEO 138559.  
10 Skin infection within 1 week prior to randomisation . To ensure safety of subjects given the potential increased risk of 
infections of the skin with LEO 138559.  
11 Current or recent (within 2 years prior to randomisation) 
gastrointestinal ulcers.  To ensure safety of subjects given the potential increased risk of 
impaired wound healing of the intestine with LEO 138559.  
12 History of any of the following: anaphylaxis, immune complex 
disease, pancreatic disease, inflammatory bowel disease, or 
known  or suspected history of immunosuppressive disorder.  Anaphylaxis : To ensure safety of subjects given the potential increased 
risk of anaphylaxis and serious allergic reactions after a dministration of 
foreign proteins.  
Immune complex disease : To ensure safety of subjects given the 
potential increased risk that antibody -antigen complexes can 
accumulate and cause a Type III allergic reaction.  
Pancreatic disease : To ensure safety of subjec ts given the potential 
increased risk of impaired wound healing of pancreas with LEO 
138559.  
Inflammatory bowel disease : To ensure safety of subjects given the 
potential increased risk of impaired wound healing of intestine with 
LEO  138559.  
Known or suspec ted history of immunosuppressive disorder : To ensure 
safety of subjects given the potential increased risk of infections of the 
skin, lung, and intestines with LEO 138559.  
13 Known or suspected hypersensitivity to any component(s) of the 
IMP.  To ensure safety of subjects . 
14 Presence of hepatitis B or C infection at screening. These are 
defined as: 1) Positive hepatitis C Ab, or 2) Positive HBsAg, or 3) 
Negative anti -HBs Ab AND positive anti -HBc Ab.  To ensure safety of subjects given the potential incre ased risk of 
infections with LEO 138559.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79633] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
15 History of human immunodeficiency virus (HIV) infection or 
positive HIV serology at screening.  To ensure safety of subjects given the potential increased risk of 
infections with LEO 138559.  
[ADDRESS_79634]  at screening . To ensure safety of subjects given the potential increased risk of 
infections of the lung with LEO 138559.  
 
17 Current diagnosis of diabetes.  To ensure safety of subjects by [CONTACT_73363] -19 infection . 
18 Serious heart conditions (e.g ., heart failure, coronary artery 
disease, congenital heart  disease, cardiomyopathies, and/or 
pulmonary hypertension).  To ensure safety of subjects by [CONTACT_73363] -19 infection . 
19 Chronic lung diseases (e.g ., chronic obstructive pulmonary 
disease, idiopathic pulmonary fibrosis, and/or cystic fibrosis).  To ensure safety of subjects by [CONTACT_73363] -19 infection . 
20 Moderate to severe asth ma [as defined by [CONTACT_73364]  (42)]. To ensure safety of subjects by [CONTACT_73365] -19 infection . 
21 Obesity (BMI ≥35).   To ensure safety of subjects by [CONTACT_73363] -[ADDRESS_79635] is pregnant or lactating.  For the safety of the unbor n/newborn child.  
[ADDRESS_79636] of the trial, or immediate 
family members of such individuals.  To ensure integrity of trial data . 
26 Any disorder at screening and/or baseline, which is not stable in the 
opi[INVESTIGATOR_73267], and integrity and validity of the trial 
data.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79637] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
27 Any significant abnormal finding at baseline and/or screening 
which may in the opi[INVESTIGATOR_73267], and integrity and validity of the trial 
data.  
[ADDRESS_79638] 4 
weeks or 5 half -lives prior to randomisation, whichever is longer . To ensure safety of subjects and ensure lack of confounding of 
measurements (e.g. , efficacy, PK, and PD).  
29 Subjects who are legally institutionalised.  To ensure compliance with Declaration of Helsinki  (38). 
[ADDRESS_79639] at screening .  To ensure safety of subjects  and tr ial site staff . 
 
 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79640] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Appendix 8: Contact [CONTACT_73366], National Lead CRA s, CRAs (blinded  and unblinded) , and 
sponsor ’s medical expert [INVESTIGATOR_73375] a separate contact [CONTACT_4111].  
Sponsor  
LEO Pharma A/S  (referred to as ‘LEO  Pharma ’ or ‘the sponsor ’ in this clinical trial protocol) 
is the sponsor of the clinical trial:  
LEO Pharma A/S  
Industriparken 55  
DK-2750 Ballerup  
Denmark  
Coordinating investigator  
  
  
 
 
 [INVESTIGATOR_73268]-000616809 - Version 4. 0
[COMPANY_003]
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79641] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Appendix  9: COVID -[ADDRESS_79642] of important safety and efficacy assessments.  
As protective/preve ntive measures to be taken in the context of the COVID -19 pandemic can 
differ across countries and regions, no general instructions from the sponsor can be provided 
and the investigators will be trusted to take appropriate action. This includes but is not limited 
to complying with recommendations and regulations issued by [CONTACT_73367], 
the increase of protective safety and hygiene measures (e.g ., wearing mask, disinfecting 
hands, social distancing) for both subject and site staff, and the frequent monitoring of the 
subject ’s health.  
To minimi se subject exposure to COVID -[ADDRESS_79643] of subjects using taxis or their own vehicle (including 
parking fees) to commute to and f rom the trial site.  
If on -site visits are not possible due to preventive measures issued by [CONTACT_19387](ies) or site obligations, the affected site(s) will postpone screening and 
randomisation of subjects until on -site visits can be conducted ag ain. 
Safety monitoring is an obligation of LEO Pharma and in case the subject, due to local 
restrictions, is prevented from coming to the trial site, the investigator can convert on -site 
visits into phone  visits  for the primary purpose of safety monitoring . At a phone  visit, the 
following data may be collected :  
• AEs.  
• Concomitant medication and concurrent procedures.  
• Urine pregnancy test. Women of childbearing potential will be provided with urine 
pregnancy tests, if needed. The subject will take the test at  home and inform the 
investigator about the result over the phone.  
• POEM and DLQI  collected on the web-based solution  by [CONTACT_73291].  
The phone  visits  must not be used for conducting the investigator ’s assessments of efficacy.  
If on -site visits are not possible, it will be at the discretion of the investigator if clinical 
laboratory samples or a serum pregnancy test are necessary to ensure subject safety.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79644] testing  positive  for COVID -19 (test taken at their own initiative ) between screening 
(at the earliest Week  -4) and washout  (Week  -1) may be rescreened once if the screening 
period does not exceed 28  days in total (see Secti on 8.4). A subject testing positive during  the 
washout period (Week  -1 to Week  0) must be withdrawn from the trial.  A subject testing 
positive for COVID -[ADDRESS_79645] igator ’s discretion.  
In general , in the context of the COVID -[ADDRESS_79646] or 
unscheduled visits w ere due to the pandemic.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79647] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Appendix  10: Protocol amendment history  
The protocol amendment summary of changes table for the current amendment is located 
directly before the table of contents.  
Amendme nt 2 (17-Nov-2021)  
This amendment is considered to be non-substantial based on the criteria set forth in Article 
10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European 
Union or subsequent regulation  because it neither sign ificantly impacts the safety or 
physical/mental integrity of subjects nor the scientific value of the trial.  
Overall rationale for the amendment  
The main purpose for this protocol amendment is to remove the cappi[INVESTIGATOR_73269] (moderate defined as EASI <21 and severe defined as EASI ≥21) 
in Sections 7.1 and 12.1.  
In the protocol a cappi[INVESTIGATOR_73270] a high 
unmet need (defined as severe subjects with a baseline EASI score ≥21). This was originally 
described in the protocol in Section 12.1: ’The minimum limit for inclusion of 50% of 
subjects with ‘stratum B ’ at baseline has been chosen to ensure inclusion of a suitable 
proportion of subjects representative of the target population t hat experiences a high unmet 
need for AD treatments. ’ This cappi[INVESTIGATOR_73271] 7.1 
stating that each stratum (‘stratum A ’ defined  as having EASI <21 and ‘stratum B ’ defined as 
having EASI ≥21) will comprise exactly 26 subjects randomised, equivalent to 50% of the 
total sample size.  
During trial conduct it has become clear that the screening process of trying to reach the exact 
distribution as original stated in Section 7.1 is more complex than anticipated. However, it has 
also become clear that severe subjects with a baseline EASI score ≥21 represent more than 
50% of subjects fulfilling the eligibility criteria, and therefore the initial aim to include 
sufficient subjects with an unmet need is no longer of concern.  
Removing the capped enrolment does not affect the total number of subjects, stat istical 
analysis methods or interpretation of the trial results, and has no impact on patient safety, thus 
no impact on the scientific value or integrity of the trial.  
All changes to the protocol are presented in the summary of changes table below except for a 
few minor editorial changes (e.g., spelling errors).  
 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79648] number add ed. 
Pre-IND 
 Editorial.  
Section 1 Protocol 
synopsis , Section 8.3 
Exclusion criteria, 
no. 10 and Appendix  7 
Short version and 
justification for 
eligibility criteria  Skin infection within 1 week prior to 
the baseline visit  randomisation.  To be more specific and consistent.  
  
Section 4 Schedule of 
trial procedures, 
footnote o)  o) Relevant concomitant medications 
/ concurrent procedures should be 
included from 3 months prior to 
baseline (Day 1)  screening  until end 
of trial ( Week 32).  To align with Section 9.6. 
Section 7.1 Overall 
trial design  Randomisation will be stratified by 
[CONTACT_22789]. One 
stratum, ‘stratum A’, will be defined 
as having EASI <21 and the other 
stratum, ‘stratum B’, will be defined 
as having EASI ≥21. Each stratum 
will comprise exactly 26 subjects 
randomised, e quivalent to 50% of 
total sample size.  IRT will be used to 
control randomisation and 
stratification factors.  To remove the cappi[INVESTIGATOR_73272]. 
However, stratified randomisation to 
assure that treatment groups are balanced 
will be maintained.  
Section 9.3 Treatment 
assignment  Subjects eligible on 
inclusion/exclusion criteria at 
baseline may be prevented from 
being randomised into the trial due to 
the applied cappin g limitation in 
baseline severity (as described in 
Section 8.2). This has been deleted as the cappi[INVESTIGATOR_73273] (see above).  
Sectio n 9.[ADDRESS_79649] receives rescue treatment 
with any TCS/TCI before Week 4, 
super potent TCS (e.g., clobetasol 
propi[INVESTIGATOR_16847] 0.05% cream) between 
Week -1 and Week 16, or systemic 
rescue treatment (besides systemic 
antihistamines and/or anti -infectives) 
at any point during the trial between 
Week -4 (or 5 half -lives, whichever is 
longer) and Week 32, treatment with 
IMP will be discontinued, and the 
subject will be withdrawn from the 
trial. For readability and to align Section 9.5 
with Section 10.1. 
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79650]  
receives the following treatment:  
Rescue treatment with any 
TCS/TCI before Week 4.  
Super potent TCS (e.g., clobetasol 
propi[INVESTIGATOR_16847] 0.05% cream) 
between Week  -1 and Week 16.  
Systemic rescue treatment (besides 
systemic antihistamines and/or 
anti-infectives) at any point 
during the trial between Week 
-4 (or from 5 half -lives of Week 
0, whichever is longer) and 
Week 16 . 
Section 10.2.1  Reasons 
for permanent 
discontinuation of IMP  In the Reporting in eC RF subsection, 
‘Death’ has been deleted.  Death is captured as an SAE and to align 
with the eCRF.  
Section 11.[ADDRESS_79651] be assessed by [CONTACT_73368] p ersonnel  a physician  
(Section  13.2). Editorial.  
Section 11.4.[ADDRESS_79652] be measured before any 
blood samples scheduled at the same 
visit.  In alignment with Section 11.1, the ECG 
measurements can be done at  any time, 
and not in any pre -specified order.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79653] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Section no. and name  [CONTACT_18054] 12.1 Scientific 
rationale for trial 
design  The combination of randomisation 
and blinding (Section 9.3.1 ) 
minimises the likelihood of 
allocation bias. The risk of 
allocation bias is further reduced 
through the use of central 
randomisation. The use o f 
randomisation also ensures that 
baseline factors will not be 
confounded with treatment. 
Randomisation within the strata 
defined by [CONTACT_22789] 
(‘stratum A’ [EASI <21] or 
‘stratum B’ [EASI ≥21]) will limit 
any potential imbalance in the 
allocation of subjects across 
baseline disease severity.  Stratified 
randomisation according to baseline 
disease severity (“stratum A” [EASI 
<21] or “stratum B” [EASI ≥21]) will 
minimise allocation bias and ensure 
balanced allocation of subjects with 
“stratum A ” vs. “stratum B” at 
baseline between the treatment 
groups, thereby [CONTACT_73369].  The minimum limit for 
inclusion of 50% subjects with 
“stratum B” at baseline has been 
chosen to ensure inclusion of a 
suitable proportion of subjects 
repre sentative of the target 
population who experiences a high 
unmet need for AD treatments.   The rational for randomisation and 
blinding has been updated to clarify and be 
more specific on how to avoid imbalance 
of allocation of subjects across baseline 
disea se severity and treatment arms.  
 
 
 
 
 
 
 
 
 
 
 
 
The cappi[INVESTIGATOR_73274] (Please refer to change in 
Section  7.1). However, stratified 
randomisation to assure that treatment 
groups are balanced will be maintained.  
Section 13.[ADDRESS_79654] be 
assessed by a physician.  Clarification.  
Appendix 1  Definitions 
of adverse ev ents and 
serious adverse events  Additionally, all malignancies, 
including skin malignancies, should 
be reported as SAEs.  Editorial.  
Appendix  10 Protocol 
amendment history  Protocol amendment 1, Summary of 
changes table moved to Appendix  10. Editorial  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79655]  at 
screening and conditions for 
rescr eening.  Correction to Amendment 1 Summary of 
changes table.  
Abbreviations : please refer to the list of abbreviations.  
Amendment  1 (07-May -2021)  
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council of the European Union 
or subsequent regulation.  
Overall rationale for the amendment  
The purpose of this protocol amendment is to allow for the clarification and addition of 
eligibility criteria  and the inclusion of additional safety assessments. The most important 
changes to the protocol are summarised in the table below. Additional minor changes, not 
listed in the table, were included for clarity and consistency.  
Summary of changes  
Section no. and 
name  [CONTACT_18054]  1 Protocol 
synopsis  
 
Section  8.2 
Inclusion c riteria  
or Section  8.3 
Exclusion criteria  
 
Appendix  7 Short 
version and 
justification for  
eligibility criteria  Changes to eligibility criteria:  
• Inclusion criterion no.  2: 18-64 years 
old (both included) at baseline  
screening .  
To ensure that subjects are at 
least 18 years  at screening when they 
provide informed consent.  
• Exclusion criterion no.  8: History of 
malignancy within [ADDRESS_79656] of care will  be included in the 
trial. 
• Exclusion criterion no.  16: Subject has 
a positive or indeterminate  
Mycobacterium tuberculosis  IFN-γ 
release assay test or a positive purified 
protein derivative ([COMPANY_003]) test at 
screening.  To ensure that only subjects wit h a 
negative tuberculosis test at screening will 
be included in the trial.  
Addition of eligibility criterion:  
• Exclusion criterion no. 30: Positive 
SARS -CoV -[ADDRESS_79657] and trial site staff 
safety.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79658] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Section no. and 
name  [CONTACT_18054]  4 
Schedule of trial 
procedures  
 
Section  11.2.4  
Other assessments  
 
Section  [IP_ADDRESS]  
Overview  
 
Section  [IP_ADDRESS]  
Investigator 
evaluation of 
laboratory 
samples  Addition of a SARS -CoV -[ADDRESS_79659] and trial site staff 
safety.  
Section  8.4 
Screening and 
screen ing failures  Addition of a provision to allow 
rescreening of subjects testing positive for 
COVID -19 at screening  and conditions for 
rescreening . 
Rescreening may be allowed after 
evaluation by [CONTACT_456]’ s medical expert 
[INVESTIGATOR_73376] [ADDRESS_79660] positive for COVID -19 (test 
taken at their own initiative)  during the 
screening period . 
Subjects testing positive between Week  -[ADDRESS_79661] 
recruitment . 
Section  4 
Schedule of trial 
procedures  Addition of a clinical 
chemistry /haematology  blood sample at 
Week  2. To increase subject safety . 
Addition of a separate line for IgE 
analysis.  To clarify that hepatitis B, C, and HIV 
testing will be conducted at screening only 
and that IgE analysis will be conducted 
from baseline at the visits indicated in the 
schedule of trial procedures.  
Section  11.1 
Overview  
Panel 6: Sequence 
of assessments  
 Groupi[INVESTIGATOR_73275] , PK blood samples , and 
pharmacodynamics  in 1 unique box in the 
panel and addition of a footnote to explain 
this.  Because the order in which safety and 
laboratory assessments, PK blood 
sampling and pharmacodynamics are 
conducted does not matter as long as all of 
the above assessments are conducted after 
the investigator assessments and before 
administration of IMP.  
TMF-000616809 - Version 4. 0
Trial ID: LP0145 -1376  Date: 31-Jan-2022  Version: 4.[ADDRESS_79662] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF  THE LEO PHARMA GROUP  
 
Section no. and 
name  [CONTACT_18054]  [IP_ADDRESS]  
Overview  Addition of analytes  tested: lactate 
dehydrogenase and C -reactive protein . To increase understanding of systemic 
inflammation . 
Section  12.1 
Scientific 
rationale for trial 
design  Addition of a rationale for the additional 
dose of  IMP given at Week  1. 
Weekly dosing from Week  0 to Week  2 
will allow 75% of the expected steady 
state exposure to be safely reached already 
after [ADDRESS_79663] keepi[INVESTIGATOR_007], 
quality control, 
and data handling  Change in the trial monitoring subsection 
and update of the monitoring method.  
The monitoring will be performed in a 
systematic, prioritised, risk -based 
approach, and as a combination of on -site, 
remote, and centralised monitoring.  To clarify how monitoring will be 
conducted.  
Abbreviations : please refer to the list of abbreviations.  
 
 
 
 
TMF-000616809 - Version 4. 0